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Abstract 
Platelets play critical roles in thrombosis, inflammation, and wound healing, which are 
essential in response to trauma. These processes are primarily driven through the 
immunoreceptor tyrosine-based activation motif (ITAM)-containing receptors, 
glycoprotein VI (GPVI) and C-type lectin-like receptor 2 (CLEC-2). This study aimed 
to investigate; (i) the effects of Alarmins released following trauma on platelet reactivity 
and the mechanisms involved; (ii) establish whether soluble GPVI (sGPVI), a platelet 
activation marker is elevated in trauma and other inflammatory conditions; (iii) 
determine whether the CLEC-2 ligand, podoplanin, is elevated in inflammatory 
conditions and (iv) establishing the role of GPVI and platelets in cutaneous wound 
healing. 
 
The nuclear-related Alarmin, histones, induced robust platelet activation both in vitro 
and in vivo. Histone-induced platelet activation was mediated through GPVI in vitro 
However, this pathway was found not to underlie histone-induced lowering of platelet 
count in vivo and is most likely to result from mediators released following vascular 
damage. GPVI shedding was shown to be induced following activation by thrombin, 
through a pathway dependent on fibrin generation. sGPVI was found to be a marker for 
platelet activation during a variety of inflammatory disorders, notably in association 
with sepsis.  Furthermore, GPVI shedding reflects platelet activation by collagen and 
potentially thrombin-induced fibrin generation.  
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CHAPTER 1 
 
GENERAL INTRODUCTION 
  
2 
 
1.1 Platelet physiology  
1.1.1 The physiological role of platelets 
Platelets are small anucleate cells with a primary role in haemostasis. Under 
physiological conditions, platelets circulate in the vascular system in a resting state 
unable to interact with the endothelium. Their small size (1-3µm) and margination by 
red blood cells (RBCs), allows platelets to make continual contact with vascular 
endothelial cells and thereby detect any injury that occurs. Following endothelial injury, 
platelets respond quickly to form a haemostatic plug.  Platelets contain numerous 
surface receptors, signalling proteins and granule contents which mediate robust 
activation through contact and interactions with sub-endothelial matrix proteins exposed 
after vascular damage (Li et al., 2010).  
 
Platelet aggregation leads to vascular plug formation at injury sites in blood vessels. 
However, pathological platelet activation, such as at sites of diseased endothelium, can 
result in a range of thrombotic disorders, including atherosclerosis, sepsis, myocardial 
infarction and stroke (Lindemann et al., 2007, Claushuis et al., 2016, Nieswandt et al., 
2005). In recent years, platelets have also been shown to have important roles in 
inflammation (Engelmann and Massberg, 2013) and maintenance of vascular integrity 
(Lee et al., 2007, Gros et al., 2014, Gros et al., 2015b). An overview of platelet 
function, activation and roles in thrombosis and inflammation will be discussed in the 
following sections. 
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1.1.2 Platelet production  
The life-span of human platelets is approximately 8-10 days, unless they undergo 
activation when they are removed by the reticuloendothelial system (Fritz et al., 1986). 
There is a constant requirement for platelets to maintain a circulating level of 150-
450x10
9
 platelets per litre.   
 
Platelets, along with all other circulating blood cells, arise from haematopoietic stem 
cells (HSC) located in the bone marrow. Figure 1.1 shows the origin of the various of 
blood cells. Platelets result from megakaryocyte maturation, differentiated from 
common myeloid progenitor cells (Patel et al., 2005). The cytokine, thrombopoietin 
(TPO) and its receptor c-Mpl play a critical role in megakaryocyte differentiation, with 
a variety of other transcription factors also having regulatory roles (Johnson et al., 2016, 
Kaushansky, 2005). Megakaryocytes form pro-platelets processes that extend into the 
vasculature and release platelets into the circulation (Kaushansky, 2005) .  
  
4 
 
 
 
Figure 1.1. Haematopoietic stem cell lineages. Lineages of different derived blood 
cells arising from the haematopoietic stem cells (HSC) in the bone marrow. Figure 
based on (Kondo et al., 2003, Johnson et al., 2016).  
 
  
5 
 
1.1.3 Platelet anatomy  
Because platelets are anucleate, they have a very limited ability to undergo de novo 
protein synthesis and consequently nearly all organelles, proteins and protein granule 
contents are synthesised in the precursor megakaryocyte. Platelets do however have the 
ability to uptake plasma proteins, such as fibrinogen. Platelets have actin cytoskeleton 
and microtubule systems supporting the plasma membrane and undergo marked 
structural changes during platelet activation and spreading (Calaminus et al., 2008, 
Hartwig, 1992). The platelet membrane contains the open canalicular system (OCS), 
which is a network of invaginations, important for increasing platelet surface area 
available for granule content release. The dense tubular system is also contained in the 
OCS, which is involved in Ca
2+
 storage and is the location of cyclooxygenase-1 (Cox-
1), an important enzyme involved in thromboxane A2 (TxA2) production. Another 
important component of the plasma membrane is phosphatidylserine (PS). This is held 
on the cytosolic side of the membrane by flippases until periods of activation and 
apoptosis, where it is exposed on the extracellular side. Once exposed, PS provides a 
procoagulant surface for thrombin generation to occur, facilitating fibrin generation 
through the coagulation cascade.    
 
Platelets contain secretory vesicles in the cytoplasm including α-granules, lysosomes 
and dense granules. Once platelets are activated, the granular contents are rapidly 
released. These granular contents include a variety of proteins, which have various 
functional roles, from promoting platelet activation feedback; recruiting new platelets 
and helping with thrombus generation, attracting leukocytes and facilitating repair at 
areas of damage. Table 1.1 shows the various contents of α-granules and dense granules 
6 
 
and their functional roles. Deficiencies in granule number, contents or ability to release 
their contents result in mild to severe abnormalities leading to bleeding disorders, such 
as grey-platelet syndrome (Raccuglia, 1971, Deppermann et al., 2013), Hermansky-
Pudlak syndrome (Hermansky and Pudlak, 1959) and platelet storage pool deficiencies 
(Bolton-Maggs et al., 2006). A wide variety of receptors and other proteins are located 
at the platelet membrane, which will be discussed in Section 1.3-1.4.  
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Table 1.1. Example contents of platelet α- and dense granules and their functional 
roles. Main contents of α- and dense granules, including their function and roles.  
 
  
α-granules dense granules 
Function Contents Role Function Contents Role 
Adhesion 
proteins 
 
Fibrinogen 
von 
Willebrand 
Factor (vWF) 
Platelet 
aggregation 
and thrombus 
formation 
Feedback 
mediators 
ADP 
ATP 
Ca
2+ 
5-HT 
(serotonin)
 Feedback 
mediators 
involved in 
platelet 
aggregation 
and 
thrombus 
growth 
Chemokines 
Platelet 
factor-4 
(PF4) 
SDF-1 
Leukocyte 
recruitment 
Polyphosphates Poly-P 
Growth 
factors 
PDGF 
EGF 
VEGF 
Wound repair and 
angiogenesis 
Membrane 
protein 
P-selectin 
Leukocyte 
binding 
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1.2 Thrombus formation 
1.2.1 Platelet activation and thrombus formation  
Thrombus formation involves multiple processes and signalling events after platelet 
adhesion and activation at damaged areas. Upon endothelium damage collagen fibres in 
the sub-endothelial matrix become exposed. Platelets then adhere to the exposed sub-
endothelial matrix and undergo activation.  This leads to further platelet recruitment, 
thrombus formation and wound occlusion (Li et al., 2010).  Several stages leading to 
thrombus formation are detailed below and in Figure 2.1  
1) Collagen exposure and tethering  
Under conditions of low shear stress, the platelet integrin α2β1 binds to exposed 
collagen fibres with a low rate of association. It remains unclear as to what extent this 
requires platelet activation and inside-out activation of the integrin. At high stress this 
association is not adequate to tether the platelets to the endothelial surface. However, 
upon vascular damage exposed collagen fibres become coated with von Willebrand 
factor (vWF), which allows interactions to occur with the GPIb-IX-V receptor on the 
platelet surface, leading to initial platelet capture, known as tethering. The fast on-off 
rate of association and dissociation of GPIb-IX-V receptor to vWF is however, not 
sufficient for stable adhesion, therefore platelets roll along the endothelium in the 
direction of blood flow (Offermanns, 2006). 
2) Stable adhesion  
Stable platelet adhesion is required for the initiation of thrombus formation. Platelet 
tethering to vWF allows the collagen fibres to become in close proximity to the major 
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collagen receptor glycoprotein VI (GPVI), resulting in platelet activation. The integrins 
αIIbβ3 and α2β1 are then converted into their active form, leading to greater 
interactions with vWF and collagen, respectively, establishing stable adhesion.  
3) Spreading and secretion  
Once platelets become activated their morphology changes from discoid to fully spread. 
Actin polymerisation following activation results in formation of filopodia and 
lamellipodia, which in turn leads to stronger platelet attachment to exposed collagen and 
vWF, as the platelet surface area is increased. Consequently, actin stress fibres are 
formed providing support for aggregate formation (Calaminus et al., 2008). GPVI and 
integrin activation leads to secretion of α- and dense granule contents, including the 
feedback messengers, adenosine diphosphate (ADP) and thromboxane (TxA2), which 
mediate further activation and aggregation (Watson and Harrison, 2007). Release of α-
granule contents, including the adhesion proteins, fibrinogen and vWF, further supports 
platelet capture supporting aggregation.  
4) Thrombus growth  
For thrombus growth, circulating platelets are recruited after pronounced platelet 
activation and secretion, promoting the growth of the thrombus. Platelet activation is 
further reinforced through thrombin generation through activation of the coagulation 
cascade. Platelets provide a pro-coagulant surface for thrombin generation, in turn 
leading to more platelet activation. Moreover, the thrombin generated converts 
fibrinogen into fibrin, which provides a network for thrombus stabilisation leading to 
effective wound occlusion at the site of injury (Renne et al., 2005).  
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Figure 1.2. Processes of thrombus formation. 1) Platelets are marginated to blood vessel walls by red blood cells (RBCs) in the direction 
of blood flow. Platelets tether to vessel wall through weak interactions of GPIb-IX-V and von Willebrand factor (vWF). 2) Tethering of 
platelets allows GPVI and exposed collagen to become close and lead to stable adhesion through integrin activation. 3) Platelets are active 
and spread, releasing granule contents. 4) Released mediators promote thrombus growth, by recruiting more platelets. Thrombin converts 
fibrinogen to fibrin which stabilises the thrombus. 
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1.3 Platelet activation and signalling  
Platelet receptors signal through various mechanisms leading to Ca
2+
 mobilisation and 
functional effects, such as secretion of granule contents. Platelet receptor activation can 
also result in the initiation of positive feedback mechanisms and inhibitory mechanisms 
to regulate platelet function. The next sections will describe the different platelet 
receptors and signalling mechanisms that are essential for platelet function and 
activation, including feedback mechanisms.  
1.3.1 G protein-coupled receptors (GPCRs)  
G protein-coupled receptors (GPCRs) are a family of seven transmembrane domain 
receptors that couple with heterotrimeric G proteins (α, β and γ) and have major roles in 
enhancing platelet activation through positive feedback mechanisms. GPCRs can bind a 
number of agonists released from platelet granules and endothelial cells in response to 
endothelial damage to enhance platelet activation. ADP is released both from damaged 
endothelial cells and platelet granules after activation and binds to P2Y1 and P2Y12, 
which are Gq- and Gi/z-coupled receptors. P2Y1 and P2Y12 receptors, give synergy with 
other receptors leading to enhancement of secretion and results in powerful aggregation 
(Dawood et al., 2007). P2Y1 receptor interactions are implicated in Ca
2+
 mobilisation 
leading to shape change. Furthermore, ADP activation of P2Y12 inhibits cyclic 
adenosine monophosphate (cAMP) formation. This blocks the cAMP inhibitory action 
and allows platelet activation to proceed (see section 1.3.4). ADP also can bind to P2X1, 
an ATP-gated Ca
2+
 ion channel. Although activation is sufficient to cause only weak 
aggregation, it can enhance platelet response to other agonists (Murugappa and 
Kunapuli, 2006). TxA2 is released from stimulated platelets (it is made de novo by the 
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action of Cox-1) and induces platelet activation through Gq-and G12/13 coupled 
thromboxane receptors, TPα and TPβ (Li et al., 2010).  
1.3.2 Protease-activated receptors (PARs)   
Protease-activated receptors (PARs) are GPCRs. Unlike other GPCR receptors, in 
which activation is mediated through direct ligand binding, PAR activation occurs by 
proteinases that cleave the amino terminus of the receptor to unmask the N-terminal 
‘tethered ligand’. This remains attached and leads to activation and signalling (Adams et 
al., 2011, Gieseler et al., 2013). PAR-1 and PAR-4 are the PAR receptors in human 
platelets, whereas PAR-3 and PAR-4 are the important ones in mice platelets. Thrombin 
cleaves PAR1 and 4 at specific extracellular N-terminus recognition sites inducing 
activation (Gieseler et al., 2013). 
1.3.3 Integrins 
Integrins are important for allowing stable platelet adhesion and aggregation for 
thrombus formation. Integrin αIIbβ3 is highly expressed with a copy number of 
approximately 80,000 per human platelet. αIIbβ3 is a heterodimer formed of α and β 
subunits. The extracellular domain of the β3 subunit contains an RGD sequence and a 
second binding site for fibrinogen (Bennett, 2005). Src family kinases (SFKs) associate 
constitutively with the β3 cytosolic tail (Arias-Salgado et al., 2005). Following platelet 
activation by ligand binding to other receptors, ‘inside-out’ signalling occurs. This, 
results in conformational changes of αIIbβ3, increasing its affinity for ligands such as 
fibrinogen and vWF.  Binding of its ligands then mediates ‘outside-in’ signalling. This 
signalling mechanism involves proteins that are also involved in platelet activation by 
immunoreceptor tyrosine-based activation motif (ITAM) receptors (Zhi et al., 2013). 
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1.3.4 Inhibition of platelet activation 
Inhibitory mechanisms are in place to prevent platelet activation on the intact 
endothelium. An important inhibitory mechanism is through generation of the 
membrane permeable gas, nitric oxide (NO); which has a short half-life and is 
continuously synthesised by endothelial cells through nitric oxide synthase (NOS) 
(Pacher et al., 2007, Naseem and Riba, 2008). Guanylyl cyclase is activated by NO 
resulting in formation of cyclic guanosine monophosphate (cGMP) which inhibits 
platelet activation (Feil et al., 2003). Platelets are also inhibited when endothelial cells 
release prostaglandin I2 (PGI2). PGI2 interacts with the platelet G protein-coupled PGI2 
receptor coupled to Gαs, causing activation, and accumulation of cAMP (Raslan and 
Naseem, 2015). cAMP and cGMP activates protein kinase A (PKA) and protein kinase 
G (PKG) respectively, leading to further phosphorylation of targeted platelet proteins, 
such as Rap1b and vasodilator stimulated phosphoprotein (VASP) (Francis et al., 2010, 
Wentworth et al., 2006). PKG also phosphorylates the IP3 receptor-associated cGMP 
kinase substrate (IRAG), which is in complex with PGK-1 and the IP3 receptor 
(Schlossmann et al., 2000). IP3- induced Ca
2+
 release is inhibited by the phosphorylation 
of IRAG and PKG-1. Another inhibitory mechanism by action of endothelial cells is 
through CD39. This is an enzyme which hydrolyses adenosine triphosphate (ATP) and 
ADP, which in turn prevents them from activating platelets through the feedback 
mechanisms (Glenn et al., 2008). 
 
Platelets also express inhibitory receptors that contain an immunoreceptor tyrosine-
based inhibitory motif (ITIM). These include platelet endothelial adhesion molecule-1 
(PECAM-1) (Dhanjal et al., 2007), G6b-B (Mori et al., 2008, Mazharian et al., 2012), 
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TREM-like transcript 1 (TLT-1) (Washington et al., 2002) and carcinoembryonic 
antigen-related cell adhesion molecule (CEACAM-1) (Wong et al., 2009).  Proteins 
containing ITIMs provide docking sites for Src homology 2 (SH2) domain–containing 
inositol-5-phosphatase-1 (SHIP-1), SH2 domain–containing protein-tyrosine 
phosphatases 1 and 2 (SHP1 and SHP2) and c-Src kinase (Csk). The two inhibitory 
phosphatases SHP1 and SHP2 dephosphorylate key proteins in platelet activation 
pathways (Senis, 2013). G6b-B is constitutively phosphorylated and inhibits 
constitutive tyrosine kinase signalling by the ITAM-containing receptors, GPVI and 
CLEC-2 (Mori et al., 2008). 
 
1.4 ITAM signalling 
An ITAM is a conserved sequence of amino acids, Yxx(L/I)x6-12Yxx(L/I), important 
for signal transduction in a range of immune and platelet receptors. ITAMs are found in 
T- cells and B-cell antigen receptors, and various Fc receptors, including FcγRI and 
FcγRIIA (Daeron, 1997). ITAMs play a critical role in the activation of Syk family 
kinases, Syk and Zap-70 (Mócsai et al., 2010).   
1.4.1 The GPVI -Fc receptor γ-chain complex  
GPVI is a type 1 transmembrane receptor of the immunoglobulin (Ig) superfamily 
(Clemetson et al., 1999). GPVI is expressed on megakaryocytes and platelets and is 
recognised as the major signalling receptor for collagen on platelets. There are between 
3700-9300 GPVI copies on the platelet surface (Burkhart et al., 2012, Best et al., 2003). 
On resting platelets, GPVI is predominately in the monomeric form, with the dimeric 
form increasing after activation (Jung et al., 2012, Loyau et al., 2012). GPVI is found in 
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association with the Fc receptor common γ-chain (FcRγ-chain), which contains one 
copy of an ITAM. The GPVI and FcRγ-chain complex was first identified by Gibbins et 
al. (1997) with further studies confirming its role as a collagen receptor in transfected 
cell lines using a NFAT-reporter assay (Tomlinson et al., 2007, Gibbins et al., 1997). 
 
GPVI activation and clustering leads to tyrosine phosphorylation of the FcRγ-chain by 
SFKs, including Fyn, Lyn and Src (Severin et al., 2012). Fyn and Lyn associate through 
their SH3 domains to a poly-proline region of the GPVI cytoplasmic tail (Suzuki-Inoue 
et al., 2002). SFK phosphorylation of FcRγ chain provides a docking site for the SH2 
domains of spleen tyrosine kinase (Syk). Syk binds to the phosphorylated ITAM and 
leads to a signalling cascade through proteins including adaptor proteins, such as the 
linker for activation of T-cells (LAT) as shown in Figure 1.3. LAT phosphorylation 
leads to the formation of a signalosome, which binds adaptor proteins Grb2 (growth 
factor receptor bound protein 2) and Gads (Grb2 related adaptor protein downstream of 
Shc), along with phospholipase C (PLC)γ2. The binding of these proteins allows the 
recruitment of SLP-76 (SH2 domain containing leukocyte protein of 76 kD), leading to 
PLCγ2 activation and Ca2+ mobilisation  (Nieswandt and Watson, 2003). Once activated 
PLCγ2 hydrolyses phosphatidylinositol-4,5 bisphosphate (PIP2). Two second 
messengers, inositol-1,4,5-trisphosphate (IP3) and 1,2-diacylglycerol (DAG) mediate 
Ca
2+
 release from intracellular stores and activation of protein kinase C (PKC), 
respectively. 
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Figure 1.3. Schematic of GPVI signalling mechanism. GPVI signalling cascade after 
stimulation with collagen, involving ITAM FcRγ-chain and the formation of the LAT 
signalosome leading to integrin activation, Ca
2+
 mobilisation and platelet activation. 
SFK: Src family kinases, ITAM: immunoreceptor tyrosine-based activation motif.   
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1.4.1.1 GPVI agonists 
GPVI is the major platelet receptor for collagen. Collagen contains glycine-proline-
hydroxyproline (GPO) helical peptide chains that activate GPVI (Knight et al., 1999). 
Synthetic peptides, including collagen-related peptide (CRP) have been developed 
which mimic collagen activity by containing GPO repeats (Smethurst et al., 2007). 
GPVI is activated by a number of different endogenous ligands, including laminin and 
extracellular matrix metalloproteinase inducer (EMMPRIN) and other 
synthetic/exogenous ligands (Inoue et al., 2006, Seizer et al., 2009, Alshehri et al., 
2015b).  GPVI can also be activated by antibodies, including JAQ1 (Nieswandt et al., 
2001) and snake venom toxins such as alborhagin, convulxin and crotarhagin (Jandrot-
Perrus et al., 1997, Polgar et al., 1997).  
 
Activation of GPVI by collagen or other GPVI agonists mentioned above is an 
important process in platelet adhesion and aggregation and can also lead to 
metalloproteolytic shedding. Deficiencies in GPVI, such as mice lacking GPVI and the 
FcRγ chain leads to defects in both adhesion and aggregation (Poole et al., 1997). 
Furthermore, mice treated with an anti-GPVI antibody to deplete GPVI display reduced 
thrombus formation in vivo using the ferric chloride injury model and with low laser 
injury (Nieswandt et al., 2001, Dubois et al., 2007). Patients with either partial or full 
GPVI deficiency are extremely rare, usually presenting with mild mucous membrane 
and skin bleeding.  In addition, their platelets show no aggregation response to collagen 
or CRP (Matus et al., 2013, Arthur et al., 2007). GPVI is also critical for maintenance of 
vessel wall integrity at sites of inflammation by sealing areas of neutrophil-mediated 
vascular damage, to reduce blood leakage (Boulaftali et al., 2013, Gros et al., 2015a). 
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1.4.2 FcγRIIa 
Another important platelet ITAM receptor, lacking in the rodent genome, is FcRIIA 
(also known as CD32A). FcRIIA a low affinity IgG receptor, belonging to the Fc 
family of receptors, which interact with IgGs. Human platelets express between 1000-
4000 copies per platelet. It contains an ITAM, similar to the FcRγ-chain with 12 amino 
acids separating the tandem YxxL sequences.  FcRIIA phosphorylation results from 
receptor clustering after binding of immune complexes, leading to platelet aggregation 
(Chacko et al., 1996, Arman et al., 2014). The association and binding of Syk leads to 
autophosphorylation and activation (Chacko et al., 1994). The main role of FcRIIA is 
in the immune response, through bacterial-induced platelet activation and binding of 
antibody coated pathogens (Cox et al., 2011, Arman et al., 2014). FcRIIA is also 
implicated in the pathogenesis of heparin-induced thrombocytopenia, through platelet 
activation mediated by antibodies clustering (Carlsson et al., 1998). 
1.4.3 CLEC-2 
C-type lectin-like receptor 2 (CLEC-2) is type II membrane receptor with a hemi 
immunoreceptor tyrosine-based activation motif (HemITAM). CLEC-2 is highly 
expressed on platelets with around 2000 copies per platelet (Gitz et al., 2014). CLEC-2 
was initially thought to be expressed on dendritic cells (DCs) and subsets of murine 
myeloid cells in resting conditions and increasingly expressed seen in various leukocyte 
subsets in response to inflammatory stimuli (Kerrigan et al., 2009, Acton et al., 2012b). 
However recent work has described a more restricted expression profile to just platelets 
and a subset of circulating inflammatory myeloid cells (Lowe et al., 2015b). 
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CLEC-2 contains a N-terminal cytoplasmic tail, a stalk region, single transmembrane 
domain and a C-terminal carbohydrate-like recognition domain (CRD), also known as a 
C-type lectin-like domain (CTLD) (Weis et al., 1998, Drickamer, 1999).  The CTLD 
does not contain key residues needed for carbohydrate binding, suggesting its ligands 
are required to bind through protein-protein interactions. CLEC-2 signals through a 
hemITAM rather than a full ITAM as it only signals by tyrosine phosphorylation of a 
single YXXL motif in the cytoplasmic tail (Suzuki-Inoue et al., 2006). Some aspects of 
CLEC-2 and GPVI signalling are similar, with signalling occurring through Src and Syk 
dependent tyrosine kinases (Hughes et al., 2010).  However, activation of Syk requires 
cross linking of two CLEC-2 receptors due to the hemITAM.  A difference between 
CLEC-2 signalling and other ITAM signalling is the hemITAM is reliant more on Syk 
rather than SFKs for the initial phosphorylation (Spalton et al., 2009, Severin et al., 
2011).  Upon CLEC-2 activation with its ligand, the hemITAM is phosphorylated, 
allowing the SH2 domain-containing Syk to be recruited. Syk then undergoes a 
conformational change, from an auto-inhibited form to an activate confirmation, before 
undergoing auto-and trans-phosphorylation by itself and SFKs. This leads to full 
activation of Syk and phosphorylation of downstream signalling proteins, resulting in 
the formation of the LAT signalosome, PLCγ2 activation and Ca2+ mobilisation, 
culminating in granule release and integrin activation (Figure 1.4).  
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Figure 1.4. Schematic of CLEC-2 signalling pathway. Upon receptor activation by 
the snake toxin rhodocytin or podoplanin, the hemITAM becomes phosphorylated by 
Syk and Src family kinases (SFK).  Syk recruitment and phosphorylation leads to 
downstream signalling events at the formation of the LAT signalosome, resulting in 
activation of PLCγ2, integrin activation and Ca2+ mobilisation.  
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Multiple studies over the years have shown that mice deficient in any of the signalling 
proteins downstream of CLEC-2, including Syk, SLP-76 and PLCγ2 exhibit 
haemorrhaging, oedema and blood-filled lymphatics during mid-gestation (Turner et al., 
1995, Bertozzi et al., 2010, Clements et al., 1999, Finney et al., 2012). There have 
however been no descriptions of CLEC-2-deficient human patients to date, potentially 
due to lethality of CLEC-2 defects in development.   
 
1.4.2.1 CLEC-2 agonists   
CLEC-2 was first identified as a platelet receptor through activation by the snake venom 
toxin, rhodocytin (Suzuki-Inoue et al., 2006). Initially it was proposed that rhodocytin-
mediated platelet activation was through integrin α2β1; however, later studies showed 
rhodocytin activation was independent of α2β1 as activation was still seen in the 
presence of a blocking antibody (Suzuki-Inoue et al., 2006). The sulphated sugar 
fucoidan and dextran sulphate can also lead to platelet activation through CLEC-2 in 
humans and mice (Manne et al., 2013, Alshehri et al., 2015b).  
 
CLEC-2 was first proposed to have an endogenous ligand through studies of platelet 
binding to HIV-1 viral particles (Chaipan et al., 2006). Chaipan et al.’s study described 
how platelets bound and internalised viral particles through a CLEC-2 and Dendritic 
Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN)-
dependent pathway (Chaipan et al., 2006).  DC-SIGN, is another C-type lectin receptor 
and was shown to bind to the viral envelope protein Env by binding to mannose sugars 
(Geijtenbeek et al., 2000). However, CLEC-2 binding was independent of Env, 
suggesting involvement of another host cell protein. Platelet aggregation occurred when 
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platelets were added to human embryonic kidney cells (HEK-293T) cells incorporated 
with HIV, suggesting the cells expressed an endogenous ligand for CLEC-2 to mediate 
aggregation (Christou et al., 2008). 
 
Podoplanin was identified as the endogenous ligand for CLEC-2 in 2007 by Suzuki-
Inoue (Suzuki-Inoue et al., 2007). Podoplanin had been shown to be expressed on 
tumour cells and was able to induce platelet aggregation when added with platelets 
(Kato et al., 2003). Suzuki-Inoue et al.’s studies went on to show podoplanin was the 
ligand for CLEC-2 following the observation that the podoplanin-expressing tumour 
cell mediated platelet aggregation with similar kinetics to rhodocytin (Suzuki-Inoue et 
al., 2007). The CLEC-2 and podoplanin interaction was confirmed using podoplanin-
expressing Chinese hamster ovary (CHO) cells and lymphatic endothelial cells (LECs) 
which also induce platelet aggregation in a CLEC-2 dependent manner (Suzuki-Inoue et 
al., 2007). The interaction between recombinant-CLEC-2 and podoplanin was shown to 
have a binding affinity (KD) of 25 µM after surface plasmon resonance was performed 
(Christou et al., 2008).  
 
Podoplanin, also known as gp38, aggrus, T1α and E11 antigen, is a 36-43 kDa type-1 
transmembrane sialoglycoprotein containing a large, heavily glycosylated extracellular 
domain, a single transmembrane domain and a short cytoplasmic tail (RKMSGRYSP 
sequence). Podoplanin consists of a transmembrane domain and an O-glycosylated 
platelet-aggregation stimulating domain (PLAG domain), which interacts with the 
CLEC-2 receptor. It has also been proposed to interact with the family of ERM (ezrin, 
radixin, moesin) proteins, through three basic amino acids in its cytoplasmic tail 
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(Martin-Villar et al., 2006). These interactions forming associations with the ERM 
proteins which increase RhoA activity demonstrating that podoplanin is also a 
signalling receptor (Martin-Villar et al., 2006).  Podoplanin was identified as the E11 
antigen on LECS in 1996 (Wetterwald et al., 1996), with the podoplanin structure being 
described on kidney podocytes in 1997 (Breiteneder-Geleff et al., 1997). Podoplanin is 
widely expressed on cells outside the vasculature including, alveolar type-1 epithelial 
cells, LECs (Schacht et al., 2003), kidney podocytes and fibroblastic reticular cells 
(FRCs) (Astarita et al., 2015). It is also upregulated under pathological conditions on T-
helper 17 (TH17 cells) (Peters et al., 2015), tumour cells (Kato et al., 2003) and 
inflammatory macrophages (Kerrigan et al., 2012). The consequences of podoplanin 
upregulation will be discussed further in Section 1.8.   
 
1.5  Platelet receptor shedding  
As previously discussed, there are multiple ways of regulating platelet receptor 
activation. Proteolytic cleavage of receptors can also regulate receptor expression and 
consequent activation. Extracellular proteolysis of receptors results in irreversible 
inactivation of receptors and can also release soluble receptor fragments into the 
plasma. Approximately 10% of all platelet receptors can be regulated by proteolytic 
cleavage, including GP1b, GPV and GPVI (Bender et al., 2016).  
1.5.1 GPVI shedding  
GPVI is one of the most intensively studied receptor that undergoes proteolytic 
cleavage. A principle mechanism for GPVI shedding in humans is through ligand-
mediated shedding. GPVI signalling has been shown to lead to proteolytic inactivation 
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of GPVI through ectodomain shedding (Qiao et al., 2010, Gardiner et al., 2004, 
Bergmeier et al., 2004, Stephens et al., 2005). GPVI shedding can occur between 
minutes and hours, depending on the conditions involved, with more powerful agonists, 
such as convulxin, inducing quicker shedding (Andrews et al., 2007). Ligand-mediated 
shedding reduces platelet reactivity in areas where there is extensive collagen exposure 
and may serve to prevent occlusive thrombus formation (Bender et al., 2016). 
Downregulation or reduced expression of GPVI has been shown to reduce the platelet 
activation response to GPVI ligands, including collagen (Snell et al., 2002, Stephens et 
al., 2005). 
 
Several non-physiological agents, including calcium ionophore, N-ethylmaleimide 
(NEM) and calmodulin inhibitors also induce GPVI shedding. NEM directly activates 
sheddases and calmodulin inhibitors, such as W7, allowing calmodulin dissociation 
from the cytoplasmic tail, thereby leading to GPVI shedding. Carbonyl cyanide m-
chlorophenylhydrazone (CCCP) can also induce GPVI shedding in mice though 
activation of sheddases (Bergmeier et al., 2004).  
 
Pathological shear stress can also induce GPVI shedding independent of platelet 
activation, also suggesting a regulatory role of shedding in preventing excessive 
thrombus formation (Al-Tamimi et al., 2012). Coagulation mediated shedding of GPVI 
through FXa activity has also been described, resulting in GPVI downregulation in 
procoagulant conditions. Furthermore, antibody-induced GPVI shedding by FcRIIA 
leads to shedding of GPVI (Rabie et al., 2007, Takayama et al., 2008), with GPVI 
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downregulation reported through shedding after treatment with anti-GPVI antibodies in 
mice (Nieswandt et al., 2001).  
 
GPVI shedding is mainly metalloproteinase-dependent.  The sheddase ADAM10 plays 
a major role in GPVI shedding, with ADAM 17 also contributing (Facey et al., 2016, 
Bender et al., 2016). ADAM10 and ADAM17 are endogenous sheddases, which are 
part of the family of a disintegrin and metalloproteinases (ADAM family) and are 
closely related to the family of matrix metalloproteinases (MMPS) (Facey et al., 2016). 
They contain a metalloproteinase domain that cleaves the receptor. In basal conditions, 
ADAMs contain an unpaired cysteine in their pro-domain, which inhibits the 
metalloproteinase domain. When ADAMs become activated, the pro-domain is 
proteolytically removed. NEM and other thiol-modifying agents can also directly 
activate the sheddases (Andrews et al., 2007). Multiple studies have shown ADAM10 to 
be the key sheddases involved in GPVI shedding. Gardiner et al. mapped the site of 
GPVI cleavage by ADAM10 and introduced mutations that prevent GPVI shedding 
(Gardiner et al., 2007). Other studies confirmed this, showing platelet ADAM10-
deficient mice do not undergo GPVI shedding after stimulation. However, these studies 
also suggested that shedding is reduced when ADAM17 is absent (Bender et al., 2010). 
ADAM17 is the main sheddase involved in GP1b shedding and plays a minor role in 
GPVI shedding in mice.  
 
Proteolytic cleavage of GPVI by the sheddases ADAM10 and ADAM17 and other 
mechanisms described, results in the release of a soluble GPVI fragment (55 kDa) into 
the plasma, leaving a remnant 10 kDa membrane bound fragment. As GPVI is only 
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found on megakaryocytes and platelets the soluble GPVI (sGPVI) fragment detected in 
the plasma can be used as a biomarker of platelet activation.  To this end, sGPVI is a 
specific platelet activation marker, which has been detected in a range of thrombotic 
disorders and is also elevated in other conditions such as Alzheimer’s disease, 
thrombotic microangiopathy and ischaemic stroke (Laske et al., 2008, Yamashita et al., 
2014b, Wurster et al., 2013). 
1.5.2 Other ITAM receptor shedding  
FcγRIIA is another ITAM receptor that can undergo cleavage. Binding of ligands such 
as antibody complexes to FcγRIIA activates calpain resulting in intracellular proteolytic 
cleavage (Gardiner et al., 2008b). Activation of FcγRIIA or GPVI can lead to shedding 
of both receptors (Gardiner et al., 2008b).  This has also been described in vivo, as 
patients with heparin induced thrombocytopenia (HIT) associated with activation of 
FcγRIIA results in elevated sGPVI levels (Qiao et al 2015). The hemITAM, CLEC-2, 
can also mediate GPVI shedding (Gitz et al., 2014), however GPVI activation cannot 
induce CLEC-2 shedding.  In mice, it is proposed that CLEC-2 is internalised (May et 
al., 2009). 
 
1.6 Platelet roles 
The major role of platelets is considered to be in haemostasis and thrombosis, and more 
recently, in maintaining vascular integrity. Over the last few years, other functional 
roles in numerous processes have been proposed including in embryonic development, 
angiogenesis and in wound healing (Bertozzi et al., 2010, Kisucka et al., 2006, Nurden 
et al., 2008). In addition, platelets play a critical role in infection and in inflammation 
(Morrell et al., 2014, Engelmann and Massberg, 2013). This section will examine the 
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different role of platelets, in particular looking at the roles associated with the 
podoplanin/CLEC-2 axis and GPVI pathways. 
1.6.1 Role of platelets in cancer 
Platelets have also been shown to contribute to cancer metastasis and facilitating tumour 
growth. Interactions between platelet receptors and ligands on tumour cells, 
predominately podoplanin and CLEC-2. Podoplanin is upregulated in a wide range of 
cancers, including colorectal adenocarcinomas (Kato et al., 2003), lung carcinomas and 
central nervous system related tumours (Kato et al., 2005, Shibahara et al., 2006a). The 
implications of podoplanin upregulation on cancer cells have yet to be fully established; 
however, roles in cell migration and presence at the tumour invasive edge have been 
proposed (Wicki and Christofori, 2006). Platelet coating of tumour cells allows 
formation of platelet/tumour aggregates, protecting tumour cells from shear stress and 
help in evasion from the immune system (Gay and Felding-Habermann, 2011, Jain et 
al., 2009). Studies using an anti-podoplanin antibody (MS-1 mAb) has given rise to 
reductions in platelet aggregation in vitro and reductions in pulmonary metastasis in 
vivo, making podoplanin a potential anti-metastatic drug target (Takagi et al., 2013). 
1.6.2 Role of platelets in infection 
Many studies have described the interactions between platelets and bacteria. Both 
Gram-negative and Gram-positive species of bacteria induce activation through a shared 
pathway that is critically dependent on FcγRIIA (Watson et al., 2016, Arman et al., 
2014). Several additional platelet receptors have been implicated in platelet-pathogen 
interactions, including Toll-like receptors (TLRs).  Platelets can also limit bacterial 
dissemination by capturing pathogens after thrombus formation (Engelmann and 
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Massberg, 2013, Morrell et al., 2014). In addition, platelets interact with viruses, 
facilitating viral capture through interactions with different receptors including TLR-9 
and CLEC-2 (Zhang et al., 2010, McCarthy et al., 2015) and mediating viral 
transmission, such as HIV  (Chaipan et al., 2006). Furthermore, CLEC-2 has recently 
been shown to be involved in bacterial-driven thrombus formation. Hitchcock et al. 
reported that the upregulation of podoplanin in livers of mice infected with Salmonella 
resulted in an inflammation-driven occlusive thrombosis, with the absence of platelet 
CLEC-2 negated thrombus formation (Hitchcock et al., 2015). 
1.6.3 Role of platelets in inflammation 
The role of platelets in the inflammatory response has been extensively studied, and in 
particular in regard to platelet adhesion to activated endothelium and to circulating 
leukocytes (Gros et al., 2015a). Platelets interact with a variety of immune cells to 
release pro-inflammatory cytokines. Platelets also have pathological roles in various 
inflammatory conditions, such as atherosclerosis and deep vein thrombosis, where they 
contribute to the initial damage to the vessel. Moreover, platelet activation is linked to 
chronic inflammatory disorders, such as rheumatoid arthritis (RA), inflammatory bowel 
disease (IBD) and in response to thermal injury and sepsis. The next section will assess 
whether platelet activation is associated with these inflammatory conditions. 
1.6.3.1 Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is a chronic systemic inflammation affecting joints which 
leads to progressive destruction of articular cartilage (Del Rey et al., 2014). Platelets 
have been implicated in this underlying damaged. Specifically, it is proposed that there 
are abundant levels of platelet microvesicles in synovial fluid which mediate pro-
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inflammatory effects (Del Rey et al., 2014, Boilard et al., 2010). GPVI signalling has 
been implicated in increasing platelet microvesicle production in RA, leading to a pro-
inflammatory response as a result of microvesicle interactions with synovial fibroblasts 
(Boilard et al., 2010). Increased CLEC-2 expression has also been observed in synovial 
arthroscopic tissue biopsies taken from RA patients (Del Rey et al., 2014). Platelet-
CLEC-2 interacts with synovial fibroblasts resulting in increased production of the pro-
inflammatory cytokines IL-6 and IL-8 (Del Rey et al., 2014). Podoplanin expression is 
also markedly increased in inflamed areas, notably on synovial fibroblast, and therefore 
may play a role in driving the inflammation (Miyamoto et al., 2013, Ekwall et al., 2011, 
Del Rey et al., 2014). 
1.6.3.2 Inflammatory Bowel Disease  
Inflammatory bowel disease (IBD) is another chronic inflammatory condition 
associated with platelet activation. IBD is a collective term for inflammatory conditions 
primarily affecting the gastrointestinal tract. The two main predominant forms of IBD 
are Crohn’s disease and ulcerative colitis (UC). Crohn’s disease is a chronic 
inflammation of the gut, mostly commonly associated with inflammation of distal end 
of the ileum in the small intestine and the colon (Pedersen et al., 2014). UC is an 
inflammatory condition mainly affecting the rectum, colon and large bowel. Both 
conditions exhibit chronic inflammation with active and non-active phases, where the 
patient experiences flare ups and times of remission. It is not established fully the direct 
cause of IBD cases or reasons for flare ups, but both genetic and environmental causes 
have been proposed (Ponder and Long, 2013).  Platelets have been shown to have roles 
in IBD as many patients present with several abnormalities in platelet dysfunction, 
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including smaller mean corpuscular volume and increased chronic activation (Giannotta 
et al., 2015, Jaremo and Sandberg-Gertzen, 1996)   
Iron deficiency anaemia is common clinical complication arising in IBD, with around 
15-20% of IBD patients developing iron deficiency anaemia with increasing prevalence 
(up to 60%) when taking into account hospitalised patients (Guagnozzi and Lucendo, 
2014, Bergamaschi et al., 2010). Iron deficiency can also affect disease severity in IBD 
patients. Chronic intestinal bleeding often occurs at inflamed sites and is a potential 
explanation for the iron-deficiency that develops, with platelet activation and 
thrombocytosis described during periods of intestinal inflammation (Voudoukis et al., 
2014). Platelet activation may occur to maintain haemostasis and vascular integrity in 
inflamed areas.  
1.6.3.3 Thermal injury 
A major inflammatory response is observed in patients with thermal burn injuries. 
Platelet activation is commonly seen due to the excessive tissue damage. In a study of 
244 patients with thermal injuries, Marck et al. reported a substantial drop in platelet 
count at day 3 post injury with rebound thrombocytosis at day 15.  Interestingly, lower 
platelet counts observed at day 3 and 15 were associated with poor patient outcomes 
(Marck et al., 2013). It is currently unknown if this drop in platelet count results from 
platelet consumption or reduced platelet formation. Measurement of a platelet activation 
marker at these early time points could indicate the degree of platelet activation and 
potentially disease prognosis.  
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1.6.3.4 Sepsis  
Sepsis is described as a majorly exaggerated systemic immune response in the response 
to pathogens, mainly bacterial infections such as Klebsiella pneumoniae. Sepsis is a 
devastating condition which can often result in mortality, even with aggressive 
antibiotic treatment (Angus and van der Poll, 2013). Sepsis has an estimated incidence 
of 19 million cases worldwide per year (Adhikari et al., 2010, Proudfoot and Summers, 
2014). Sepsis development can result from many conditions including acute lung injury 
and is a critical complication of thermal injury due to the vast amounts of tissue damage 
causing increased susceptibility to bacterial infection. Although advancements in the 
treatment of initial thermal injury have been greatly improved, sepsis development and 
associated mortality remains a major challenge for recovery (Mann et al., 2012).  
Clinical diagnosis of sepsis is very difficult and prolonged with many criteria needing to 
be met. The diagnosis of the causative pathogen can also become difficult with positive 
blood cultures being required. Sepsis diagnosis criteria can also be masked by the 
systemic inflammatory response syndrome (SIRS) that can also develop in these 
patients (Levy et al., 2003). An effective biomarker with a strong predictive value 
would enable rapid treatment and thus lead to a reduction in mortality.  
 
Sepsis is also strongly associated with thrombocytopenia (Sharma et al., 2007). 
Thrombocytopenia is a common clinical presentation in critically ill patients who go 
onto develop sepsis and can impair the patient’s response to infection and lead to 
increased mortality (Claushuis et al., 2016). This has also been shown in mice, for 
example where thrombocytopenia impaired the host response to Klebsiella pneumoniae 
infection, leading to enhanced bacterial growth in the blood and lungs (de Stoppelaar et 
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al., 2014). These studies illustrate that platelets have a potential role in host defence 
against pathogens and sepsis development.  
1.6.4.5 Other inflammatory conditions  
Platelets are also implicated in multiple sclerosis (MS); an auto-immune inflammatory 
disorder affecting the brain and central nervous system as a result of demyelination. 
Studies have shown the interaction of CLEC-2 and podoplanin can have a positive 
effect on the resolution of inflammation (Peters et al., 2015). Platelets have also 
described to contribute to the initial damage to the vascular wall that leads to the onset 
of atherosclerosis and in deep vein thrombosis (Huo et al., 2003, Lindemann et al., 
2007, Nieswandt et al., 2005, Brill et al., 2012). The CLEC-2 ligand is expressed in 
atherosclerotic plaques with the level of expression correlating with plaque severity 
(Hatakeyama et al., 2012).  
 
1.7 Role of platelets in trauma  
Trauma is the leading cause of death in people under 40 in the UK (NCEPOD, 2007). 
The leading cause of mortality in trauma is through excessive bleeding, although a large 
number of other factors are also associated, including coagulation defects and severe 
inflammation. Together these lead to multi-organ failure (MOF). Trauma research over 
recent years has produced several acute treatment therapies to prevent excessive blood 
loss and thereby save lives. However, there is now a focus on therapeutic developments 
targeting a wide range of secondary complications resulting from different severity and 
types of trauma, including amplified inflammation and MOF. Platelets have been 
described to have a role in activating the innate immune response through antigen 
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recognition and presentation to immune cells. Platelets may also play a role in the 
increased immune response, resulting in the initiation of SIRS and increased mortality. 
1.7.1 Systemic inflammatory response syndrome (SIRs) 
SIRS is a substantially amplified inflammatory response that can lead to tissue damage, 
MOF and mortality.  A dynamic inflammatory response after trauma is usually required 
for tissue repair and regeneration (Hirsiger et al., 2012). However, after severe trauma, 
the release of inflammatory mediators and cytokine production is exaggerated causing 
an excessive, tissue-damaging inflammatory response and SIRS  (Hirsiger et al., 2012). 
The causes of the amplified inflammatory are now being studied extensively, with 
danger associated molecular pattern molecules (DAMPs) and Alarmins proposed to be 
key players.  
1.7.2 Alarmins and DAMPs  
Danger Associated Molecular Pattern molecules (DAMPs) are danger signals released 
from stressed or damaged cells. Mazinger (1994) was the first to describe the danger 
theory where host cells recognise and respond to danger signals released from the 
body’s own cells, and it is now believed that this may give rise to its own cells and has 
become the basis of how SIRS may develop (Matzinger, 1994). DAMPs are proposed as 
the host’s version of Pathogen Associated Molecular Pattern molecules (PAMPs). 
PAMPs are microbial-derived molecules that are recognised by pattern recognition 
receptors (PRRs), such as TLRs, which upon binding their ligands, cause activation of 
the innate immune response in order to destroy the pathogen. DAMPs are believed to 
initiate the immune response in a similar way but without the presence of a 
pathogenic/microbial agent. SIRS therefore develops after release of DAMPs resulting 
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in enhancement of cytokine production and immune system activation under sterile 
conditions. Alarmins are a subset of endogenous DAMPs that are elevated in response 
to trauma.  They can remain at high levels for days after initial trauma. Alarmins bind to 
corresponding Alarmin receptors inducing intracellular signalling pathways eliciting the 
pro-inflammatory response described above (Manson et al., 2012).  
1.7.3 Nuclear-related Alarmins  
Nuclear-related Alarmins are nuclear protein and material released after damage to the 
nucleus. These include DNA, high-mobility-group-box-1 protein (HMGB-1), 
nucleosomes and histones. 
1.7.3.1 Histones  
Histones are highly positively charged nuclear proteins with an important role in DNA 
organisation and chromatin formation (Doenecke and Albig, 2001).They are a main 
component of Neutrophil Extracellular Traps (NETs; discussed in Section 1.7.3.3), and 
can be released into the circulation having been released after nucleosomes breakdown.  
Histones can be elevated 200 fold in trauma patients, reaching levels in the order of 250 
μg/ml. There are four main histone proteins, H2A, H2B, H3 and H4, with H3 and H4 
having the greatest effect on cells.  Histones have multiple effects on many cell types, 
including vascular endothelial cells, resulting in cytokine activation and thrombin 
generation (Semeraro et al., 2011). Histones are extremely cytotoxic and elevated 
histones levels have been reported to induce acute lung injury (Abrams et al., 2013). 
1.7.3.2 High-mobility-group-box-1 (HMGB-1)  
Another nuclear related Alarmin, HMGB-1 interacts with other nuclear proteins to 
regulate DNA organisation and gene transcription. HMGB-1 levels have been measured 
in a range of inflammatory conditions, including sepsis (Klune et al., 2008) and has 
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been shown to be elevated 30 fold after trauma (Park et al., 2004). HMGB-1 has been 
described to signal through a variety of receptors from TLRs to Receptor for Advanced 
Glycation Endproducts (RAGE) to activate immune cells. Interactions between HMGB-
1 and TLR-4 have also been shown to promote NET formation (Tadie et al., 2013). 
HMGB-1 has been described to promote inflammatory cell recruitment to damaged 
areas via forming complexes with CXCL12, which change the conformation of CXCR4 
leading to signalling and recruitment (Schiraldi et al., 2012).  HMGB-1 has been 
described to have many inflammatory roles through a variety of mechanisms, however 
the role of HMGB-1 in platelet activation has yet to be established. 
1.7.3.3 DNA 
Released after cell damage, cell free-DNA is present in the plasma of patients and is a 
marker of disease, including sepsis (Hampson et al., 2016). Although DNA can be 
released from different immune cells, neutrophils have been the predominate source of  
DNA studied due to the release of NETS through a process known as NETosis (Yipp et 
al., 2012) NETs are made up of extracellular DNA, serine proteases and anti-microbial 
molecules which play a critical role in trapping and elimination of bacteria (Brinkmann 
et al., 2004). Long extracellular extrusions are the main structure of NETs giving the 
possibility for platelets to adhere to the NETs and undergo activation (Fuchs et al., 
2010). Platelets have been shown to be activated by NETs (Fuchs et al. 2010), but the 
underlying mechanism remains unclear. 
1.7.3.4 Mitochondrial DNA (MtDNA)  
DNA released from mitochondria following damage has been shown to be elevated in 
the plasma of trauma patients and to remain elevated for up to 24 hours (Zhang et al., 
2010). MtDNA has been shown to increase endothelial permeability during systemic 
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inflammation (Sun et al., 2013) and to be associated with acute lung injury (Hauser et 
al., 2010). The effect of MtDNA is believed to be due to its close evolutionary 
relationship with bacterial DNA, with similar CpG DNA repeats (Zhang et al., 2010). 
MtDNA activates many of the same receptors as bacterial DNA, including TLR-9, 
which is expressed in platelets. 
1.7.4 Oxidised low density lipoprotein (OxLDL) and Advanced Glycation 
End Products (AGE) 
AGE are glycated proteins that have undergone protein modifications and are 
implicated in conditions such as diabetes and atherosclerosis (Goldin et al., 2006). 
Studies by Zhu et al. suggested AGE gives a prothrombotic phenotype, enhancing 
platelet reactivity through CD36 signalling (Zhu et al., 2012). OxLDL, a lipid-based 
DAMP, has been associated with hyperlipidaemia and site of atherosclerotic lesions 
(Matsuura et al., 2008). OxLDL forms after lipids and apolipoprotein B (apoB) 
components undergo lipid per oxidation (Stewart et al., 2005). It has been proposed that 
Alarmins, such as AGE and OxLDL, may not induce platelet aggregation directly but 
may modulate platelet responses to other agonists. 
1.7.5 Alarmin receptors  
A large number of Alarmin receptors have been characterised, including TLRs, formyl 
peptide receptor (FPR1), heat shock protein receptors (HSPR) and the ATP receptor, 
P2RX7. Platelets express a number of Alarmin/DAMP receptors which support a pro-
inflammatory response. The direct signalling mechanisms behind Alarmin-induced 
platelet activation however have yet to be fully established.  The main Alarmin receptor 
type recognised as potential platelet Alarmin receptors are TLRs.  
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1.7.5.1 TLRs  
TLRs are a family of receptors involved in host defence against pathogens, which 
recognise PAMPs, activating the immune response (Cognasse et al., 2005) . Eleven 
TLRs have characterised with functional roles, with TLR2, TLR4 and TLR9 having 
been described on the platelet surface (Cognasse et al., 2005). TLR2 and TLR4 have been 
shown to have roles in recognition of bacterial-derived molecules. Platelet TLR4 is also 
associated with platelet-neutrophil interactions (Clark et al., 2007) and with NET 
formation. As discussed above, TLR9 has been shown to recognise bacteria DNA and 
MtDNA. TLR signalling in platelets has been proposed to involve NF-kB/TRIF/Myd88 
signalling cascades but a full understanding of the mechanisms between TLR activity 
and platelet activation has yet to be fully established, in part because of their low levels 
and that of their signalling proteins  (Garraud and Cognasse, 2010). 
1.7.5.2 CD36 (GPIIIb) 
The class B scavenger receptor CD36 has been proposed as a potential DAMP receptor. 
CD36 is expressed on the platelet surface with a copy number of 20,000 per platelet 
(Saboor et al., 2013). It is the major receptor involved in OxLDL signalling and has also 
been shown to bind microparticles (Ghosh et al., 2008).  CD36 also supports long-chain 
fatty acid transport (Su and Abumrad, 2009)  CD36 has been implicated in 
atherosclerosis, hyperlipidaemia, and insulin insensitivity in diabetes mellitus  (Podrez 
et al., 2007). CD36 may also play a role in sterile inflammation through formation of a 
CD36-TLR4-TLR6 heterotrimer (Stewart et al., 2005). However, the CD36 signalling 
mechanism has yet to be fully established. 
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1.7.5.3 Receptor for Advanced Glycation Endproducts (RAGE) 
The 35kDa scavenger receptor, RAGE, is expressed at low levels on endothelial cells 
and leucocytes cells but upregulated at sites of inflammation sites RAGE has been 
shown to interact with AGE and to contribute to persistent NF-κB activation potentially 
leading to hyperglycaemia in patients with diabetes (Bierhaus and Nawroth, 2009). 
RAGE is located on platelets and is proposed to be a receptor for HMGB-1 in 
inflammation and cancer (Sims et al., 2010).  
 
1.8 The role of platelets in vascular integrity 
1.8.1 Other cell interactions in inflammation and vascular integrity  
Platelets play a critical role in the maintenance of vascular integrity during development 
and at sites of inflammation. Vascular integrity is maintained through the interactions 
with endothelial cells. As previously mentioned (section 1.4.2), CLEC-2 has been 
shown to maintain integrity of the cerebrovasculature in mid-gestation through 
association with podoplanin (Lowe et al., 2015a). The GPVI/ FcRγ-chain complex has 
been shown to maintain vascular integrity in inflamed blood vessels by opposing the 
action of neutrophils (Gros et al., 2015a). This extends an earlier study that reported 
critical roles for CLEC-2 and GPVI-FcR γ-chain in prevention of bleeding at sites of 
inflammatory challenge (Boulaftali et al., 2013). 
 
Podoplanin undergoes marked up-regulation at sites of inflammation (Ekwall et al., 
2011, Astarita et al., 2012b) . The consequences of podoplanin upregulation however, 
seems to vary depending on the type of inflammation and cell types that are involved, 
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with the podoplanin/CLEC-2 interaction sometimes being beneficial and on other 
occasions promoting inflammation. Podoplanin upregulation has been observed on 
fibroblastic reticular cells (FRCs), with the interaction between CLEC-2 on platelets 
and podoplanin on FRCs being shown to underlie lymph node expansion (Astarita et al., 
2015). In addition, maintenance of lymph node high-endothelial venule (HEV) integrity 
requires platelet-expressed CLEC-2 and podoplanin-expressed FRCs; absence of either 
leads to the appearance of blood-filled lymph nodes (Herzog et al., 2013). In a mouse 
model of autoimmune encephalomyelitis, upregulation of podoplanin on TH17 cells is 
associated with their inhibition, leading to improved recovery (Miyamoto et al., 2013). 
Likewise, podoplanin expressed on fibroblastic macrophages, a F4/80
+
 subtype 
macrophage found in the red pulp of the spleen, is upregulated in response to zymosan 
induced peritonitis and this upregulation leads to increased phagocytosis (Hou et al., 
2010). On the other hand, upregulation of podoplanin on inflammatory macrophages or 
upregulation on tumour cells can lead to platelet aggregation and thrombosis (Kerrigan 
et al., 2012, Jain et al., 2009). Upregulation of podoplanin on liver macrophages (F4/80
+ 
cells) of Salmonella-infected mice triggers CLEC-2-mediated thrombosis (Hitchcock et 
al., 2015). The consequence of podoplanin upregulation on human cells however is not 
known.   
1.8.2 Role of platelets in wound healing 
Platelets have been shown to play critical roles in wound healing, most notably during 
the immediate response to injury through formation of a vascular plug and prevention of 
excessive blood loss. The formation of the thrombus also provides a matrix scaffold for 
recruited cells to infiltrate the damaged area (Li et al., 2007). Platelets release a number 
of chemo-attractants and growth factors, including both pro-angiogenic and anti-
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angiogenic proteins, various growth factors including, platelet-derived growth factor 
(PDGF), transforming-growth factor-β (TGF-β), and chemo-attractants such as platelet 
factor 4 (PF4) which act to recruit immune cells (Li et al., 2007). The platelet releasate 
has been shown to increase the rate of granulation and to promote tissue granulation; 
involving fibroblast proliferation, deposition of extracellular matrix (ECM) proteins and 
new blood vessel formation (Li et al., 2007).  The range of cytokines and growth factors 
released help to increase the rate of granulation and promote tissue granulation (Ksander 
et al., 1990a, Li et al., 2007). 
 
Relatively few studies however have investigated the effect of platelet depletion 
immediately following wound injury because of their critical role in the haemostatic 
process. This question can be addressed through the targeted deletion of platelet 
proteins implicated in wound repair but not the haemostatic process such as CLEC-2.  
For example, the critical role of CLEC-2 in maintenance of vascular integrity as shown 
in the reverse passive Arthus (rpA) reaction model (Boulaftali et al., 2013) may also 
translate to a role in wound repair. Additionally, platelet CLEC-2 has also been shown 
to regulate migration of keratinocytes in vitro and this may be important at all stages of 
wound healing (Asai et al., 2016). The role of platelets in wound healing may play a 
critical role in the context of trauma which leads to a reduction in platelet count as 
described above. 
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1.9 Aims of the thesis  
Platelet activation is associated with many aspects of trauma and inflammation, from 
initial damage and associated bleeding and the resulting release of Alarmins and 
platelet-activating mediators, to platelet activation occurring post injury during a 
recovery phase and development of secondary complications. Furthermore, platelets 
also play a role in the maintenance of vascular integrity that may also be important in 
the wound healing process. While, many of these roles have been described, we still 
have a rudimentary understanding of the role of platelets in trauma and other 
inflammatory conditions, and also in wound repair, as well as the underlying 
mechanisms of platelet activation and interactions with other cells in these processes.  
In this thesis, the overall aim is to further our understanding of the regulation and role of 
platelets in trauma and in inflammation and to identify a soluble marker of platelet 
activation that correlates with disease progression.  The specific aims are:  
1) To investigate the effect and underlying mechanisms of DAMPs and nuclear-
related Alarmins on platelet function and activation in vitro and in vivo. 
2) To investigate whether the product of the proteolytic cleaving of GPVI in the 
plasma, known as soluble GPVI, as a marker of platelet activation and disease 
pathogenesis in trauma and other inflammatory disorders. 
3) To study the functional consequence of upregulation of podoplanin on 
inflammatory macrophages and to measure the levels of podoplanin and in 
trauma and in inflammatory diseases. 
4) To investigate the role of GPVI and CLEC-2 on platelets and podoplanin on 
wound repair. 
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1. Materials  
2.1.1. Antibodies and reagents  
Details of the agonists, antagonists and inhibitors and cytokines used in the course of 
this thesis ae listed in Tables 2.1, 2.2 and 2.3, respectively. Table 2.4 lists the antibodies 
used. If unstated, materials used were from Sigma (Poole, UK).  
Table 2.1 Agonists 
Reagents used  Source  
Advanced Glycation End Product (AGE)-
BSA 
Biovision (San Franciso, USA) 
Calf thymus histones (CTH) Worthington Biochemical Corporation 
(Reading, UK) 
Collagen (Kollagen Reagens HORM 
suspension) 
Takeda (Linz, Austria)  
Collagen related peptide (CRP) Dr R.W. Farndale (Cambridge University, UK) 
Glycoaldehyde-AGE-BSA Cell Biolabs, INC (San Diego, USA) 
Oxidised Low Density Lipoprotein 
(OxLDL) 
Source Bioscience LifeSciences (Nottingham, 
UK) 
PAR-1 Peptide (SFLLRN) AltaBioscience (Birmingham UK) 
PAR-4 Peptide (AYPGKF) AltaBioscience (Birmingham UK) 
Rhodocytin Dr. J.A. Eble (University of Münster 
 
Table 2.2 Antagonists and inhibitors 
Reagents used  Use Source  
DAPT γ-secretase inhibitor Sigma (Poole, UK) 
Dasatinib Src and Bcr/Abl 
inhibitor 
LC Laboratories (Woburn, MA). 
44 
 
GI254023 ADAM10 inhibitor Sigma (Poole, UK) 
GM6001 Broad MMP inhibitor Calbiochem (San Diego, USA) 
Hirudin Thrombin inhibitor Sigma (Poole, UK) 
Prostacyclin (PGI2) Platelet inhibitor Cayman Chemicals (Cambridge, 
UK) 
PRT060318 Syk inhibitor Portola Pharmaceuticals Inc (San 
Francisco, CA). 
 
Table 2.3. Recombinant Cytokines (human) 
Reagents used  Use Concentration  Source  
GM-CSF Pro-inflammatory  50 ng/ml PeproTech (New Jersey, 
USA) M-CSF Anti-inflammatory 100 ng/ml 
 
Table 2.4. Antibodies  
Antibody  Host 
species  
Use* Source  
PRIMARY     
204-11 Fab (GPVI dimer 
monoclonal antibody)  
Mouse  FC: 1/20  
25 µg/ml 
Dr S. Jung (Cambridge, UK) 
β-Tubulin (human) Mouse  WB: 1/2000  Sigma (Poole, UK) 
CLEC-2 (human) Goat IP: 2 µg/ml R+D Systems (Abingdon, 
UK) 
CLEC-2 (human) AYP1   Mouse  IP: 2 µg/ml Dr A. Pollitt (Reading, UK) 
CD62-P (P-selectin: 
human) 
Mouse FC: 1/100 BD Biosciences (Oxford, 
UK) 
CD45- APC (human) Mouse  FC: 1/100 Beckman Coulter 
(California, USA) 
CD38- FITC Mouse  FC: 1/100 EBioscience (Hatfield, UK) 
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CD66b-PerCP Mouse  FC: 1/100 EBioscience (Hatfield, UK) 
CD41-PE Mouse  FC: 1/100 EBioscience (Hatfield, UK) 
GPVI (human) polyclonal 
Ab -  
Rabbit ELISA: 1 μg/ml Dr E. Gardiner (Canberra, 
Australia) 
1A12 (human: GPVI 
monoclonal Ab) 
Mouse  ELISA: 1 μg/ml Dr E. Gardiner (Canberra, 
Australia 
PLCγ2 sc-407 Rabbit IP: 1/500 
WB: 1/1000 
Santa Cruz Biotechnology 
(Heidelberg, Germany) 
Phosphotyrosine (4G10)  
 
Mouse  WB: 1/1000 Millipore (Bucks, UK) 
Podoplanin NZ-1.3 
(human) – PE and 
Unconjugated  
Rat  FC: 1/100 
ELISA: 1& 5 
µg/ml 
WB: 5 µg/ml 
EBioscience (Hatfield, UK) 
IgG2a κ Isotype control) – 
PE and Unconjugated 
Rat FC: 1/100 
ELISA: 1& 5 
µg/ml 
WB: 5 µg/ml 
EBioscience (Hatfield, UK) 
Podoplanin 18H5 Mouse  FC: 1/100 
ELISA: 1& 5 
µg/ml 
WB: 5 µg/ml 
Santa Cruz Biotechnology 
(Heidelberg, Germany) 
Novus Biologicals 
(Colorado, USA) 
Podoplanin/gp36 
(ab109059) 
Rabbit FC: 1/400 
 
Abcam (Cambridge, UK) 
Podoplanin 8.1.1 - mouse Syrian 
hamster 
IH: 1/500 M.Goodall (Birmingham, 
UK) 
Podoplanin (mouse – 
monoclonal) 
Syrian 
hamster 
IH: 1/500 EBioscience (Hatfield, UK) 
Rabbit IgG – polyclonal - 
isotype control 
 FC: 1/400 Abcam (Cambridge, UK) 
Syk Rabbit IP: 1/500 Dr M.G. Tomlinson 
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 (Birmingham, UK) 
Syk-sc1077 Rabbit  WB: 1/200 Santa Cruz Biotechnology 
(Heidelberg, Germany) 
Syk-sc-573 Rabbit IP: 1/500 Santa Cruz Biotechnology 
(Heidelberg, Germany) 
SECONDARY    
Hamster IgG HRP 
conjugated - sc-2905 
Goat IHC: 1/500 Santa Cruz Biotechnology 
(Heidelberg, Germany) 
Mouse IgG, F(ab')2 
Fragment Specific -AF647 
Goat  FC: 75 µg/ml Stratech Scientific Ltd 
(Newmarket, UK) 
Mouse IgG HRP conjugate  
 
Sheep WB:1/1000 Amersham Bioscience 
(Bucks, UK) 
Mouse IgG HRP conjugate Rabbit ELISA: 2.6 μg/ml Dako (Denmark) 
Rabbit IgG HRP conjugate  
 
Donkey  WB:  1/10000 Amersham Bioscience 
(Bucks, UK) 
Rat IgG HRP conjugate  
 
Goat ELISA: 2.6 µg/ml  
WB:  1/10000 
Dako (Denmark) 
 
*IP:  Immunoprecipitation, WB:  Western Blot, FC:  Flow cytometry, ELISA: Enzyme-
linked immunosorbent assay, AF: Alexa Fluor®, IHC: Immunohistochemistry 
2.1.2. Constructs and plasmids  
The following constructs and plasmids were used for CLEC-2 and GPVI transfections 
into cells for NFAT-luciferase assays as previously described (Tomlinson et al., 2007). 
Human CLEC-2 sub-cloned into pEF6 vector with a C-terminal Myc tag, human GPVI 
in pcDNA3 with a C-terminal Myc tag and human FcRγ (untagged) in pEF6 were made 
in the lab (Fuller et al., 2007, Berlanga et al., 2007). The nuclear factor of activated T-
cells (NFAT)-luciferase reporter containing three copies of the distal NFAT site from 
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the IL-2 promoter as described in (Shapiro et al., 1997) was donated from Prof A. Weiss 
(UCSF School of Medicine, USA).   
 
2.1.3. Recombinant proteins  
Recombinant human GPVI was obtained from Dr Andrew Herr (Cincinnati Children's 
Hospital Medical Center, USA). The dimeric form of GPVI was fused with human Fc 
immunoglobulin (GPVI-Fc2), as described (Miura et al., 2002). 
Recombinant human Pdpn (rPdpn) was obtained with a non-cleavable C-terminal His-
tag from M. Hoellerer (Oxford, UK).   
 
2.1.4. Transgenic mice  
All animal experimentation was performed in accordance to licenses PPL30/2721, PPL 
70/8359 and PPL 70/8286. Gp6
-/-
 mice and Clec1b
fl/fl;PF4-Cre 
used in Chapter 3 have been 
previously been described (Kato et al., 2003, Finney et al., 2012). GPVI and CLEC-2 
double deficient mice (Gp6
-/-
;Clec1b
fl/fl;PF4-Cre
) were produced by crossbreeding the two 
strained. Clec1b
fl/fl
 or C57BI/6 were used as wild type (WT) controls. For wound 
healing studies in chapter 5, Gp6
-/-,
 Clec1b
fl/fl;PF4-Cre 
, Gp6
-/-
;Clec1b
fl/fl;PF4-Cre 
, 
Pdpn
fl/fl
VAV-1
-Cre 
were used and compared to C57BI/6, WT1F- ER
T2Cre-  
and ROSA
-EYFP
, 
as WT controls.  
 
2.2. Blood Collection  
2.2.1. Human blood collection 
Healthy control (HC) donors: Ethical approval for blood donation from healthy 
volunteers was granted by Birmingham University Internal Ethical Review (ERN_11-
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0175). Venous blood was collected from consenting, healthy drug free volunteers. 
Blood was drawn in to sodium citrate (4% citrate 1:9 ratio) or in 3.2% trisodium citrate 
BD vacutainers (Becton Dickinson, Oxford, UK) depending on corresponding patient 
group tested. For some experiments blood was drawn into EDTA, Hirudin or Lithium 
Heparin BD Vacutainers or S-Monovettte hirudin vacutainers (SARSTEDT, Germany). 
On occasions blood was drawn into hirudin (50 µg/ml, REVASC) or sodium heparin 
(10 U/ml, Heparin (mucous) injection BP).  
Rheumatoid arthritis (RA) patients:  Blood was collected into 3.2% trisodium citrate BD 
vacutainers (Becton Dickinson, Oxford, UK), obtained from patients with rheumatoid 
arthritis under informed consent approved by the local ethics committee (071Q270612) 
(Gitz et al., 2014). All patients with rheumatoid arthritis satisﬁed the 1987 American 
College of Rheumatology criteria for rheumatoid arthritis and clinical details are stated 
in Gitz et al. (2014) and Arnett FC (1988)(Arnett et al., 1988, Gitz et al., 2014). 
Inflammatory Bowel Disease (IBD) patients: Blood was collected into 3.2% trisodium 
citrate BD Vacutainers from 42 patients with inactive or active Crohn’s disease and/or 
ulcerative colitis. IBD disease activity state was based on specialist diagnosis, 
determined by clinical records, endoscopy results and C-reactive protein levels. Clinical 
parameters and full blood counts were collected from routine hospital measurements 
and with the Sysmex XN-1000-Hematology Analyzer (Sysmex UK, Milton Keynes, 
UK). 
Thermal injury patients: Patients with thermal injury were admitted to the Queen 
Elizabeth Hospital Birmingham Burns Centre and recruited to the Scientific 
Investigation of the Biological Pathways Following Thermal Injury Study (SIFTI - 
REC:12/EM/0432). For patient recruitment details and parameters see Table 4.2 and 
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(Hampson et al., 2016). Blood samples were collected into 3.2% trisodium citrate BD 
Vacutainers at intervals following injury (day 1 [< 24 h post-injury], day 3 [+/- 1 day], 
day 7 [+/- 1 day], day 14 [+/- 3 days], day 21 [+/- 3 days], day 28 [+/- 3 days], month 2 
[+/- 3 days], month 3 [+/- 7 days], month 6 [+/- 7 days] and month 12 [+/- 7 days]. 
Patients were categorised into septic or non-septic groups based on fulfilling at least 
three American Burn Association sepsis criteria (Greenhalgh et al., 2007) with a 
positive culture or response to antibiotics as stated in Hampson et al. (2016). Platelet 
counts were initially measured using the Beckman Coulter UniCel DxH 800 Cellular 
Analysis System followed by the Sysmex XN-1000-Hematology Analyzer (introduced 
mid-way through the study). Both analyzers measured platelet impedance.  
Sepsis patients: Blood was collected into 3.2% trisodium citrate or Lithium Heparin BD 
Vacutainers from patients from the intensive care unit (ITU) and respiratory wards at 
the Queen Elizabeth Hospital Birmingham. Samples were donated by Dr D. Thickett 
(University of Birmingham, UK) under the ethics of different septic studies including 
BALTI (β-Agonist Lung Injury Trial: see (Perkins et al., 2006)) and SNOOPI 
(Simvastatin to modify neutrophil function in older patients with septic pneumonia: see 
(Greenwood et al., 2014)). 62 septic patients with different sepsis forms, including 
severe sepsis, patients with acute respiratory syndrome (ARDS) and 22 aged matched 
HCs were obtained. 
 
2.2.2. Mouse blood collection  
For basal blood counts, samples were taken from the tail vein 100 μl EDTA (20 mM). 
Platelet counts were measured by the ABX Pentra60 haematology counter (HORIBA 
Scientific, UK). For platelet studies, blood was obtained by terminal cardiac puncture. 
50 
 
Blood was taken from the vena cava of CO2-asphyxiated mice anaesthetised with 
isoflurane and collected into 1:9 (v:v) acid citrate dextrose (ACD – 120 mM sodium 
citrate, 110 mM glucose, 80 mM citric acid), 4% citrate (1 in 9)  in Modified Tyrode’s 
buffer (134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20 mM 
HEPES(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 5 mM glucose, and 1 mM 
MgCl2; pH 7.3) or where stated, hirudin (50 µg/ml). 200 µl of Modified Tyrode’s buffer 
was added to samples post collection before further processing.  
 
2.3. Human Platelet preparation  
2.3.1. Platelet Rich Plasma  
Anti-coagulated blood was centrifuged for 20 min at 200 g at room temperature (RT) 
using a Sanyo Harrier 18/80 centrifuge. Blood was separated and the top layer of 
platelet-rich-plasma (PRP) was extracted, avoiding the buffy coat layer.  Platelet-Poor-
Plasma (PPP) was obtained following a 10 min centrifugation spin of remaining blood 
at 1000 g to use as a blank for light transmission aggregometry (LTA). Collected 
platelet concentrations were determined by the Coulter Zcs counter (Beckman Coulter 
Ltd, High Wycombe, UK). 
 
2.3.2. Washed platelet preparation   
Washed platelets were prepared by adding 10% acid citrate dextrose (ACD) to citrated 
blood before centrifugation at 200 g for 20 min. The top layer of PRP was removed, 
avoiding the buffy coat layer. Prostacyclin (PGI2; 1 µg/ml) was added to PRP before 
centrifugation at 1000 g for 10 min. The supernatant was discarded and the platelet 
pellet was resuspended in Modified Tyrode’s buffer (with 5 mM glucose, and 1 mM 
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MgCl2; pH 7.3). The pellet was then washed in Modified Tyrode’s buffer containing 
ACD and PGI2 (1 µg/ml) and again centrifuged at 1000 g for 10 min. The washed 
platelets were then resuspended to the required platelet concentration; 2x10
7
/ml for flow 
cytometry and platelet spreading, 2x10
8
- 5x10
8
 platelets/ml for aggregation and 5x10
8
- 
1x10
9 
platelet/ml for lysate preparation (unless otherwise stated).  Washed platelets 
were rested for 30 min before experiments. 
 
2.3.3. Plasma preparation  
Platelet-free-plasma was obtained from anti-coagulated blood of patients and HCs after 
two centrifugation steps. For the thermal injury patients, blood was centrifuged at 2000 
g for 20 min. The supernatant isolated was centrifuged again at 13 000 g for 20 min 
(Hampson et al. 2016). For all other patient cohorts and HCs, blood was centrifuged 
twice at 2500 g for 15 min at RT with no brake. The supernatant from the first 
centrifugation step was isolated and placed into a new tube before the second 
centrifugation step. Supernatants were used for experiments or frozen in aliquots for 
storage at -80
o
C. Plasma from septic patients and HC cohort were obtained after 
centrifugation at 560 g for 10 min at RT. To compare the different centrifugation 
protocols, HC plasma was also obtained in this manner.  
 
2.3.4. Microvesicle preparation  
Microvesicles were isolated from double centrifuged plasma (double spun plasma) after 
whole blood (taken in either citrate or EDTA) was centrifuged twice at 2500 g for 15 
min at RT (no brake). Supernatants from the first centrifugation were extracted into a 
new tube before the second centrifugation step. 
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2.4. Cell isolation from blood  
2.4.1. Peripheral blood mononuclear cells (PBMC) isolation  
Isolation of PBMCs and other blood cells were performed in a laminar flow hood under 
sterile conditions and cells were incubated in Sanyo MCO-17AIC CO2 incubators. 
Citrated blood was centrifuged at 200 g for 20 min to deplete platelets. The remaining 
blood was diluted 1/5 in complete media (RPMI; Gibco life technologies, supplemented 
with 10% foetal bovine serum (FBS; 100 U/mL penicillin, 100 μg/mL streptomycin and 
2 mM L-glutamine) and placed on a ficoll-paque PLUS (GE Healthcare, Bucks, UK) 
gradient and centrifuged for 400 g for 30 min RT. The top plasma layer was removed to 
access the PBMC ring. PBMCs were extracted and washed twice in complete RPMI by 
centrifugation for 10 min at 300 g. RPMI was removed to leave cell pellet. Cells were 
resuspended in 1 ml of complete RPMI, counted and diluted to required concentrations.  
 
2.4.2. Monocyte isolation and monocyte-derived macrophage differentiation 
Where stated, isolated PBMCs were cultured in flasks or in 6-well plates for 1-3 h. 
Monocytes readily adhere to surfaces and remained on the surface once media was 
removed. Ice cold PBS was added to detach non-adherent monocytes. Cells were 
collected, washed in PBS for 5 min at 300 g and resuspended in media before counting 
and diluting to required concentrations. Where stated, monocytes were isolated by 
negative selection to avoid activation with the PAN monocyte isolation kit and 
separation columns (MACS miltenyi biotec, Woking, UK) following manufacturer’s 
instructions. Monocytes contained in the blocking buffer (BSA 1% in PBS) used for 
isolation, were collected into 10% FBS, washed and counted. Cells were diluted in 
complete media to the required concentrations. CD14/CD38 staining of cells was 
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measured by flow cytometry using the BD Accuri C6 flow cytometer (BD Biosciences, 
Oxford, UK) to confirm monocyte isolation.  
THP-1 cells (a human monocytic leukaemia cell line; (Auwerx, 1991)) were also used. 
THP-1 cells were cultured in complete RPMI, supplemented with 50 µM 2-
mercaptoethanol. 
Monocyte derived macrophage differentiation: isolated monocytes were treated with 
GM-CSF (50 ng/ml) or M-CSF (100 ng/ml) for 5/6 days for differentiation to M1 and 
M2 cells before LPS (100ng/ml) stimulation for 16 h for macrophage differentiation. 
CD68 staining confirmed the percentage of macrophage differentiation.  
 
2.5. Mouse platelet preparation  
2.5.1. Platelet-rich-plasma (PRP) 
Anti-coagulated blood was centrifuged at 2000 rpm for 5 min in a microcentrifuge 
(ThermoScientific, Paisley, UK). PRP with the top third of erythrocytes were extracted 
before centrifugation at 200 g for 6 min (Sanyo Harrier) and PRP retained. To increase 
platelet yield, 200 µl of Modified Tyrode’s buffer was added to the remaining sample, 
mixed and centrifuged at 200 g for 6 min and top layer extracted again. Samples were 
before pooled and platelet counts measured using the Coulter Zcs counter (Beckman 
Coulter Ltd, High Wycombe, UK). 
 
2.5.2. Washed platelet preparation   
Modified Tyrode’s buffer was added to PRP to give a total volume of 1 ml.  PGI2 (1 
µg/ml) was added to the sample before centrifugation at 1000 g for 6 min. The 
supernatant was removed, and the platelet pellet was resuspended with Modified 
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Tyrode’s buffer. Platelets were counted, resuspended in Modified Tyrode’s buffer to 
required concentration and rested for 30 min before experimentation.   
 
2.6. Platelet function testing  
2.6.1. Light transmission aggregometry (LTA)  
Platelet aggregation and granule secretion was monitored using a Lumi-Dual channel 
aggregometer (Chrono-log Model 460VS; Chronolog, Labmedics, Manchester, UK).  
Aggregometer tubes (with stirrer bars) containing PRP or washed platelets were pre-
warmed at 37
o
C for 2 min, and stirred at 1200 rpm for 1 min before agonist stimulation. 
Where stated, CaCl2 (1 mM) or inhibitors were added at least 5 min before stimulation. 
For AGE experiments, PRP was incubated with AGE-BSA 30 min before LTA was 
performed. Modified Tyrode’s buffer or PPP were used as blanks to measure platelet 
optical density against. Aggregation traces were usually recorded for 5 min.  For 
measuring dense granule secretion, Chronolume, a luciferin/luciferase reagent, 
(Chronolog, Manchester, UK) was added during sample warming. ATP secreted in 
response to agonist stimulation catalyesd the luciferase reaction.  An ATP standard (1.6 
nmol) was added at the end of each aggregation, to allow ATP secretion to be 
calculated. 
 
2.6.2. Lysate preparation.   
Washed platelets were prepared to the required concentrations. Where stated, integrilin 
(9 µM; an αIIbβ3 inhibitor), apyrase (2 U/ml) and indomethacin (10 µM) were added 
before stimulation. Stimulations were performed in aggregometer tubes as described 
above. After agonist stimulation, 2X ice cold lysis buffer containing protease inhibitors 
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(300 mM NaCl, 20 mM Tris, 2 mM EGTA, 2 mM EDTA, and 2% IGEPAL CA-630 
[NP-40 equivalent], pH 7.4, plus 2 mM Na3VO4, 100 μg/mL AEBSF (4-(2-aminoethyl) 
benzenesulfonyl fluoride hydrochloride), 5 μg/mL leupeptin, 5 μg/mL aprotinin, and 0.5 
μg/mL pepstatin) was added for 30 s to terminate reactions. Lysates were placed on ice 
or stored at -20
o
C for Western blotting or immunoprecipitations. Whole cell lysates 
(WCLs) were prepared by adding equal volume of lysate to 2X Laemmli sample buffer 
(20% glycerol, 10% β-mercaptoethanol, 4% SDS, 50 mM Tris, trace of Brilliant Blue).  
 
2.6.3. GPVI shedding experiments  
400 µl of washed platelets were pre-incubated with CaCl2 (1 mM) for 5 min in 
aggregometer tubes. Where stated, inhibitors (GI254023 2 µM, GM6001 10 µg/ml, 
DAPT 10 µM, PRT060318 10 µM or dasatinib 10 µM) were added. Tubes were 
warmed at 37
o
C for 1 min before addition of integrilin (9 µM). Platelet suspensions 
were stirred at 1200 rpm for 1 min before agonist addition. Aggregation traces were 
monitored for 5 min and samples left to stir for 1 h. For fibrin treatment conditions, 
fibrinogen (100 µg/ml) was added prior to the pre-incubation step. After 3 min of 
fibrinogen treatment, thrombin (1 U/ml) was added and aggregation recorded for a 
further 5-8 min. To produce monomeric fibrin, GPRP (10 mM) was added with the 
fibrinogen, before thrombin stimulation. After 1 h under stirring conditions, 400 µl of 
2X ice cold lysis buffer containing protease inhibitors was added for 30 s. Lysates were 
extracted and placed in tubes on ice or stored in the freezer (-20
o
C).  
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2.6.4. Immunoprecipitations (IPs).  
Lysates were pre-cleared by adding 10 µl of Protein A Sepharose (PAS) or Protein G 
Sepharose (PGS) beads (Pierce, Rockfield, IL) and placed on a rotator at 4
o
C for 30 
min. Samples were centrifuged at 8600 g for 15 min in a microcentrifuge at 4
 o
C 
(Eppendorf 5477 centrifuge, Germany). Supernatants were transferred to tubes 
containing primary antibodies against the proteins of interest and PAS or PGS beads 
and left to incubate for 1 h or overnight at 4
o
C depending on antibody used. Samples 
were centrifuged at 8600 g for 1 min at 4
 o
C. The supernatant was aspirated and 
discarded before the pellet was washed three times with 1X lysis buffer. Samples were 
centrifuged once more at 8600 g for 1 min at 4
 o
C. Supernatant was extracted for future 
IP preparations or eluted in 2X Laemmli sample buffer for Western blotting.  
 
2.6.5. Platelet spreading 
Coverslips (13 mm) were coated with 200 μl of agonists (CTH (10-50 μg/ml), HMGB-1 
(10-50 μg/ml), OxLDL (10-50 μg/ml), Collagen (10 μg/ml) or PBS-BSA as a control) 
overnight at 4
o
C. Protein coated coverslips were washed 3 times with PBS and blocked 
with heat inactivated BSA (5 mg/ml) blocking buffer for 1h at room temperature. After 
blocking, coverslips were washed with PBS before addition of 200 μl washed platelets 
(2x10
7
/ml).  Where stated platelets were pre-incubated with inhibitors such as dasatinib 
(10 µM), PRT (10 µM) or PP2 (10 µM). Platelets were allowed to spread for 45 min at 
37
o
C. Non-adherent platelets were removed by gently washing coverslips with Modified 
Tyrode’s buffer before extraction. 300 μl of formalin was then added to each well for 10 
min at RT. PBS washes were performed before mounting onto glass slides with 
Hydromount (National Diagnostics, Atlanta, USA). Platelets were imaged using a 
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differential interference contrast (DIC) microscope (Zeiss Axiovert 200, 63x oil 
immersion). Adherent platelets were counted and platelet surface area was measured 
using Image J software (NIH, Bethesda, USA). At least 7 fields of view were taken per 
condition.   
 
2.6.6. Monolayer phosphorylation samples  
Plates (10 cm diameter) were coated with agonists overnight at 4
o
C, washed and 
blocked with heat-inactivated BSA (5%) blocking buffer. Washed platelets (5x10
8
/ml) 
were pre-treated with apyrase (2 U) and indomethacin (10 μM) before being added to 
immobilised protein-coated plates for 45 min at 37
o
C.  Non-adherent platelets (basal 
samples) were removed and lysed in ice cold 2X lysis buffer. Adherent cells were lysed 
for 15 min on ice with 1X lysis buffer (1 ml). Protein concentration of the lysates was 
measured to adjust for equal protein levels for Western blotting. 
 
2.6.7. SDS-PAGE and Western blotting 
WCLs and IPs containing sample buffer were heated to 100
o
C for 5 min, and 
centrifuged at 8600 g for 5 min, before being run on either; pre-cast sodium dodecyl 
sulphate polyacrylamide gels (4-12%), NuPage gel (Novex, Life Technologies) or a 4-
12% gradient BOLT gel (Invitrogen, UK). Pre-stained molecular weight markers (Bio-
Rad, Hemel Hempstead, UK) were run alongside samples to determine molecular 
weights of proteins of interest. Samples were separated by SDS-polyacrylamide gel 
electrophoresis and transferred onto a polyvinylidene difluoride (PVDF) membrane. 
Membranes were blocked in 3% BSA in TBS-T (Tris-buffered saline (200 mM Tris, 
1.37 M NaCl; pH 7.6) with 0.2% Tween20 and 0.1% w/v sodium azide) for 1 h at RT or 
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overnight at 4
o
C depending on antibody used. Membranes were then incubating with 
primary antibody diluted in 3% BSA-TBS-T (primary antibody concentration dependent 
on experiment) for 1 h at RT or overnight at 4
o
C. Membranes were washed 4 times for 
10 min in TBS-T incubation with HRP-conjugated secondary antibody (GE Healthcare, 
UK) in TBS-T for 1 h at RT. Enhanced chemiluminescence reagent (ThermoScientific 
Paisley, UK) was added to the blots before imaging on autoradiographic film or imaged 
with the Licor Odyssey-FC imager (Chemiluminescence channel; Cambridge, UK) for 
band quantitation.  
 
In experiments where membranes required reprobing, membranes were incubated with 
stripping buffer (TBST-T containing 2% SDS) containing 1% β-mercaptoethanol for 20 
min at 80˚C. The stripping buffer was removed and stripping buffer without β-
mercaptoethanol was added for a further 20 min at 80˚C.  After 4 washes of 10 min in 
TBS-T, membranes were processed again for Western blotting.  Li-cor Image Studio 
software was used for protein band quantitation. A blank area of the membrane was 
defined as background and densitometry measurements were made after the area was 
placed over the bands. The imaging software subtracted the background from the signal 
to give integrated intensity of each measured band. 
 
2.6.8. NFAT luciferase reporter assays.  
Jurkat T-cells were grown in complete RPMI media. 2×10
7
cells were transfected in 0.4 
ml of either 1% serum or serum-free RPMI by electroporation using a GenePulser II 
(Bio-Rad).  GenePulserII was set at 350 V and 500 μF for DT40 cells and 250 V and 
950 μF for Jurkat cells.  DT40 cells were transfected with 15 μg of the NFAT-luciferase 
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reporter and 2 μg of both human GPVI and human FcRγ-chain. Where described 10 μg 
of human CLEC-2 was added (constructs detailed above). For Jurkat cell transfection, 
cells were transfected with 3.75 μg of the NFAT-luciferase reporter, 0.5 μg each of 
human GPVI and human FcRγ-chain and where stated 2.5 μg of human CLEC-2. 
Complete RPMI media was added to the transfect cells and cells were incubated at 37
o
C 
overnight. After 20 h, cells were counted and diluted to 2×10
6
cells/ml in complete 
RPMI media or serum-and antibiotic-free media as stated. Agonist were added to wells 
of a 96 well plate at 2X required concentration in a 50 µl volume. Phorbol 12-myristate-
13-acetate (PMA: 50 ng/ml) and ionomycin (1 µM) were used as positive controls. 50 
µl of cells were added to the agonist well. RPMI was used for basal samples. Cells were 
incubated with agonists for 6 h at 37
o
C, before luciferase assays were performed in 
triplicate.  Luciferin (1 mM) in ddH20 was add to wells and used also to prime the 
luminometer. 11 µl of luciferase harvest buffer (1M KPO4, 12.5% Triton X-100 and 1 M 
dithiothreitol (DTT)) was added to each well and plate was left to incubate for 5 min at 
RT. 90 µl of luciferase assay buffer (1 M KPO4, 1 M MgCl2, 0.1 M ATP and ddH20) 
was transferred to an opaque 96-well plate before measurements with the microplate 
luminometer (Berthold Technologies, Wildbad, Germany). The instrument was primed 
with luciferin (1 mM) followed by sequential injection into the wells (50 µl, counting 
time 10 s per well). Measured luminescence was averaged across triplicates and 
normalised relative to basal. 
 
2.7. Animal Experimentation and In vivo models  
Collagen and histone infusion work performed in collaboration with  
2.7.1. Collagen infusion thrombosis model  
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WT and GP6
-/- mice were injected into the tail veins with collagen (25 μg) and 
adrenaline (1 μg) to induce thrombocytopenia as described (Abrams et al., 2013). 
Decrease in platelet count was calculated by comparing the platelet count from a basal 
sample, collected from a tail bleed taken before injection and the platelet count taken by 
a terminal cardiac puncture taken 3 min after agonist injection.  
 
2.7.2. Histone infusion thrombosis model  
A histone infusion in vivo model was used to assess whether histones activate platelets 
through GPVI by injecting CTH (2.5-75 mg/kg) into tail veins of WT and Gp6
 -/- 
mice. 
A basal platelet count (tail vein bleed) was measured before CTH infusion and 3 min 
post CTH injection (terminal cardiac puncture). The drop in platelet count from the 
basal level indicated the level of platelet aggregation through histone-induced 
thrombocytopenia. Where stated, hirudin (10 mg/kg) was injected by intraperitoneal 
injection 5 min before CTH injection (25 mg/kg).  
 
2.7.3. Wound punch biopsies  
‎ helped with anaesthesia monitoring during surgery, restraining of 
mice for wound healing measurements and with staining of collected wounds.  
Punch biopsies were taken from GP6
-/-
, Pdpn
fl/fl 
Vav-1-Cre, Clec1b
fl/fl
 PF4-Cre mice and 
WT mice. Mice were given buprenorphine 30 min before surgery. Mice were 
anaesthetised using isoflurane and area undergoing biopsy was shaved before a small (4 
mm) full-thickness punch biopsy was taken from the flank skin under sterile surgical 
conditions. Analgesia was given daily for two days post biopsy. Wound diameters were 
imaged and measured daily for 10 days to establish the rate of wound closure. Mice 
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were culled by Schedule-1 methods to collect skin biopsies for Hematoxylin and 
Eosin (H&E) staining to define structure (section 2.7.4) and collect blood for platelet 
count measurements (see section 2.2.2).  
 
2.7.4. Immunohistochemistry  
Paraffin embedding and sectioning  
Skin wound biopsies collected were washed in PBS three times before being fixed in 
4% paraformaldehyde (PFA) overnight. Samples were then dehydrated in increasing 
concentrations of ethanol (ETOH), 70% ETOH or 1 h, 2 x 95% ETOH for 30 min and 2 
x 100% ETOH for 30 min, followed by Histoclear (National diagnostics, Hessle, UK) 
for 2 h. Samples were embedded in paraffin at 58
o
C for 2 h.  Paraffin embedded 
samples were oriented, mounted into blocks and stored at RT.  Tissue sections of 4-8 
µm thickness were collected onto polylysine adhesion slides (ThermoScientific Paisley, 
UK) for staining.   
Staining  
For H&E staining, paraffin was removed by dehydrating in Histoclear twice for 5 min 
and 3 min, followed by rehydration in concentrations of ETOH; 100% ETOH for 3 min, 
90% ETOH for 1 min, 75% ETOH for 1 min, 55% ETOH for 1 min, 30% ETOH for 1 
min. Samples were placed in H20 for 3-5 min.  Slides were stained for 2 min in Harris’ 
Haematoxylin and washed three times with tap water before being dipped twice in 0.3% 
acid alcohol. Slides were rinsed in tap water, added briefly to Scott’s tap water and then 
dipped 10 times in Eosin. Slides were rinsed further in water and dehydrated once more 
in 70% ETOH>90% ETOH >100% ETOH for 3 min each step. Slides were then placed 
in Xylene substrate overnight. The following day slides were mounted onto coverslips 
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using Hydromount (National Diagnostics, Hessle, UK) mounting media. Slides were 
imaged and analysed using the Zeiss Axio Scan.Z1 microscope.  
 
For antibody staining, after rehydration, sections were boiled in citric acid buffer (pH 
6.0) for 15 min. Sections were cooled to RT and washed in PBS-T (0.1% Tween20). 
Endogenous peroxidase was blocked with 3% H2O2 for 10 min, followed by blocking 
with 5% goat serum plus 1% BSA-PBS-T for 1 hour at RT. Sections were then 
incubated with the primary antibody (anti-podoplanin monoclonal antibody 1/500 in 3% 
BSA-PBS-T) overnight at 4°C. Slides were then washed in PBS-T before incubation 
with the secondary antibody (goat anti-hamster IgG HRP-conjugated 0.8 µg/ml) in 
PBS-T for 1 h at RT. After further washes in PBS-T, ImmPACT DAB
® 
peroxidase 
substrate (SK-4105, Vectorlab) was added for 2.5 min. Tissue sections were counter 
stained for haematoxylin, dehydrated, mounted and analysed as above. 
 
2.8. Flow cytometry 
2.8.1. Microvesicle experiments  
Podoplanin expression on microvesicles: 30 µl of double spun plasma (section 2.3.4) 
from patients and HCs were incubated in the dark at RT for 20 min with 20 µl of 
antibody mix of rat anti-human podoplanin–PE antibody (1/100) or the IgG2a κ control 
(1/100) and the anti- CD45- APC antibody (1/200). After incubation the sample was 
further diluted in Tyrode’s buffer + 0.2% formaldehyde before analysis by flow 
cytometry (BD Accuri). 
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2.8.2. GPVI dimerisation studies  
Washed platelets (5x10
7
 cells/ml) were stimulated with agonists at concentrations used 
for platelet aggregation. 10 μl of stimulated platelets were incubated for 10 min with 10 
μl of the 204-11 primary antibody (F.C. 25 µg/ml), that detects GPVI dimers, followed 
by incubation with the secondary antibody conjugated to AF-647 (F.C. 75 µg/ml), for 
10 min. GPVI dimers on the platelet surface were measured by flow cytometry (BD 
Accuri) before and after stimulation. Resting controls containing both antibodies, no 
primary antibody and only were also analysed. 
 
2.9. ELISAs 
2.9.1. Soluble GPVI (sGPVI) ELISA  
sGPVI levels in patient plasma and HCs were measured using a recognised sGPVI 
sandwich ELISA (Al-Tamimi et al., 2009). Nunc MaxiSorp® micro-titer 96 well plates 
(ThermoScientific, Paisley, UK) were coated overnight at 4
o
C with a rabbit polyclonal 
anti-human GPVI antibody (1 μg/ml) that recognises the N-terminal extracellular 
portion of cleaved GPVI. Plates were washed 6 times in 0.2% v/v Tween20 in PBS 
before blocking in BSA (1%) in PBS for 1 h. After 6 washes in PBS-T, test samples or 
sGPVI standards generated by the serial dilution of GPVI ectodomain (prepared from 
N-ethylmaleimide [NEM]-treated platelet-rich plasma) into GPVI-depleted plasma (5% 
in PBS) were added to the plate and left to incubate for 1 h at RT. After 6 further PBS-T 
washes, samples were incubated with a mouse anti-human GPVI monoclonal antibody 
(IA12: 1 μg/ml) for 1 h. Samples were washed 6 times in PBS-T before incubation with 
a polyclonal rabbit anti-mouse immunoglobulins/HRP antibody (DAKO, Denmark; 2.6 
μg/ml) for 1 h at RT. Plates were washed 6 times in PBS-T before. 100 μl of 
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SuperSignal ELISA Pico chemiluminescent substrate (Pierce, Rockford, IL, USA), was 
added for 1 min before detection of the chemiluminescence signal using the Wallac-
Victor3 luminescence plate reader (PerkinElmer, Massachusetts, USA) for 10s/well. 
sGPVI concentrations for the patient samples were extrapolated from the standard curve 
generated. 
 
2.9.2. GPVI binding to immobilised agonists 
Binding of GPVI to immobilised agonists including fibrin/fibrinogen was measured 
using an adapted version of a sGPVI ELISA (section 2.9.1). Wells of Nunc MaxiSorp® 
micro-titer plates were coated with agonists overnight at 4
o
C. Wells were washed six 
times with 100 μl of 0.2% v/v Tween20 in PBS before being blocked with 1% (w/v) 
BSA for 1 h at RT. After 6 washes in TBS-T, the GPVI ectodomain (again prepared 
from NEM treated plasma) was added to the wells and incubated for 1 h at RT. A 
standard curve was generated by a series dilution of GPVI ectodomain added into GPVI 
depleted plasma (5%) as in section 2.9.1. Primary and secondary antibody incubation 
steps and washes were performed as stated in section 2.9.1. Levels of GPVI bound were 
extrapolated from the standard curve generated. 
 
2.9.3. Podoplanin (Pdpn) ELISAs  
Sandwich ELISA: A Pdpn sandwich ELISA was developed to measure human 
recombinant podoplanin (rPdpn) and plasma Pdpn in septic patients and HCs. Nunc 
MaxiSorp® micro-titer 96 well plates (Thermo Scientific, Paisley, UK) were coated 
overnight at 4
o
C with mouse anti-human Pdpn antibody (18H5: 0.5 µg/ml) that 
recognises the PLAG1/2 domain in the Pdpn extracellular tail. Plates were washed 6 
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times in 0.2% v/v Tween20 in PBS before blocking in BSA (1%) PBS for 1 h at RT. 
After 6 washes in PBS-T, a serial dilution of human rPdpn (0.3 µg/ml to 10 µg/ml) in 
ddH20 was added to the plate and left to incubate at RT for 1 h. Samples were washed 6 
times in PBS-T washes before incubation of a rat anti-human Pdpn antibody (NZ-1.3: 1 
μg/ml) for 1 h at RT. Six more PBS-T washes occurred before incubation with a 
polyclonal goat anti-rat HRP antibody (DAKO, Denmark; 2.6 μg/ml) for 1 h at RT. 
Plates were washed 6 times in PBS-T before incubation in SuperSignal ELISA PICO 
chemiluminescence substrate added for bound antibody detection. Chemiluminescence 
signal (wavelength 425nm) was detected by the Wallac-Victor3 luminescence plate 
reader (PerkinElmer, Waltham, MA). Pdpn standard curve was generated using 
GraphPad Prism software (version 5).  
Competitive ELISA:  Nunc MaxiSorp® micro-titer 96 well plates (Thermo Scientific, 
Paisley, UK) were coated for 1 h at RT with human rPdpn (3 µg/ml). Plates were 
washed 6 times in PBS-T before blocking for 1 h in BSA-PBS (1%). Samples were 
washed again 6 times in PBS-T. Human rPdpn at various concentrations (0.3 µg/ml – 10 
µg/ml) and rat anti-human Pdpn antibody (NZ-1.3: 1 μg/ml) were added to separate 
tubes for 1 h incubation. Samples from this tube were transferred to the ELISA plate 
coated in human rPdpn (3 µg/ml) and left to incubate for 1 h at RT. Wash steps, 
incubation step with the polyclonal goat anti-rat HRP antibody (DAKO, Denmark; 2.6 
μg/ml) and chemiluminescence signal detection was performed as with the sandwich 
Pdpn ELISA above. Pdpn standard curve was also generated using GraphPad Prism 
software (version 5). 
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Commercial ELISA – A commercial Pdpn ELISA (Biomatik, Ontario, Canada) was 
used to detect rPdpn and Pdpn in plasma samples from septic patients and HCs, 
following manufacturer’s instructions. A standard curve was generated using the 
manufacture’s reagents. A series dilution of recombinant Pdpn was added to the plate to 
compare standard curves. Three HC plasma samples and four septic patient samples 
were tested for detection of plasma podoplanin.  
 
2.10. Podoplanin (Pdpn) upregulation  
2.10.1. Podoplanin upregulation after LPS stimulation  
Whole blood (in 4% citrate) was stimulated by adding LPS 0111 (0.1, 1 µg/ml) in the 
presence of GPRP (10 µM) and integrilin (9 µM). Blood was diluted 1/5 in RPMI and 
left on a shaker at 37
o
C for 4 h and 24 h. Unstimulated blood was used for 
compensation at corresponding time points. 100 µl of blood from each time point was 
incubated with antibody mix of CD45-APC or CD14-APC and CD41-FITC and Pdpn-
PE or isotype or CD41-PE for 20 min at RT. RBCs were then lysed and samples fixed 
using the BD Cytofix kit (BD biosciences, Oxford, UK). Pdpn upregulation and 
neutrophil/monocyte platelet complexes were measured by flow cytometry. 
 
2.10.2. Podoplanin upregulation on stimulated cells.  
PBMCs: PBMCs isolated (in section 2.4.1) were on a 6-well plate at 1x10
6
/ml and 
treated with staurosporine (1 µM) and cycloheximide (25 µg/ml) or LPS 0111 (100 
ng/ml) for 16 h. Untreated cells were used as controls. Cells were blocked using 10% 
FBS-TBS buffer, washed and stained for CD38, Pdpn (Anti-Pdpn NZ-1.3 Antibody) 
and Annexin V (BD Biosciences; Oxford, UK) in 1% FBS-TBS buffer + CaCl2 (1 mM) 
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for 20 min, before washing again in 1% FBS-TBS + CaCl2 (1 mM) buffer. Pdpn 
upregulation was measured on Annexin V+ cells (activated/ dying cells) and Annexin 
V- cells.  
  
Monocytes:  Isolated monocytes isolated (see section 2.4.2) were incubated on 6-well 
plates at 1x10
6
/ml. THP-1 were also used for stimulations. Monocytes were treated with 
staurosporine (1 µM) and cycloheximide (25 µg/ml) or LPS (0111: 100 ng/ml) for 16 h. 
Untreated cells were used as controls. Cells were washed, blocked and stained for 
CD14, Pdpn (Anti-Pdpn NZ1.3 Antibody) and Annexin V as above.  Pdpn upregulation 
was compared on Annexin V+ and Annexin V- cells.  
 
Macrophages: Monocyte-derived macrophages were differentiated from GM-CSF (50 
ng/ml) and M-CSF (100 ng/ml) treated monocytes (see section 2.4.2) and were then 
treated with staurosporine (1 µM) and cycloheximide (25 µg/ml) or LPS 0111 (100 
ng/ml) for 16 h.  Cells were washed, blocked and stained for CD68, Pdpn (Anti-Pdpn 
NZ1.3 Antibody) and Annexin V. Pdpn upregulation was compared on Annexin V+ and 
Annexin V- cells.  
 
2.10.3. Platelet activation by cells with upregulated podoplanin  
Isolated human monocytes were differentiated into macrophages using GM-CSF and 
M-CSF and stimulated with LPS (100 ng/ml) for 16 h. Macrophages (0.3 million 
cells/ml) were incubated with platelets (2x10
7
/ml) from the same donor in the presence 
of integrilin (9 µM) and stirred at 1200 rpm for 10 min at 37
o
C. PGI2 (10 µg/ml) and 
FBS (10%) was added to prevent further interactions for 10 min before antibody 
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staining for 20 min. Cells were fixed in PFA (4%) and platelet activation was 
determined by flow cytometry. A P-selectin antibody (CD62P) was added used to 
determine if adhered platelets were activated. Stimulated washed platelets (2x10
7
/ml) 
were stained for CD41 and P-selectin as positive controls.  NZ-1.3 anti-Pdpn Ab 
(unconjugated; 10 µg/ml) was added to washed platelets and macrophages before 
stirring to block Pdpn and determine if platelet/macrophage interactions mediated 
platelet activation.  
 
2.10.4. Trypsin cleavage of 293T cells  
Human 293T cells (embryonic kidney cells) were grown in complete RPMI. When 
confluent cells were isolated from flasks and centrifuged at 300 g for 5 min and 
resuspended in RMPI to required concentrations. Trypsin (10%) was added to the cells 
for 15 min and 30 min and 1 h. Cells were centrifuged at 300 g for 5 min. Supernatant 
was removed and cell pellet resuspended in 1 ml of 10% FBS in TBS (FBS-TBS). 100 
µl of supernatant was extracted for staining, whilst the rest was centrifuged at 2500 g 
for 15 min. Resuspended cells and supernatants were stained with Pdpn antibodies (NZ-
1.3 and 18H5) and isotype controls for 20 min in 1% FBS-TBS buffer. Cells were 
washed and podoplanin expression measured by flow cytometry.  
 
2.11. Statistical analysis  
2.11.1. General statistical analysis  
Results are shown as mean ± SD, unless stated otherwise. D’Agostino-Pearson 
normality tests were performed to determine normality. Student’s T-tests were 
performed when there were two groups and data showed normal distribution. Mann-
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Whitney tests were performed when the data was not normally distributed. One-way 
ANOVA with a Bonferroni post-test or Kruskal-Wallis tests with Dunn’s post tests 
were performed when there were more than two groups for comparisons when the data 
was shown to be normally distributed or not normally distributed respectively. 
Statistical tests were performed using GraphPad Prism (version 5) software.  
 
2.11.2. Logistic regression and longitudinal analyses of sGPVI in thermal injury 
patients  
Analysis performed by Jonathan Bishop as part of the SIFTI study.  
Categorical variables were compared using a Chi-squared test. Logistic regression 
analyses examined the relationships between sGPVI at pre-specified sample days (e.g. 
day 7) and sepsis presence. Discriminatory power was assessed through the area under 
the receiver operator characteristic curve (AUROC). Longitudinal analyses were 
performed using linear mixed-effects models.  Sample day was included as a restricted 
cubic spline to allow for a flexible non-linear relationship between time and response 
variable. Analysis was performed using SPSS (IBM) and R version 3.0.1 (http://www.r-
project.org) statistical software packages alongside Ime4, effects, rms and pROC 
packages. 
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CHAPTER 3 
 
ALARMIN-MEDIATED PLATELET 
ACTIVATION 
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3.1 Introduction  
A major new focus of trauma research, alongside preventing extensive blood loss, is 
targeting a wide range of secondary complications that can occur post injury due to the 
complexity of different traumas, including amplified inflammation resulting in multiple 
organ failure (MOF). Alarmins is a term given to endogenous danger associated 
molecular pattern molecules (DAMPs) released from damaged cells (Harris and Raucci, 
2006). Binding of Alarmins to corresponding Alarmin receptors on the surface of 
immune cells induces intracellular signalling pathways mediating a pro-inflammatory 
response (Manson et al., 2012). Several of the described Alarmin receptors are located 
on the platelet surface, providing a potential avenue for Alarmin-mediated platelet 
activation and further cytokine release (Clark et al., 2007, Zhang et al., 2010, Zhu et al., 
2012).  
 
The ‘danger theory’ behind the action of DAMPS was first described by Mazinger 
(1994). This was the theory that DAMPs are the host version of Pathogen Associated 
Molecular Pattern molecules (PAMPs), with PAMPs being microbial derived molecules 
which bind to pattern recognition receptors (PPRs), which include a number of toll-like 
receptors (TLRs) (Matzinger, 1994). PAMPs bind to PPRs, leading to activation of 
signalling mechanisms, antigen presentation or production of pro-inflammatory 
cytokine production (Kono and Rock, 2008, Manson et al., 2012). DAMPs are thought 
to work through a similar mechanism, which when released after damage will signal 
through PPRs and TLRs after binding, mediating a pro-inflammatory response resulting 
in increased cytokine production (Manson et al., 2012, Kono and Rock, 2008). In 
unchallenged conditions, DAMPs will remain hidden in the cell and not released. Figure 
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3.1 shows a schematic of the control of DAMPs. If the cell is programmed to die, the 
living cell will undergo apoptosis in a controlled manner, where the DAMPs will 
remain hidden as the cell is phagocytosed and removed, meaning that no inflammatory 
response will occur. When the cell undergoes severe damage, as observed with trauma, 
cells will become necrotic, releasing their contents and DAMPs. These DAMPs are then 
able to circulate and find their corresponding DAMP receptors eliciting the pro-
inflammatory response, with increased production of cytokines, such as IL-1 (Srikrishna 
and Freeze, 2009, Chan et al., 2012).  Cytokine levels remain elevated for several days 
after injury and can lead to development of systemic inflammatory response syndrome 
(SIRS) and increased MOF incidence and higher mortality rates  (Jastrow et al., 2009, 
Hranjec et al., 2010).  
3.1.1 Trauma Alarmins  
Alarmins is the term give for DAMPs released in response to trauma. There are a wide 
range of Alarmins released from multiple cell types which have various effects leading 
to a pro-inflammatory phenotype. Table 3.1. lists a number of the most extensively 
studied Alarmins which are elevated after trauma, with the predominate group being 
nuclear-related Alarmins. These are nuclear material/proteins released after damage to 
the nucleus and include DNA, high-mobility-group-box-1 protein (HMGB-1) and 
histones.  
 
HMGB-1 interacts with other nuclear proteins to regulate DNA organisation along with 
helping to support gene transcription.  HMGB-1 levels have been measured in patients 
with sepsis and other inflammatory conditions (Klune et al., 2008) and can be elevated 
30 fold after trauma (Park et al., 2004). HMGB-1 has been proposed to signal through  
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Figure 3.1 - Schematic of the control of DAMP release in controlled and 
inflammatory settings (based on (Kono and Rock, 2008)). In healthy cells DAMPs are 
kept inside the cell or located in the nucleus. With normal controlled cell death, cells 
undergo apoptosis, where the DAMPs remain hidden, as cells are phagocytosed by 
immune cells and DAMPs are never released. Under inflammatory challenge or 
damage, cells undergo necrosis, releasing DAMPS. These exposed DAMPs are then 
able to bind to innate immune cells and induce a pro-inflammatory response, increasing 
pro-inflammatory cytokine production. 
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TLRs and Receptor for Advanced Glycation Endproducts (RAGE) to activate immune 
cells. HMGB-1 has been implicated in promoting neutrophil extracellular trap (NET) 
formation through interactions with TLR4 (Tadie et al., 2013). HMGB-1 has been 
described to have several inflammatory roles, including promoting pro-inflammatory 
cell recruitment to damaged areas through forming a complex with CXCL12 (Schiraldi 
et al., 2012).  The role of HMGB-1 in platelet activation has yet to be established.  
 
DNA is another nuclear-related Alarmin which can be measured in the plasma of 
patients. Cell-free DNA, is DNA released from cells and is a marker of disease severity 
and a strong predictive marker for sepsis in patients with thermal injury (Margraf et al., 
2008, Hampson et al., 2016). DNA released from neutrophils in the form of NETs has 
been extensively studied. NETs are made up of extracellular DNA, serine proteases and 
anti-microbial molecules, involved in trapping and elimination of bacteria (Clark et al., 
2007). Long extracellular extrusions of NETs have been show to provide surfaces for 
platelets to adhere and undergo activation (Fuchs et al., 2010).  
 
Mitochondrial DNA (mtDNA), is DNA released from mitochondria after damage. 
MtDNA can also be measured in the plasma of trauma patients, remaining elevated for 
24 hours (Zhang et al., 2010). MtDNA been shown to increase endothelial permeability 
during systemic inflammation (Sun et al., 2013) and is associated with acute lung injury 
and neutrophil activation (Hauser et al., 2010). MtDNA has been shown to bind to 
TLR9 and may potentially bind other pathogen recognition receptors, as mtDNA 
contains similar unmethylated CpG DNA repeats to those seen in the bacterial genome, 
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resulting from endosymbiosis, which suggests mtDNA can signal in a similar fashion to 
bacterial DNA (Fang et al., 2016, Zhang et al., 2010). 
 
Histones are a major component of NETs and another type of nuclear-related Alarmins. 
Histones are highly positively charged with important roles in DNA organisation and 
chromatin formation. Histones have multiple effects on different cell types and can 
mediate cytokine activation and thrombin generation (Semeraro et al., 2011). Histones 
are also elevated in the circulation in response to lung injury and trauma (Abrams et al., 
2013). Circulating histones can be cytotoxic to endothelial cells, causing substantial cell 
damage. Histones are proposed to activate platelets through TLR4 interaction (Fuchs et 
al., 2011b, Semeraro et al., 2011). However, the charge of histones could disrupt 
membranes allowing potential binding to other receptors. Several studies have shown 
that therapeutics prevent histones induced thrombocytopenia and increase survival after 
histone treatment, ranging from heparin treatment to active protein C (APC) (Fuchs et 
al., 2011b, Xu et al., 2009). Therefore, mechanisms of histone-induced platelet 
activation are yet to be fully established. 
3.1.2 DAMPs implicated in inflammation 
Oxidised low density lipoprotein (OxLDL) is a lipid-based DAMP, associated with 
hyperlipidaemia and has been shown to accumulate in atherosclerotic lesions (Matsuura 
et al., 2008). OxLDL is formed after lipid peroxidation of lipids and apolipoprotein B 
(apoB) components (Stewart et al., 2005). OxLDL has been shown to bind to the 
scavenger receptor CD36, which is abundantly expressed on platelet surfaces, with a 
copy number of 20, 000 per platelet (Saboor et al., 2013). OxLDL therefore has the 
potential to bind to platelets and affect platelet function. Advanced Glycation End 
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Products (AGE) are another type of DAMPs which have been implication in conditions 
such as diabetes and atherosclerosis (Goldin et al., 2006). AGE are glycated proteins 
that have undergone further protein modifications. Studies have shown AGE can elicit a 
prothrombotic phenotype by enhancing platelet reactivity through CD36 signalling. 
3.1.3 Alarmin receptors 
A number of Alarmin receptors identified on other cell types have been described 
(Figure 3.2). Some of these Alarmins shown such as TLRs are located on the platelet 
surface, therefore giving a potential mechanism for platelets to contribute to the pro-
inflammatory response.  
3.1.3.1 Toll-like receptors (TLRs) 
TLRs are recognised Alarmin receptors on a range of immune cells.  Signalling results 
in a pro-inflammatory response. TLRs are a family of receptors involved in host defence 
against pathogens, which recognise PAMPs and DAMPs, activating the immune 
response (Cognasse et al., 2005). Eleven TLRs have been characterised with functional 
roles, with TLR2, TLR4 and TLR9 having been described on the platelet surface 
(Cognasse et al., 2005). TLR signalling involves the NF-kB/TRIF/Myd88 signalling 
cascades (Garraud and Cognasse, 2010). TLR2 and TLR4 have been shown to have 
roles in recognition of bacterial-derived molecules. Platelet TLR4 is also associated 
with platelet-neutrophil interactions and implicated in NET formation (Clark et al., 
2007). TLR9 recognises bacteria DNA and MtDNA. TLR9 recognises MtDNA as it 
contains bacterial-derived CpG DNA repeats, which entered the mitochondrial genome 
after the endosymbiosis event (Zhang et al., 2010) .  
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3.1.3.2 Scavenger receptors  
RAGE is a 35kDa scavenger receptor, expressed at low levels in normal tissue, but is 
upregulated at inflammatory sites (Chavakis et al., 2004). RAGE has been shown to 
interact with ligands such as AGE to contribute to persistent NF-κB activation, which 
may result in hyperglycaemia (Bierhaus et al., 2001). RAGE has also been described as 
a receptor for HMGB-1 in different inflammatory settings and cancer (Sims et al., 
2010).   
 
CD36, also referred to as (GPIIIb) is a class B scavenger receptor.  It is described as the 
major receptor implicated in OxLDL signalling, facilitating microparticle binding 
(Ghosh et al., 2008) and long-chain fatty acid transport (Su and Abumrad, 2009). CD36 
has been implicated in atherosclerosis, hyperlipidaemia, and insulin insensitivity in 
diabetes mellitus   (Podrez et al., 2007). CD36 has also been implicated in sterile 
inflammation, due to increased CD36-TLR4-TLR6 heterodimer complex assembly 
being observed (Stewart et al., 2010). The CD36 signalling mechanism has yet to be 
fully established.   
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Table 3.1. A range of Alarmins implicated with trauma – based on Alarmins 
reviewed in Manson et al. (2012). List of Alarmins, source they are released from after 
damage, proposed receptor to induce and elevated levels in response to trauma. HC = 
healthy controls.  
 
 
 
 
 
 
Alarmin Source 
Propose
d 
Recepto
r 
Raised levels in 
trauma  
Fold 
increase 
compared 
to HCs 
References 
ATP Mitochondria P2X7 - - 
(Schneider et al., 
2006) 
DNA Nucleus - 
181 000 
kilogenome-
equivalents/l 
(Median) 
57-fold 
increase 
 
(Lo, 2000) 
HMGB-1 Nucleus 
TLR2/ 
TLR4 
/RAGE 
 526 ng/ml   
(Median) 
30-fold 
increase 
(Bianchi and 
Manfredi, 2007) 
(Park et al., 2004) 
(Cohen et al., 2010) 
(Peltz et al., 2009) 
Histones Nucleus - 
10 – 230 μg/ml 
 
200-fold 
increase 
 
(Abrams et al., 2013) 
(Xu et al., 2009) 
DNA Nucleus - 
181 000 
kilogenome-
equivalents/l 
(Median) 
57-fold 
increase 
 
(Lo, 2000) 
MtDNA Mitochondria TLR9 
2.7 ± 0.94 µg/ml 
(Median) 
1000-fold 
increase 
(Zhang et al., 2010) 
Nucleoso
mes 
Nucleus - 
53 units/ml 
(Median) 
 
- 
(Zeerleder et al., 
2003) 
sRAGE Extracellular - 
1500 pg/ml 
(Median) 
- (Cohen et al., 2010) 
Uric acid Cytoplasm 
TLR2, 
TLR4, 
CD14, 
- - 
(Rock et al., 2005) 
(Shi et al., 2006) 
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Figure 3.2. Alarmins and their corresponding receptors (Based on (Manson et al., 
2012)). Trauma Alarmins released after damage bind to the corresponding Alarmin 
receptors on innate immune cells and potentially platelets (red), leading to intracellular 
signalling pathways and the production of inflammatory cytokines, resulting in the pro-
inflammatory response. FPR: Formyl peptide receptor, HMGB: High-mobility-group 
box-protein-1, TLR: Toll-like receptor, MtDNA: Mitochondrial DNA, RAGE: Receptor 
for Advanced Glycation Endproducts, HSPR: Heat-shock protein receptor, P2RX7: 
Purinergic receptor 
  
80 
 
Alarmins released in response to cell damage have the potential to affect platelet 
function. TLR, RAGE and CD36 are potential Alarmin receptors proposed to be 
involved in platelet activation as well as enhancing the inflammatory response (Stewart 
et al., 2010, Fuchs et al., 2011b, Clark et al., 2007). The signalling mechanisms of these 
receptors after Alarmin activation are inconclusive, with multiple receptors being 
suggested to have an involvement. The potential of these receptors to also be involved 
clustering of other receptors, including ITAM receptors, leading to platelet activation 
has not been fully explored. The main aim of this chapter is to firstly determine which 
Alarmins induce platelet activation and which ones do not. Different categories of 
Alarmins, including nuclear-related Alarmins, lipid-based DAMPs and other DAMPs 
such as AGE will all be tested. The Alarmins which mediate platelet activation will then 
be studied further to uncover the mechanism behind the Alarmin response in vitro and 
in vivo.  
  
Routine platelet function assays, such as flow cytometry and light transmission 
aggregometry (LTA), will be performed to test Alarmin effects on platelet function, and 
determine if they activate, inhibit or modulate platelet function. The ability of the 
Alarmins to affect platelet activation when they are immobilised on a surface will also 
be studied.  The signalling mechanisms behind the Alarmin response on platelets will be 
assessed both when the Alarmin is in suspension and immobilised on a surface, using 
western blotting for analysis of key signalling proteins. Inhibitors and platelets deficient 
in certain receptors will be used to determine mechanism behind Alarmin mediated 
responses.  The Alarmins which have the greatest effect on platelet function will be 
further analysed in vivo using infusion models to determine if the Alarmins mediate 
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platelet activation in vivo. Various inhibitors will be tested to see if activation can be 
prevented, in the hope of finding potential therapeutic targets.  
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3.2 Results  
3.2.1 AGE does not induce platelet activation or increase response to ADP  
AGE are formed after modifications of proteins produced from reactions between 
sugars and the amino groups (Hogan et al., 1992). AGE has been implicated as a 
mediator of inflammation in diabetes and atherosclerosis (Giacco and Brownlee, 2010, 
Ono et al., 1998). Previous studies have also suggested that AGE can amplify the 
response of platelets to other agonists, such as ADP, both in mice and humans (Zhu et 
al., 2012). AGE has been described to signal through the scavenger receptors RAGE 
and recently through CD36. Both are potential Alarmin receptors located on platelet 
surfaces; therefore, AGE is a potential Alarmin candidate inducing pro-inflammatory 
response through platelets. The effect of AGE on platelet function was examined by 
light transmission aggregometry (LTA). Stimulation of platelet-rich-plasma (PRP) with 
AGE complexed with bovine serum albumin (BSA, a carrier protein for AGE; 300 
μg/ml) alone did not induce platelet aggregation, giving similar results to a PBS control. 
To determine if AGE-BSA could enhance platelet aggregation to other agonists, PRP 
was pre-treated with AGE-BSA (300 µg/ml) for 30 min before ADP (1, 3 and 10 µM) 
stimulation. AGE-BSA pre-treatment did not enhance the response of platelets to ADP 
at any of the classical ADP concentrations usually used to induce platelet aggregation 
(Figure 3.3A).  A wide range of AGE-BSA concentrations were also tested, from 10 
μg/ml to 300 μg/ml, however there was no enhancement of ADP induced platelet 
aggregation (results not shown), which is contradictory to results previously shown 
(Zhu et al., 2012).  
83 
 
 
Figure 3.3 - No significant increase in ADP induced aggregation with AGE-BSA 
pre-treated human and mice platelets. A) Human platelet-rich-plasma (PRP) was pre-
treated with AGE-BSA (300 µg/ml: Biovision (BV)) or BSA control (300 µg/ml) for 30 
min before stimulation with ADP (vehicle) at different concentrations (1, 3 and 10 µM). 
Percentage aggregation measured by light transmission aggregometry (LTA). N=3 (per 
condition), mean ±SEM shown. Two-way ANOVA performed with Bonferroni post-
test. No significance shown. B) Human PRP pre-treated with AGE-BSA (60 µg/ml) 
from Biovision (BV) and Cell Biolabs (CB) or BSA (60 µg/ml) for 30 min before 
stimulation of ADP (3 µM). (i) Representative trace of 3 separate experiments. (ii) 
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Average aggregation response for each condition from 3 separate experiments, mean 
±SEM shown. One-way ANOVA performed with Bonferroni post-test; no significance 
shown C) Mouse PRP pre-treated with AGE-BSA (75 µg/ml) from BV and CB or BSA 
(75 µg/ml) for 30 min before stimulation of ADP (3 µM). (i) Representative trace of 3 
separate experiments. (ii) Maximum aggregation response per condition from 3 
experiments, mean ±SEM shown. One-way ANOVA performed with Bonferroni post-
test; no significance shown.    
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To investigate whether this was due to the source of the AGE, two different commercial 
sources of AGE-BSA (Biovision and Cellbiolabs) were compared at similar 
concentrations used in the Zhu et al. (2012) study. However, neither source of AGE-
BSA had an effect on platelet aggregation on its own or in response to ADP. 
Specifically, neither preparations of AGE-BSA at intermediate concentrations altered 
the time course or magnitude of response to intermediate concentrations of ADP (3 µM) 
in human PRP (Figure 3.3B; n=3).  Similar findings were observed with AGE-BSA 
treated mouse PRP of mice, with no substantial enhancement of ADP-medicated 
aggregation (Figure 3.3C).  
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3.2.2 Oxidised Low Density Lipoprotein (OxLDL) induces minor aggregation of 
washed platelets  
Platelets were stimulated with the lipid-based DAMP, OxLDL to determine effects on 
platelet aggregation. There was minor increase in platelet aggregation in response to 
OxLDL in washed platelets (compared to a PBS vehicle), which varied between donors 
and was all or nothing response (rather than dose-dependent). A wide range of OxLDL 
concentrations were initially tested based on established concentrations in the literature 
and previous work performed in our laboratory. The OxLDL concentration of 10 µg/ml 
gave the greatest response of 16.1 ± 14.7% aggregation (mean ±SD, n=4; Figure 
3.4Ai&ii).  There was no increase in aggregation response above the PBS vehicle 
control, with all concentrations of OxLDL tested (Figure 3.4Aiii). The degree of 
aggregation induced by OxLDL in washed platelets was substantially less than collagen 
(10 µg/ml), which caused 74.0 ± 13.8% aggregation (Figure 3.2Aii) A small shape 
change was induced in response to OxLDL. OxLDL has been shown to signal through a 
Src and Syk dependent pathway downstream of CD36 (Wraith et al., 2013). I used 
inhibitors of Src and Syk tyrosines to investigate the involvement of GPVI and other 
ITAM receptors in the OxLDL response. There was no significant reduction in the 
platelet response to OxLDL (10 µg/ml) observed in the presence of Src inhibitors, 
dasatinib (10 µM) and PP2 (10 µM) or with the Syk inhibitor PRT060318 (10 µM), 
when used at concentrations well characterised in our laboratory and in the literature, 
compared to PBS and DMSO vehicle controls, whereas all inhibitors at substantially 
reduced the collagen response (***p<0.005, n=4; Figure 3.4B), suggesting no major 
involvement of Src and Syk in the shape change and OxLDL aggregation response.  
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Interestingly, when the OxLDL-mediated tyrosine phosphorylation was examined 
through western blotting of whole cell lysates, it was observed that OxLDL induced a 
similar phosphorylation pattern to collagen-stimulated platelets (Figure 3.4C). The level 
of increase in whole cell phosphorylation over basal and phosphorylation of specific 
bands were both similar. There was reduced phosphorylation of signalling proteins 
mediated by OxLDL stimulated platelets in the presence of the Src and Syk inhibitors, 
which again was similar to the response to collagen in the presence of inhibitors (Figure 
3.4Ci). Immunoprecipitates for the key signalling proteins Syk, FcRγ-chain and PLCγ2 
were performed and showed increased phosphorylation above basal conditions, with 
Syk and PLCγ2 Figure 3.4Cii). There was however a reduced response compared to 
GPVI ligands, collagen and CRP, but similar levels observed with the CLEC-2 ligand, 
rhodocytin (Figure 3.4Cii).  Increases in phosphorylation of the FcRγ-chain were not 
observed with OxLDL and rhodocytin stimulation (Figure 3.4Cii). There was also no 
phosphorylation of CLEC-2 seen after OxLDL stimulation (Figure 3.4Ciii), showing 
there is no involvement of CLEC-2 in the OxLDL response. Overall this suggests there 
is a Src and Syk dependent signalling mechanisms alternative to GPVI and CLEC-2 
behind the OxLDL response. 
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Figure 3.4 - OxLDL induces weak aggregation response in human washed 
platelets. A(i) Dose response curve after stimulation of human washed platelets 
(2x10
8
/ml) with different concentrations of OxLDL (Source Biosciences; 1-50 µg/ml). 
Representative of trace of 4 experiments. A(ii) Mean aggregation ±SEM; n=4. One-way 
ANOVA with Bonferroni’s post-hoc test performed to compare OxLDL concentrations 
with the collagen (10 µg/ml) control, ***p<0.005. A(iii) Dose response curve after 
stimulation of PRP with different concentrations of OxLDL (1-50 µg/ml). Mean 
aggregation shown as ±SEM; n=3. One-way ANOVA with Bonferroni’s post-hoc test 
performed to compare OxLDL concentrations with the collagen (10 µg/ml) control, 
***p<0.005. B) Washed platelets pre-incubated with dasatinib (10 µM), PRT (10 µM) 
and PP2 (10 µM) 1 min before OxLDL (10 µg/ml) or collagen (10 µg/ml) stimulation. 
Mean aggregation shown ±SEM; n=4. Unpaired T-test performed to compare 
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aggregation responses in the presence of inhibitors., ***p<0.005. C(i) Phosphorylation 
response to different concentrations of OxLDL (10, 30 and 50 µg/ml) and the OxLDL 
(10 µg/ml) response in the presence of inhibitors (dasatinib (10 µM), PRT (10 µM) and 
PP2 (10 µM) compared to collagen (10 µg/ml) controls after Western blotting with the 
monoclonal 4G10 antibody. C(ii) Syk and PLCγ2 were immunoprecipitated (IP) after 
washed platelets were stimulated with collagen (10 µg/ml), rhodocytin (300 nM), CRP 
(10 µg/ml) and OxLDL (10 µg/ml).  IPs samples were Western blotted for 
phosphotyrosine. Proteins were re-probed using corresponding antibodies (anti-Syk-
sc1077 and anti-PLCγ2 – sc407) for determining loading control. Image representative 
of 4 experiments. C(iii) CLEC-2 IP after washed platelets (1x10
9
/ml) were stimulated 
with rhodocytin (300 nM) and OxLDL (10 µg/ml).  IPs samples were Western blotted 
for phosphotyrosine. Proteins were re-probed with anti-CLEC-2 antibody to 
determining loading control. Image representative of 2 experiments. 
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3.2.3 Mitochondrial DNA (mtDNA) does not induce platelet activation 
Nuclear-related Alarmins were also assessed to determine their effects on platelet 
function. To test mtDNA effects on platelet function, mtDNA was isolated from 
PBMCs of a healthy control (HC) and used to stimulate washed platelets in suspension 
at concentrations previously shown to affect other cells. MtDNA did not induce 
significant platelet aggregation above the PBS vehicle control at any of the MtDNA 
concentrations tested (12-60 µg/ml; Figure 3.5A), which were based on concentrations 
used in other studies and high levels observed in trauma patients (Zhang et al., 2010). 
MtDNA did not have an effect on modulating responses to other agonists, including 
ADP and collagen (results not shown). Due to the lack of effect with isolated mtDNA 
and the difficulties in the isolation process only giving a small yield of mtDNA for 
testing, other nuclear-related Alarmins were then tested.  
 
3.2.4 High-Mobility-Group-Box-1 (HMGB-1) does not affect platelet aggregation 
in suspension  
HMBG-1 is another nuclear-related Alarmin shown as a pro-inflammatory mediator 
(Hauser et al., 2010). HMGB-1 was used to stimulate washed platelets in suspension at 
concentrations shown to have effects in other cell types (Schiraldi et al., 2012, Tadie et 
al., 2013). HMGB-1 did not induce significant platelet aggregation at any of the 
concentrations used, based on concentrations shown to have effects on other cell types 
in other peer studies (Figure 3.5B). There was no visible shape change after stimulation 
nor was there a dose-dependent response (Figure 3.5Bii), HMGB-1 had no effect on 
modulating platelet responses to other agonists as no synergy or increased levels of 
aggregation were seen in response to collagen with pre-treatment of washed platelets  
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Figure 3.5 - MtDNA and HMGB-1 have no effect on platelet aggregation in human 
washed platelets.  A) Human washed platelets (2x10
8
/ml) were stimulated with isolated 
mtDNA. A(i) Dose response curve after stimulation with different mtDNA 
concentrations (12, 24 and 60 µg/ml). A(ii) Maximum aggregation in response to 
mtDNA compared to collagen (10 µg/ml) control. N=1. B) Human washed platelets 
(2x10
8
/ml) were stimulated with HMGB-1 (1, 10, 30 and 50 µg/ml). B(i) Dose response 
cure of platelets stimulated with HMGB-1. Representative trace of 6 experiments. B(ii) 
Mean aggregation induced by HMGB-1. Mean ±SEM showed. One-way ANOVA 
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performed with Bonferroni post-hoc test to compare HMGB-1 responses with collagen 
(10 µg/ml) control (n=6); ***p<0.005. C(i) Human washed platelets (2x10
8
/ml) were 
treated with HMGB-1 (10 µg/ml) before addition with collagen (1 -10 µg/ml). 
Aggregation of synergy shown as mean ±SEM; n=4. C(ii) Human PRP was treated with 
HMGB-1 (10 µg/ml) for 1 before collagen (1 -10 µg/ml) stimulation. Aggregation of 
synergy shown as mean ±SEM; n=3. 
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and PRP with HMGB-1 (Figure3.5Ci&ii). HMGB-1 therefore does not affect platelet 
aggregation. 
 
3.2.5 Calf thymus histones (CTH) induces platelet aggregation in washed platelets 
and PRP 
CTH experiments were in collaboration with two undergraduate students – Najiat 
Sarker and Paul Carter, who performed some experiments as stated in the Figures. 
Some experimental data for this section has been published (Alshehri et al., 2015b).  
Histones are another extensively studied nuclear-related Alarmin released after 
nucleosome breakdown following damage (Abrams et al., 2013). Calf thymus histones 
(CTH) are a commercial source of histones, containing a heterogeneous mixture of 
histone fractions, including the most active ones in effecting other cells, H3 and H4 
(Fuchs et al., 2011b). Histones have close sequence homology between species, 
therefore CTH was used as an agonist for stimulation of washed platelets and PRP. 
CTH induced a dose-dependent response causing shape change and full platelet 
aggregation after stimulation of human washed platelets and PRP (Figure 3.6A&B 
respectively). The dose response curve of CTH stimulation of washed platelets is 
approximately 10 times lower than in PRP, suggesting plasma protein binding to 
histones may reduce bioavailability to platelets in PRP. CTH aggregation in washed 
platelets is integrin αIIbβ3-dependent as aggregation is blocked in the presence of the 
αIIbβ3 inhibitor, integrilin (eptifibatide 9 μM; Figure 3.6Cii), at a concentration well 
recognised in our laboratory to block aggregation to other agonists, although secretion is 
still retained (Figure3.6Cii) The CTH dose response curve for aggregation and secretion 
are PRP sigmoidal (Figure 3.6Bii&iii). 
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Figure 3.6 - Calf thymus histones (CTH) induce platelet aggregation in washed 
platelets and PRP. A) Human washed platelets (2x10
8
/ml) were stimulated with CTH. 
A(i) Dose response curve after stimulation with different CTH concentrations (5, 24 and 
60 µg/ml). A(ii) Aggregation in response to increasing concentrations of CTH shown as 
mean ±SEM. B) CTH does response in human PRP. B(i) Representative CTH dose 
response of 4 experiments. B(ii) Aggregation response to CTH in PRP. Mean ±SEM 
shown, n=4. B(iii) ATP secretion in response to CTH stimulation of human PRP at 
different concentrations, mean ± SEM shown (secretion result of project student Najiat 
Sarker). C) CTH (2 mg/ml) stimulation of human PRP pre-incubated with integrilin (9 
µM). C(i) Representative aggregation trace of 3 separate experiments. C(ii) ATP 
secretion in response to CTH (2 mg/ml) in the presence of integrilin (9 µM). C(iii) 
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Aggregation response of CTH stimulation with and without integrilin (9 µM). Results 
are shown as mean ± SEM; n=3, ***p<0.005 (Integrilin results of project student Paul 
Carter).  
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3.2.6 CTH induced platelet activation is Src and Syk dependent  
Histone induced aggregation was blocked by inhibitors of Src and Syk tyrosine kinases. 
Washed platelets were pre-treated with dasatinib (10 µM) and PRT060318 (10 µM) for 
5 min before CTH stimulation. Both dasatinib and PRT060318 significantly inhibited  
histone-mediated aggregation (Figure3.7A). CTH stimulated strong phosphorylation in 
mouse washed platelets above the unstimulated basal levels (Figure 3.7B).  PLCγ2 and 
Syk were among the predominant phosphorylated proteins, with phosphorylation of 
FcRγ-chain also observed (Figure 3.7Bi&ii). The increase in tyrosine phosphorylation 
was similarly observed in human washed platelets (Figure 3.7Biii).  In the presence of 
dasatinib, phosphorylation of all these signalling proteins was blocked. In the presence 
of PRT060318, only PLCγ2 phosphorylation was completely blocked, with reduced 
phosphorylation of Syk being observed, consistent with Syk and FcRγ-chain 
phosphorylation lying downstream of Src kinases in mouse washed platelets 
(Figure3.7Bi&ii), which was also observed in human washed platelets. There was 
negligible phosphorylation of CLEC-2 after histone stimulation of mouse platelets 
(Figure 3.6Bii). No CLEC-2 phosphorylation was observed after CTH stimulation of 
human washed platelets (data not shown).  These results suggest that histones stimulate 
phosphorylation through the GPVI- FcRγ-chain complex. 
 
3.2.7 CTH mediated synergy with adrenaline is Src-dependent 
CTH induced strong aggregation at concentrations of 50 µg/ml in washed platelets and 
500 µg/ml in PRP. Although these concentrations fall in the range of levels measured in 
in trauma patients (10-230 μg/ml), histones have however, been shown to have 
cytotoxic affects at concentrations as low as 10 µg/ml (Abrams et al., 2013). Therefore,  
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Figure 3.7 - CTH phosphorylation response is blocked with Src and Syk inhibitors 
in mice. A) Mouse PRP pre-incubated with dasatinib (10 µM), PRT060318 (10 µM) or 
vehicle were stimulated with CTH (1 mg/ml) A(i) Aggregation trace representative of 3 
experiments. A(ii) Aggregation response to CTH in the presence of inhibitors. Results 
shown as mean ±SEM, n=3, unpaired T-test performed **p<0.01, ***p<0.005. B) 
Mouse washed platelets (5x10
8
/ml) were stimulated with CTH (50 µg/ml) in the 
presence of dasatinib (10 µM), PRT060318 (10 µM) or vehicle and analysed for 
tyrosine phosphorylation. Lysates prepared in the presence of integrilin (9 µM), 
indomethacin (10 µM) and apyrase (2 U/ml).  B(i) Whole cell lysate representative of 3 
experiments, molecular mass (kDa) indicated as numbers on left-hand side. B(ii) IPs for 
Syk, PLCγ2 and CLEC-2 separated by SDS/PAGE and Western blotted for 
phosphotyrosine using mAb 4G10. Representative image of 4 experiments (work 
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completed by project student Najiat Sarker). B(iii) IPs for Syk, PLCγ2 and CLEC-2 at 
CTH stimulation of human washed platelets (5x10
8
/ml) separated by SDS/PAGE and 
Western blotted for phosphotyrosine using mAb 4G10. Representative image of 4 
experiments. 
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Figure 3.8 - Synergy seen between adrenaline and sub-threshold levels of CTH in 
human washed platelets, which is blocked with Src inhibitors. A) Human washed 
platelets (2x10
8
/ml) were treated with adrenaline (10 µM) for 1 min before CTH (10 
µg/ml) treatment. A(i) Aggregation trace of synergy with adrenaline and CTH, 
representative of 6 experiments. A(ii) Aggregation of synergy shown as mean ±SEM. 
Unpaired T-test performed. **p<0.01, n=6. B) Adrenaline and CTH synergy observed 
when washed platelets pre-incubated for 1 min with dasatinib (10 µM), PP2 (10 µM) 
and PRT060318 (10 µM). B(i) Aggregation trace representative of 3 experiments. B(ii) 
Aggregation of synergy in the presence of inhibitors shown as mean ±SEM, n=3. 
Unpaired T-test performed to assess synergy in presence of inhibitors, *p<0.05.    
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the ability of histones to modulate platelet function at lower concentrations was 
examined. During the preparation of washed platelets, platelets become desensitised to 
ADP and adrenaline due to loss of activation of the Gq-coupled P2Y1 receptor and 
adrenaline 2-receptor. This allows the testing for synergy between CTH activation and 
the Gi-coupled P2Y12 ADP or adrenaline 2-receptor. Washed platelets were stimulated 
with a strong dose of adrenaline (10 µM), at a concentration greater than found in 
physiological conditions, which gives minimal platelet aggregation in washed platelets 
alone but has been previously shown in our laboratory to induce robust platelet 
aggregation in PRP,  before addition of sub-threshold levels of CTH (10 µg/ml), which 
alone induce minimal aggregation. In the presence of adrenaline, CTH gave robust 
platelet aggregation (Figure 3.8Ai), which was significantly greater than the sum of the 
responses to the individual agonist (**p<0.01; n=6; Figure 3.8Ai). When tested in the 
presence of Src inhibitors, dasatinib and PP2, the synergy in washed platelets was 
blocked (*p<0.05, n=3; Figure 3.8B). A slightly smaller effect in reducing the synergy 
response was observed with PRT060318, suggesting a great role for Src kinases in the 
CTH-adrenaline synergy.  
 
3.2.8 Platelets bind and activate to immobilised CTH and OxLDL but not HMGB-
1 
Of the Alarmins and DAMPs tested, CTH was the most effective at inducing 
aggregation, with OxLDL and HMGB-1 only having a small response when used to 
stimulate platelets in suspension. To determine if the Alarmins and DAMPs can activate 
platelets when immobilised on a surface, platelets were added to agonist coated-
coverslips and levels of adhesion and activation were assessed. Platelets adhered to  
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Figure 3.9 - Platelets bind and activate on immobilised CTH and OxLDL but not 
HMGB-1. Human washed platelets (2x10
7
/ml) were incubated on pre-coated slides 
with immobilised agonists; collagen (10 µg/ml), CTH (10 & 30 µg/ml), OxLDL (30 
µg/ml), HMGB-1 (30 µg/ml) and the BSA-PBS control. A) Images of spread platelets 
on different immobilised agonists. Representative images of 6 separate donors. Scale 
bar = 10 µm. B(i) Number of total platelets, spread and unspread platelets adhered on 
immobilised agonist, results shown as mean ±SEM. Unpaired T-test to compare number 
of platelets to BSA controls, n=6, *p<0.05, **p<0.01. ***p<0.005. B(ii) Number of 
spread platelets observed per field of view on immobilised CTH (10 µg/ml) with pre-
treatment of platelets for 5 min with dasatinib (10 µM), PP2 (10 µM) and PRT060318 
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(10 µM) compared to collagen (10 µg/ml) control. Results shown as ±SEM, n=4. 
Unpaired T-test was performed to compare differences of spread platelets on 
immobilised CTH compared on collagen and compare difference in the number of 
spread platelets on CTH in the presence of inhibitors, *p<0.05 and **p<0.01. 
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immobilised CTH (10-30 µg/ml) to a similar level on collagen (10 µg/ml). Platelets did 
not significantly adhere to coated OxLDL (30 µg/ml), with even fewer platelets 
adhering to HMGB-1 (30-50 μg/ml) near to levels of the PBS-BSA control (Figure 
3.9Aand Bi). Platelets adhered and spread on immobilised CTH at significantly higher 
levels than the BSA-PBS control (**p<0.01, n=6; Figure 3.9Bi), although the number of 
spread platelets was less with CTH compared to the collagen control coated surfaces. 
When platelets were pre-treated with dasatinib and PRT, platelets still adhered to CTH 
surfaces, but remained in an inactive state, as less spread platelets were observed 
(**p<0.01, n=4; Figure 3Bii). There was a significant reduction in number of platelets 
spreading on CTH when pre-treated with the Syk inhibitor, PRT (*p<0.05).  
 
To determine whether tyrosine phosphorylation caused by CTH was similar when CTH 
was presented as a monolayer rather than in solution, lysates were prepared from 
platelets following adhesion to the immobilised agonists. Non-adhered cells were 
removed and lysis buffer was then added to the adhered platelets. Whole cell lysates of 
adhered samples showed there was an increase in tyrosine phosphorylation in platelets 
adhered to CTH (10 µg/ml), OxLDL (30 µg/ml) and collagen (10 µg/ml), compared to 
the non-adherent basal platelets (Figure 3.10A). There were very minimal increases in 
phosphorylation after HMGB-1 (30 µg/ml) stimulation of washed platelets. When 
immunoprecipitating samples for Syk, FcRγ-chain and PLCγ2, there was increased 
phosphorylation in platelets adhered to collagen, CTH and OxLDL, with minor 
phosphorylation of PLCγ2 seen after HMGB-1 stimulation (Figure 3.10B&C.  
However, collagen had a greater level of phosphorylation then the other agonists. Also, 
when comparing tyrosine phosphorylation of platelets after CTH stimulation at low 
concentrations, less tyrosine phosphorylation of key signalling proteins was observed  
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Figure 3.10 - Platelets bind and activate leading to phosphorylation of key 
signalling proteins when incubated on immobilised CTH and OxLDL but not 
HMGB-1. A) Washed platelets (5x108/ml) were added on to plates coated with immobilised 
agonists; collagen (10 µg/ml), CTH (10 µg/ml), OxLDL (30 µg/ml), HMGB-1 (30 
µg/ml) for 45 min. Non-adherent (NA) cells were extracted and lysed. Adherent cells 
were also lysed. A) Whole cell lysate representative of 4 experiments. B) IPs for Syk 
and PLCγ2 separated by SDS/PAGE and Western blotted for phosphotyrosine using 
mAb 4G10. C) IPs of lysates prepared from washed platelets (5x10
8
/ml) stimulated with 
agonists as above in suspension for 5 min at 1200 rpm.  
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after CTH stimulation in suspension compared to stimulation by immobilised CTH 
(Figure 3.10C), whereas there was phosphorylation when CTH was immobilised. 
 
3.2.9 GPVI transfected cells do not signal after incubation on immobilised CTH 
To confirm that immobilised CTH can activate and signal through GPVI, immobilised 
CTH was used to stimulate Jurkat cells (a human T-lymphocyte cell line) transfected 
with GPVI using a NFAT luciferase assay. Jurkat cells were transfected with vectors 
and GPVI and FcRγ constructs before being incubated on immobilised surfaces 
including collagen (100 µg/ml) and CTH (100 µg/ml) for 6 h. The readout of the NFAT  
luciferase reporter assay was the luciferase signal in response to cells binding and being 
activated by the immobilised agonists. The relative luciferase activity of GPVI 
transfected cells on immobilised histones and collagen were compared to basal 
(unstimulated) samples and cells transfected with a mock (empty) vector. Increases in 
relative luciferase activity of Jurkat cells transfected with GPVI above the basal samples 
and vector controls were only seen when cells were incubated on immobilised collagen 
surfaces (*p<0.05, n=4; Figure 3.11Ai). There was no increased luciferase activity when 
GPVI- transfected Jurkat cells were incubated on CTH coated surfaces (Figure 3.11Ai).  
 
After the initial NFAT luciferase assays were performed with immobilised CTH and a 
range of other agonists tested (as described in (Alshehri et al., 2015b)), it was suggested 
that the serum and antibiotic added to the transfection media could interfere with the 
binding of the transfected cells to the immobilised agonists, which may have reduced 
the luciferase signal. The assay was then repeated after Jurkat cells were transfected 
with GPVI in transfection made that did not contain any antibiotic or serum, which  
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Figure 3.11 - GPVI binds to immobilised CTH in vitro but cannot confer signalling 
in a cell line. A) A NFAT luciferase reporter assay was performed to assess if Jurkat 
cells transfected with GPVI become activated when incubated with immobilised CTH 
(100 µg/ml) and collagen (100 µg/ml). Cells were transfected with a mock(empty) 
vector or GPVI-FcR-γ-chain and a NFAT-luciferase reporter. Cells were incubated on 
immobilised agonists for 6 h and luciferase activity measured. A(i) Results shown as 
relative NFAT luciferase activity above basal control. N=4, results shown as mean 
±SEM. Unpaired T-test performed to assess luciferase activity above basal and empty 
vector, *p<0.05. A (ii) NFAT luciferase assay performed as before, however, no 
antibiotic was present in the transfection media during GPVI transfection into Jurkat 
cells.  Cells were also transfected with CLEC-2 vector for which rhodocytin was used as 
a positive control agonist. Results representative of three experiments, and means 
shown ±SEM. *p<0.05, ***p<0.001. B) GPVI ectodomain ELISA binding assay. GPVI 
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ectodomain (80 ng/ml) from NEM-treated plasma was incubated on pre-coated 
microtiter plates with immobilised agonists, collagen (100 µg/ml) and CTH (100µg/ml) 
compared to BSA-PBS control. GPVI concertation bound was calculated using the 
ectodomain standard curve generated. Results shown as mean ±SEM, n=3. Unpaired T-
test was performed to compare levels of binding to BSA control.  **p<0.01 
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increased the luciferase signal to give a higher fold increase over basal with the positive 
control agonist, collagen (*p<0.05, n=3; Figure 3.11Aii). There was however, no 
difference in signalling of GPVI transfected cells after incubation with immobilised 
CTH. For the second set of NFAT luciferase reporter assays, Jurkat cells were also 
transfected with CLEC-2 constructs to see if immobilised CTH could induce CLEC-2 
signalling.  There were no increases in luciferase activity when transfected cells were 
incubated with immobilised CTH, whereas a large signal was seen when transfected 
cells were activated by the CLEC-2 ligand, rhodocytin (***p<0.005, n=3; Figure 
3.11Aii). These results suggest that in a cell line, CTH was not able to activate GPVI or 
CLEC-2 signalling. 
 
3.2.10 GPVI ectodomain binds to immobilised CTH  
We next sought to measure direct GPVI binding to CTH, to determine if GPVI can 
directly bin to CTH. A GPVI ELISA binding assay was then developed based on an 
existing GPVI ELISA (Al-Tamimi et al., 2011a). GPVI ectodomain (80 ng/ml) 
produced from N-ethylmaleimide (NEM) treated plasma (which cleaves GPVI) was 
incubated with immobilised agonists on a 96 well plate before washing and addition of 
GPVI antibodies. Chemiluminescence signal was measured using a Wallac-Victor2 
luminescence plate reader and concentrations of bound-GPVI were extrapolated from a 
generated standard curve. CTH bound to the GPVI ectodomain at similar levels to 
collagen (12 ± 1.7 ng/ml and 15 ± 20.6 ng/ml respectively) and were significantly 
higher than binding to the BSA-PBS control (0.19 ± 0.3 ng/ml; **p<0.01, n=3; Figure 
3.11B).  
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3.2.11 CTH mediates platelet aggregation in mice through GPVI and not CLEC-2   
CTH induced platelet aggregation is Src and Syk dependent. These are important 
proteins involved in ITAM signalling. To determine if GPVI is an important ITAM 
receptor predominantly involved in the histone response and not the hemITAM 
receptor, CLEC-2, platelets from GPVI knock out mice (GPVI
-/-
) and mice deficient in 
platelet CLEC-2 (CLEC-2
-/-
) were stimulated with CTH histones. CTH-induced 
aggregation and shape change were blocked in GPVI
-/- 
mice (Figure 3.12A). There was 
no effect on the response to CTH in CLEC-2-deficient mice, with full aggregation and 
shape change occurring to similar levels as wild type (WT) mice (Figure 3.12A). When 
studying tyrosine phosphorylation, there was reduced phosphorylation after CTH 
stimulation of washed platelets from GPVI
-/-
 mice, which was similar to the reduction in 
tyrosine phosphorylation observed in mice platelets deficient in both CLEC-2 and 
GPVI
-/-
 mice (Figure 3.12Bi). There was a weak increase in tyrosine phosphorylation 
after CTH stimulation of GPVI/CLEC-2 double deficient platelets compared to basal 
(Figure 3.12Bi) The key signalling proteins, Syk, FcRγ-chain and PLCγ2 showed 
reduced phosphorylation in the GPVI/CLEC-2 double-deficient platelets (Figure 
3.12Bii). There were no reductions in phosphorylation were observed after stimulation 
of CLEC-2 deficient platelets.  
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Figure - 3.12 CTH mediates platelet aggregation in mice through GPVI and not 
CLEC-2. A) PRP was stimulated with CTH (1 mg/ml) for 5 min from WT mice, GPVI
-
/- 
mice and mice deficient in platelet CLEC-2 (CLEC-2
-/-
). A(i) Aggregation trace 
representative of 3 experiments. A(ii) Aggregation results shown as mean ±SEM, n=3, 
***p<0.005 (experiments from project student Najiat Sarker). B) Lysates prepared after 
CTH (1 mg/ml) stimulation of PRP from WT mice and GPVI
-/-
/CLEC-2
-/-
 (DKO) mice 
in the presence of integrilin (9 µM), indomethacin (10 µM) and apyrase (2 U/ml).  B(i) 
Whole cell lysate separated by SDS/PAGE and Western blotted for phosphotyrosine 
using mAb 4G10. B(ii) IPs for Syk and PLCγ2 of WT and DKO samples stimulated 
with CTH compared to basal.    
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3.2.12 GPVI
-/- 
mice are not protected from CTH-induced thrombocytopenia  
Histone-medicated aggregation and phosphorylation is GPVI dependent in vitro, as 
CTH response is lost after CTH stimulation of GPVI-deficient platelets. Histone 
infusion models in mice were used to determine if CTH activation in vivo is also GPVI 
dependent. CTH induced thrombocytopenia over a concentration range of 2.5-75 mg/kg 
(Figure 3.13A). Basal platelet counts were measured in blood taken from mice 
immediately prior to CTH injection. After 3 min mice were sacrificed and platelet count 
measured again. The drop in platelet count indicated platelet consumption. CTH 
injections of 7.5mg/kg and above significantly reduced platelet count in the mice, with 
25 and 75 mg/kg injection inducing a severe level of thrombocytopenia, to 
approximately 20% of basal levels (Figure 3.13A). 
 
CTH was injected into GPVI
-/- 
mice to determine whether CTH-induced 
thrombocytopenia could be rescued in the absence of GPVI. A collagen-adrenaline 
infusion model was set up based previous studies to induce thrombocytopenia (Abrams 
et al., 2013), to establish the levels of rescue that could be expected in GPVI
-/-
. Collagen 
and adrenaline (25 µg and 1 µg) were injected into WT and GPVI
-/-
 for 3 min and the 
drop in platelet count was measured as before. The collagen and adrenaline infusion 
induced thrombocytopenia to similar levels as with CTH infusion, being significantly 
lower than the basal counts (Figure 3.13B). The reduction in platelet count was 
significantly reduce in GPVI
 -/-
 (n=3).  
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Figure 3.13-CTH induces thrombocytopenia in mice which is not rescued in 
 GPVI
-/- 
mice or with hirudin treatment. A) Platelet count drop measured after WT 
mice were injected with different doses of CTH (2.5-75mg/kg) for 3 min. Platelet 
counts were measured from samples taken before injection (basal) and after a terminal 
bleed. Mean shown, individual points represent one mouse. T-test was performed to 
compare counts after injection with basal levels, *p<0.05, ***p<0.005. B) Collagen and 
adrenaline infusion model. WT mice and GPVI-/- mice were injected with a mixture of 
collagen (25 µg) and adrenaline (1 µg). Platelet counts were measured from blood 
samples before and after injection. Mean shown. *p<0.05, **p<0.01 and ***p<0.005. 
C) CTH infusion model. WT mice and GPVI-/- mice were injected with 25 mg/kg CTH. 
In some experiments mice were injected subcutaneously with hirudin (10 mg/kg). 
Platelet counts were measured pre and post CTH infusion. Mean shown, ***p<0.005. 
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GPVI is the major platelet receptor for collagen. To establish if GPVI is also an 
important receptor for CTH in vivo, it would be expected that the degree of rescue in 
the platelet count after CTH infusion would be similar to that of collagen infusion in 
GPVI
-/-
 mice. CTH (25 mg/kg) was injected into WT and GPVI
-/-
 mice. There was no 
prevention of the reduction of platelet count in GPVI
-/-
 mice as the levels of activation 
and thrombocytopenia induced were similar to WT and all significantly different to 
basal count (***p<0.005; Figure 3.13C). Therefore, CTH-induced aggregation in vivo 
is not GPVI dependent.   
 
Histones have been shown to activate the coagulation cascade and to lead to thrombin 
generation (Fuchs et al., 2011b, Semeraro et al., 2011). To assess if the strong CTH-
aggregation in vivo was a result of thrombin generation by histones leading to platelet 
activation observed, the direct thrombin inhibitor, hirudin (10 mg/kg) was injected 5 
min before CTH infusion (Figure 3.13C). No rescue was seen with pre-treatment of 
hirudin in WT mice GPVI
 -/-
 mice, with levels of thrombocytopenia induced remaining 
the same (36%- and 35%- of basal count respectively) Therefore, CTH-mediated 
platelet activation was not dependent on GPVI or thrombin.  
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3.3 Discussion  
Alarmins and DAMPs released in response to trauma have been proposed to lead to 
inflammation after interacting with Alarmin receptors located on immune cells and 
increasing production of pro-inflammatory cytokines (Manson et al., 2012). Alarmins 
have the potential to interact with and activate platelets, as some of the identified 
Alarmin receptors have been described on the platelet surface (Cognasse et al., 2005, 
Zhu et al., 2012). A number of Alarmins including DNA and histones have been shown 
to activate platelets. The aim of this chapter was to assess a several Alarmins and 
determine if they can activate or modulate platelets and establish any signalling 
mechanisms behind the Alarmin-mediated response.  
 
One of the first Alarmins/DAMPs tested was AGE. AGE has been implicated in a range 
of conditions including diabetes and consequent cardiovascular events (Lapolla et al., 
2007, Ono et al., 1998, Giacco and Brownlee, 2010). AGE has been shown to signal 
through RAGE and CD36, a scavenger receptor located on the platelet surface (Saboor 
et al., 2013, Zhu et al., 2012). AGE has been proposed to modulate ADP aggregation 
after stimulation of platelets pre-incubated with AGE-BSA through CD36 (Zhu et al., 
2012). To confirm this finding, different concentrations of ADP were used to stimulate 
platelets pre-incubated with AGE-BSA for 30 min under the same conditions previously 
described (Zhu et al., 2012). However, the AGE-BSA tested was unable to induce 
aggregation after direct stimulation or be able to modulate the ADP response when 
platelets were pre-treated with AGE-BSA at a range of concentrations and different 
doses of ADP.  This finding was confirmed in both mice and human platelets, even with 
different AGE-BSA sources being tested. AGE-BSA was found not to modulate ADP 
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response, which differs from the findings of the Zhu et al. (2012) studies. An 
explanation for this result is unclear, as the source and concentrations of AGE-BSA 
used, along with the experimental conditions described in Zhu et al. (2012) studies 
being the same. The previous study did however only show a weak potentiation of the 
ADP response, which along with these findings suggests AGE is not an important 
DAMP for mediating platelet activation or modulating platelet responses to other 
agonists.  
 
Oxidised Low Density Lipoprotein (OxLDL) has been implicated in atherosclerosis 
(Matsuura et al., 2008, Jackson and Calkin, 2007, Ghosh et al., 2011). OxLDL is also a 
lipid based DAMP and was tested to see if OxLDL could induce platelet activation. 
OxLDL, along with AGE-BSA has been shown to interact with the scavenger receptor 
CD36, therefore giving a potential route for platelet activation. OxLDL was shown in 
this study to induce weak aggregation in washed platelets and no aggregation in 
platelet-rich-plasma (PRP). Other studies have shown a greater platelet aggregation 
response after OxLDL stimulation of washed platelets (Wraith et al., 2013). However, 
this response may depend on the oxidation process to produce the OxLDL. In this set of 
experiments I have used a commercial source of OxLDL, which may have given a 
reduced response compared to a self-produced OxLDL. Comparisons of the different 
oxidation process and consequent OxLDL products would be a future approach to 
establish fully the effects of OxLDL on platelet aggregation. Platelets did not however 
significantly adhere to immobilised OxLDL above the BSA-PBS control, with the level 
of adhesion also being much less than to other platelet agonists such as collagen. 
OxLDL induced a small shape change after stimulation of washed platelets, which was 
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not blocked with Src and Syk inhibitors, suggesting no major involvement of Src and 
Syk in OxLDL-induced aggregation.   
 
An interesting finding with OxLDL however was observed when examining the 
tyrosine phosphorylation after OxLDL stimulation, with a similar increase in tyrosine 
phosphorylation above basal observed after OxLDL and collagen stimulation of washed 
platelets, suggesting a similar ITAM signalling mechanism. The level of increase in 
phosphorylation of key GPVI signalling proteins such as, Syk, FcRγ-chain and PLCγ2 
were however much lower than observed with collagen.  Other studies have since 
shown that OxLDL induces mild platelet activation and shape change through a Src and 
Syk kinase dependent mechanism downstream of CD36 and a Src/RhoA kinase 
(ROCK) dependent pathway, which overall lead to myosin light chain (MLC) 
phosphorylation and the OxLDL aggregation response (Wraith et al., 2013). It is 
therefore unclear why Src and Syk kinases had no effect on the aggregation and 
phosphorylation response to OxLDL in this present study. Further experiments looking 
at immunoprecipitates of different signalling proteins and the use of phospho-specific 
antibodies to other signalling proteins would allow further investigation of the OxLDL 
phosphorylation patterns and clarification of the signalling proteins involved in the 
OxLDL signalling pathway.  
 
The DAMPs, OxLDL and AGE did not induce extensive platelet activation. Therefore 
the effects of a variety of nuclear-related Alarmins were also assessed. Alarmins are a 
term for DAMPs released after trauma. Mitochondrial DNA (mtDNA) can be released 
from mitochondria after cell damage and has been shown to mediate inflammatory 
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responses (Zhang et al., 2010). MtDNA are proposed to interact with TLR-9, which has 
been shown to be expressed on the platelet surface (Zhang et al., 2010) and therefore 
could potentially induce platelet activation. MtDNA was extracted from mitochondria 
from the blood of a healthy control donor and used to stimulate platelets at 
concentrations previously shown to affect other cells (Sun et al., 2013, Hauser et al., 
2010).  MtDNA failed to have a major effect on platelet aggregation at all 
concentrations tested. The MtDNA studies were limited as the isolation of mtDNA from 
donated blood did not give a high yield of mtDNA to perform an adequate number of 
experiments per donor. There were no further mtDNA experiments performed due to 
the limited aggregation response observed and the small yield produced.  The use of a 
commercial or recombinant source of mtDNA would allow further experiments to be 
performed and useful in confirming whether mtDNA does not affect platelet function.  
 
High-mobility-group-box 1 (HMGB-1) was an alternative nuclear-related Alarmin 
tested. HMGB-1 been shown to be elevated after trauma (Peltz et al., 2009) and is a 
potent inflammatory mediator (Schiraldi et al., 2012). HMGB-1 has been proposed to 
interact with TLR4 and therefore could induce platelet activation. A commercial source 
of HMGB-1 was used to stimulate washed platelets and PRP. There was minimal 
platelet aggregation in response to HMGB-1 stimulation at any of the concentrations 
tested, previously shown to have effects on other cells. Platelets did not significantly 
adhere and bind more to immobilised HMGB-1 above the BSA coated control. Recent 
studies have however shown that platelets can be activated and substantial aggregation 
can be induced with recombinant HMGB-1 (Yang et al., 2015). This suggests there is a 
potential issue with the isolation process of HMGB-1, which could affect reactivity. 
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HMGB-1 can also be released after platelet activation, therefore comparisons between 
isolated HMGB-1, recombinant HMGB-1 and different sources of HMGB-1 would be 
crucial to confirm whether HMGB-1 can mediate platelet activation.  
 
Histones are the most extensively studied Alarmin. Histones are released in the plasma 
after nucleosome breakdown and are elevated after trauma and sepsis developed 
(Abrams et al., 2013, Xu et al., 2009). Histones are very reactive and can cause damage 
to endothelial cells (Abrams et al., 2013). Histones have been shown to activate 
platelets through TLR4 mechanisms (Semeraro et al., 2011, Fuchs et al., 2011b), 
however the signalling mechanisms have not been fully established, with multiple TLRs 
and other receptors such as TLR-2 have also been implicated in the histone-mediate 
aggregation (Xu et al., 2011). This study first set out to confirm that histones can 
mediate platelet activation in vitro and secondly to further investigate the signalling 
mechanisms behind the histone-mediated response.  
 
CTH were used to stimulate platelets to examine the histone response. CTH are a 
heterogeneous mixture of different types of histones (H1-H4) and have been used in 
many previous histone studies (Fuchs et al., 2011b, Xu et al., 2009). CTH induced full 
platelet aggregation in both washed platelets and PRP in mice and humans, which was 
αIIbβ3 dependent, supporting the finding that histones-induced aggregation was the 
result of platelet agglutination only. The CTH concentrations used for stimulations were 
high in comparisons available plasma concentration, with histone concentrations as low 
as 10 µg/ml shown to have cytotoxic effects on endothelial cells (Abrams et al., 2013). 
The ability of histones to modulate the response to other agonists were therefore 
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studied. Sub-threshold levels of CTH were able to synergise with other agonists such as 
adrenaline in washed platelets to amplify the response and cause robust platelet 
activation, giving an explanation as to how histones can mediate effects at the lower 
concentrations. This along with platelets adhering and spreading on immobilised CTH 
at low concentrations supports the ability of histones to mediate platelet activation at 
physiological concentrations.  
 
The signalling mechanisms behind the CTH-mediated activation were studied. CTH 
induced aggregation was Src and Syk dependent, with the CTH response being 
diminished in platelets pre-treatment with the Src inhibitor, dasatinib and the Syk 
inhibitor, PRT060318. Aggregation was reduced in the presence of the Src and Syk 
inhibitors and increases in tyrosine phosphorylation above basal of key signalling 
proteins such as Syk, FcRγ-chain and PLCγ2 was abolished. The synergy with 
adrenaline was significantly reduced in the presence of Src inhibitors, dasatinib and 
PP2, however there was no reduction observed in the presence of PRT060318, 
suggesting a Src dependent mechanism being involved in CTH/adrenaline synergy over 
a Syk dependent mechanism. Platelet spreading after adhesion to immobilised CTH was 
reduced in the presence of the Syk inhibitor. Overall, the aggregation, phosphorylation 
and spreading results in response to CTH stimulation suggests a Src and Syk dependent 
mechanism behind CTH mediated platelet activation.  
 
Src and Syk are major signalling proteins involved in ITAM signalling (Senis et al., 
2014). Therefore, to determine if CTH-induced aggregation was dependent on ITAM 
signalling, CTH was used to stimulate platelets from GPVI
-/-
 and CLEC-2
-/-
 mice. 
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Deficiencies in CLEC-2 did not affect CTH-induced aggregation and phosphorylation. 
CTH aggregation was reduced after CTH stimulation of platelets from GPVI
-/-
 mice and 
there was no increase in phosphorylation of Syk, FcRγ-chain and PLCγ2 signifying a 
role of GPVI in CTH-induced platelet aggregation response.  
 
To confirm if histones can induce GPVI signalling, Jurkat cells were transfected with 
GPVI and added to immobilised CTH before an NFAT luciferase reporter assay was 
performed. This assay measured the luciferase activity of the transfected cells, where 
increased luciferase signal represented signalling of GPVI in the transfected cells. There 
was no increase in NFAT-luciferase activity in the transfected GPVI cells incubated 
with immobilised CTH in contrast to the response to collagen. One explanation for this  
is due to the limitations of the NFAT assay and use of cell lines to transfect with GPVI. 
Activation by the positive control agonist collagen was lower than expected, suggesting 
the transfection efficacy may not be substantial enough to show activation by CTH. 
Other factors may have also interfered with binding and activation, such as antibiotics 
in the media, as in the absence of antibiotics the collagen response was increased. 
Another explanation is that activation of GPVI in platelets by CTH is indirect and 
requires other co-factors or receptors to be present to bind and active GPVI. A direct 
binding assay showing the binding of the GPVI ectodomain to immobilised histones 
was shown to be similar to that for collagen. Future experiments performing surface 
plasmon resonance would confirm whether there was direct binding of CTH to GPVI. 
 
To determine if CTH could induce platelet aggregation in vivo, histone infusion assays 
were performed in mice. CTH infusion induced a rapid dose dependent reduction in 
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platelet count, with a CTH dose of 25-75 mg/kg causing thrombocytopenia to 
approximately 10% of basal count after 3 min. Interventions were tested to establish if 
any could improve the severe reduction in platelet count. A collagen-adrenaline infusion 
assay was performed as a proof of concept based on Abrams et al. studies (Abrams et 
al., 2013). WT mice experienced a severe drop in platelet count after infusion of 
collagen and adrenaline, with a less severe reduction in platelet count being observed in 
GPVI
-/- 
mice. GPVI is a major signalling receptor on platelets; therefore the collagen-
induced thrombocytopenia would be rescued because collagen would not be able to 
interact with GPVI to induce platelet activation and aggregation. A full recovery, 
representing no reduction in platelet count would not be observed as other minor 
collagen receptors on the platelet surface, including scavenger receptors wound be able 
to bind collagen and induce a small degree of platelet activation. If the CTH-induced 
aggregation in vivo was mediated through GPVI, then the same level of rescue of the 
platelet count to collagen would be expected. A CTH dose of 25 mg/kg was chosen for 
injection as it delivered a substantial level of thrombocytopenia in the mice. A CTH 
dose of 7.5 mg/kg only induced a moderate decrease in platelet count, therefore any 
further reduction in platelet count would be minimal. WT mice injected with CTH (25 
mg/kg) experienced the substantial reduction in platelet count. There was no rescue in 
the reduction of platelet count after CTH infection in GPVI
-/- 
mice, suggesting 
alternative mechanisms were involved in the CTH-induced thrombocytopenia.  
 
Histones have been shown to enhance thrombin generation (Semeraro et al., 2011). 
Hirudin, a direct inhibitor of thrombin, was injected into the mice before CTH infusion 
to assess if it could neutralise the CTH-induced thrombocytopenia by reducing fibrin 
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formation through inhibiting thrombin’s activity to convert fibrinogen to fibrin. There 
was however no rescue in the reduction of platelet count in WT mice pre-treated with 
hirudin or in GPVI
-/-
 mice pre-treated with hirudin, suggesting that the CTH-induced 
aggregation and thrombocytopenia observed was independent of GPVI and thrombin, 
with alternative mechanisms being involved. The hirudin treatment may however, not 
been effective enough to inhibit the CTH-induced aggregation, with heparin treatment, 
another thrombin inhibitor, previously been shown to reduce the effects of histones 
(Fuchs et al., 2011b). Another explanation for the insufficient effect of hirudin and 
GPVI could result from other factors, such as the cytotoxic effect of histones on other 
cell types potentially leading to platelet activation. Histones have been shown to 
damage endothelial cells (Abrams et al., 2013), which could then release mediators 
causing platelet activation and aggregation. Staining for endothelial cell damage after 
histone injection or investigating for endothelial markers in the future would help show 
role for endothelial cells in the histone response. An alternative explanation may result 
from histones interacting with other receptors, such as the TLRs, resulting in platelet 
activation. Most therapeutic targets for preventing histone-mediated effects are with the 
use of anti-histone blocking antibodies or developing antibodies against multiple TLRs 
to give the most therapeutic value (Abrams et al., 2013, Semeraro et al., 2011, Fuchs et 
al., 2011b). 
 
Histones are highly positively charged molecules, which could cause disruption to the 
membrane due to the charge affects. It is therefore proposed that the disruption of the 
membrane caused by the charged histones can lead to clustering of receptors, such as 
GPVI and result in the Src and Syk signalling mechanism mediating the platelet 
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aggregation. This new alternative GPVI signalling mechanism by charge interactions 
was also confirmed with other agonists such as diesel exhaust particles (Alshehri et al., 
2015b). Histone-induced aggregation may also be mediated by a similar mechanism 
causing clustering of other receptors such as the TLRs that have previously been shown 
as receptors for histones. The histone charge effect would support the findings that 
heparin injections and treatment can reduce histone effects and increase survival of mice 
histone-induced thrombocytopenia and heparin-mediated cytotoxicity in a rat model 
(Fuchs et al., 2011b, Iba et al., 2015). Heparin is a heavily negatively charged molecule, 
which has been shown to bind to positively charged histones to neutralise the charge 
effect (Wildhagen et al., 2014). Therefore, this gives a potential explanation as to how 
heparin can have a more effective response against histones than hirudin and how 
survival is improved. Further studies investigation histone induced thrombocytopenia 
after pre-treatment of heparin would be useful to determine if the histone response is 
due to increased thrombin generation or whether the histone charge effect is a more 
important factor and if the in vivo histone-mediated aggregation could be rescued.  
 
The aim of this study was to assess a variety of Alarmins to establish which Alarmins 
could activate platelets and determine the mechanism behind this.  AGE and OxLDL are 
DAMPs implicated in a range of inflammatory conditions, but were unable to directly 
induce platelet activation or modulate responses to other agonists. Of the nuclear-related 
Alarmins, only histones effected platelet function. Histones were found to be powerful 
mediators of platelet activation in vitro and in vivo. More work is required to establish 
interventions that are sufficient to prevent histone-induced platelet activation. Direct 
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neutralisation of the histone charge, a crucial aspect of their action has the greatest 
potential to reduce histone-mediated activation.  
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CHAPTER 4 
 
SOLUBLE GPVI (sGPVI) AS A 
MARKER OF PLATELET 
ACTIVATION IN 
INFLAMMATION 
  
126 
 
4.1 Introduction  
Platelets have been implicated in the pathophysiology of a wide range of thrombotic and 
inflammatory conditions, including atherosclerosis, diabetes and inflammatory bowel 
disease (IBD) (Lindemann et al., 2007, Ponder and Long, 2013). Markers of platelet 
activation have been proposed to have clinical relevance as prognostic markers and 
relate to disease severity. Most markers proposed are based on detection of plasma 
protein levels, including various granule proteins released from α- and dense-granules 
after platelet activation, such as fibrinogen and ATP, respectively (Ang et al., 2013, 
Ghoshal and Bhattacharyya, 2014).  Importantly these markers are not specific to 
platelets as they can originate from a number of other cells, such as endothelial cells 
(Gurney et al., 2002). Therefore, there is a requirement to identify and study a specific 
platelet activation marker.  
 
Membrane glycoproteins on platelets, including P-selectin, the integrin αIIbβ3 and 
Glycoprotein V (GPV), are potential candidate markers. P-selectin is an extensively 
studied glycoprotein, which is a 140 kDa adhesion molecule that binds to P-selectin 
glycoprotein ligand-1 (PGSL-1) on leukocytes, allowing platelet-leukocyte interactions. 
P-selectin is predominately located on platelet α-granules, and upon activation, becomes 
exposed on the platelet surface. P-selectin surface expression can be measured by flow 
cytometry and increased expression is a marker of platelet activation. Soluble P-selectin 
(sP-selectin) is elevated in the plasma in patients with thrombotic conditions, such as 
atherosclerosis, myocardial infarction and stroke (Blann et al., 1997, Shimomura et al., 
1998, Liu et al., 2005) and has been reported as a predictor of cardiovascular events 
(Ridker et al., 2001). Although sP-selectin has been proposed as a platelet activation 
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marker, questions surrounding its value have not been conclusive, with more sensitive 
markers being described (Naitoh et al., 2015, Gurbel et al., 2000).  Endothelial cells 
express P-selectin on their surface so difficulties arise in discriminating between platelet 
and endothelial sP-selectin. Platelets internalise sP-selectin which will alter plasma 
measurements.  
 
GPVI is the major signalling collagen receptor found on platelets. GPVI can be shed 
after activation through various mechanisms resulting inactivation (Gardiner et al., 
2004). Cleavage of GPVI results in the release of a soluble 55-kDa GPVI fragment, 
which can be measured in plasma, leaving a 10-kDa remnant fragment membrane 
bound (Figure 4.1). Soluble GPVI (sGPVI) is a specific marker of platelet activation, as 
GPVI is restricted to platelets and megakaryocytes. Multiple groups have reported 
elevated levels of sGPVI in thrombotic conditions including microangiopathy and 
ischaemic stroke (Wurster et al., 2013, Al-Tamimi et al., 2011a).   
 
The sheddase A disintegrin and metalloproteinase domain-containing protein 10 
(ADAM10) has been shown to play the major role in GPVI shedding in humans, with 
ADAM17 also contributing to shedding in mice (Bender et al., 2010, Facey et al., 2016, 
Bergmeier et al., 2004). ADAM10 and ADAM17 are type 1 transmembrane proteases 
that are closely related to matrix metalloproteinases (MMPs) and which regulate levels 
of several surface receptors and ectoenzymes (Facey et al., 2016). The transmembrane 
of ADAM10 is thought to critical for regulation of ADAM10 activity. ADAM10 and 
ADAM17 are expressed on a wide variety of cells (Matthews et al., 2016, Facey et al., 
2016). 
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GPVI shedding can be mediated by a range of mechanisms. Ligand-mediated shedding 
occurs when ligands such as collagen, collagen-related peptide (CRP), and the snake 
venom toxins alborhagin, crotarhagin and convulxin activate and signal through GPVI 
leading to ADAM10 activation (Gardiner et al., 2004, Wijeyewickrema et al., 2007, 
Stephens et al., 2005, Bergmeier et al., 2004). GPVI shedding can also be induced to be 
induced by activation of the other two platelet ITAM receptors, FcγRIIA and CLEC-2 
(Gitz et al., 2014, Gardiner et al., 2008a). GPVI shedding can also be induced by shear 
stress and FX activation (Gardiner et al., 2008a, Al-Tamimi et al., 2011b). 
 
An established sGPVI sandwich- ELISA method has been developed to measure sGPVI 
in the plasma of patients (Al-Tamimi et al., 2009) and used to show its elevation in 
thrombotic conditions (Wurster et al., 2013, Al-Tamimi et al., 2011a). The recent 
observation that GPVI is also activated by fibrin (Alshehri et al., 2015a, Mammadova-
Bach et al., 2015) however makes it unclear whether the increase in GPVI is a reflection 
of activation by collagen or by fibrin, or by both ligands.  Furthermore, platelets are 
now recognised as key players in inflammation and in a variety of 
thromboinflammatory disorders such as deep vein thrombosis and sepsis.  Under these 
conditions, sGPVI may potentially be activated by exposure to fibrin or to other 
pathways of platelet activation alongside classical collagen activation.  
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Figure 4.1 Schematic diagram of soluble GPVI (sGPVI) release into the plasma 
after GPVI cleavage by ADAM10. Activation of the sheddase ADAM10 (and 
ADAM17 in mice) leads to cleavage of GPVI leading to a 10-kDa membrane bound 
remnant and a 55-kDa fragment (sGPVI) that is released into the plasma and which can 
be measured by an established sGPVI ELISA.   
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The main aims of this chapter are (i) compare the level of shedding of GPVI ligands by 
collagen and CRP alongside activation by, G protein-coupled receptor (GPCR) agonists 
and fibrin; and (ii) the level of sGPVI in the plasma of patients with a variety of 
inflammatory conditions, namely rheumatoid arthritis (RA), thermal injury, clinically 
diagnosed sepsis or inflammatory bowel disease (IBD). 
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4.2 Results  
4.2.1 GPVI is not detected in GPVI deficient patients 
To confirm the validity of the anti-GPVI antibody, lysates were collected from 
unstimulated and fibrin stimulated samples of patients with GPVI deficiencies (Matus et 
al., 2013) and blotted for GPVI using an anti-GPVI antibody to the cytosolic tail, which 
recognises full length GPVI and the 10 kDa membrane remnant. Reductions in full 
length GPVI and the appearance of the remnant tail represent shedding of the 
glycoprotein receptor. As expected, no GPVI or tail remnant was recognised in the 
samples from the patients with GPVI deficiencies compared to healthy controls (HCs; 
Figure 4.2). GPVI shedding was observed in stimulated samples of HCs, supporting the 
finding that the anti-GPVI only detects GPVI and the tail remnant is also of GPVI 
origin.  
 
4.2.2 Classical GPVI agonists induce GPVI shedding  
This study initially set out to quantitate GPVI shedding by classical GPVI ligands. 
GPVI ligands, collagen and CRP, along with A23187, a potent GPVI shedding 
stimulus, were used to activate platelets under stirring conditions (1200 rpm) for 1 h in 
the presence of the αIIbβ3 blocker integrilin (eptifibatide; 9 µM) and CaCl2 (1 mM). 
Lysates were prepared and blotted for GPVI using an anti-GPVI antibody to the 
cytosolic tail and again reductions in full length GPVI and the appearance of the 
remnant tail represent shedding of the glycoprotein receptor. Collagen, CRP and 
A23187 induced shedding of GPVI as shown by the reduction of full length protein and 
appearance of a doublet, with a major band of approximately 14 kDa and a smaller band 
below (Figure 4.3Ai).   
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Figure 4.2 – GPVI is not detected in GPVI deficient patients. Washed platelets 
(5x10
8
/ml) of patients with GPVI deficiencies (P1 and P2) were stimulated with 
thrombin (1 U/ml) in the presence of fibrinogen (100 µg/ml: polymerised fibrin) under 
stirring conditions in the presence of eptifibatide (9 µM) and blotted for GPVI using the 
anti-GPVI antibody.  Washed platelets from healthy controls (HCs) were also 
stimulated with thrombin (1 U/ml) in the presence of fibrinogen (100 µg/ml), thrombin 
(1 U/ml) in the presence of fibrinogen (100 µg/ml) and GPRP (10 mM). This 
experiment was performed once experiment with two unrelated families. 
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Figure 4.3 - Stimulation of platelets with GPVI and ITAM ligands induces GPVI 
shedding. A(i) Washed platelets (5x10
8
/ml) were stimulated with collagen (30 µg/ml), 
CRP (30 µg/ml), thrombin (1 U/ml), rhodocytin (300 nM) and caclium ionophore 
(A23187: 10 µM), a potent shedding medaitor, in suspension under stirring conditions 
for 1 h at 37
o
C, in the presence of eptifibatide (9 µM) and CaCl2 (1 mM). Membranes 
were blotted with an anti-GPVI antibody for GPVI (60-65-kDa) and the GPVI remnant 
band (10-17-kDa). Representative figure of stimulations from 8 separate donors. A(ii) 
Quantitation analysis of GPVI shedding after platelet stimulation with various GPVI 
and ITAM ligands. GPVI shedding represented as % of intact GPVI remaining after 
stimulation compared to unstimulated GPVI levels. Results are shown as mean ±SEM. 
One-way ANOVA performed with Bonferroni post-test, n=8, ***p<0.005. Bi) Western 
blot for GPVI after platelet treatment with collagen, CRP and thrombin for 5 min or 1 h 
stimulation. Representative figure of at least 6 donors. B(ii) Quantitation analysis of 
134 
 
GPVI shedding after 5 min and 1 h stimulation with GPVI ligands and thrombin. GPVI 
shedding represented as % of GPVI remaining compared to unstimulated GPVI levels. 
Results are shown as mean ±SEM. One-way ANOVA performed with Bonferroni post-
test, n=6, ***p<0.005. 
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Shedding could be first observed after 5 min as illustrated by the increase in the remnant 
tail, but was more prominent after 60 min (Figure 4.3B). There was no evidence of 
shedding of GPVI in unstimulated samples as shown by the absence of the membrane 
remnant.  There was minimal shedding observed with calf thymus histones (Figure 
4.3Ai). The level of GPVI shedding was calculated using a Li-cor Odyssey-FC imager 
and Image Studio software based on the percentage of GPVI left after stimulation.  
Collagen (30 µg/ml), CRP (30 µg/ml), and A23187 (10 µM) reduced the level of GPVI 
on platelets to 51.0 ± 22.4%, 40.1 ± 25.3% and 29.5 ± 18.1% (± SD, n=7) relative to 
unstimulated controls (Figure 4.3A).   
 
GPVI cleavage has also been shown to be mediated by the two platelet ITAM receptors, 
FcγRIIA and CLEC-2 (Gitz et al., 2014, Gardiner et al., 2008b). The CLEC-2 ligand, 
rhodocytin (300 nM) reduced the level of GPVI to 49.6 ± 27.0% of unstimulated GPVI 
samples (figure 4.3B). These results show that GPVI is shed by several mechanisms, 
namely by direct receptor activation, by the hemITAM receptor CLEC-2 and by the 
Ca
2+
 ionophore CLEC-2.  The former all induce a similar level of shedding of GPVI 
after 1 h, namely approximately 50% of controls.  A23187 induced a great degree of 
shedding in the order of 75% of control levels. 
 
4.2.3 Activation of G protein-coupled receptors does not induce GPVI shedding 
Studies were performed to investigate whether G protein-coupled receptors (GPCRs) 
could induce GPVI shedding.  To address this, the GPCR agonists, ADP, a P2Y1 and 
P2Y12 ligand, PAR-1 peptide (SFLLN), a PAR-1 receptor ligand and thrombin, a PAR-
1 and PAR-4 agonist, were used to activate platelets under stirring conditions for 1 h in  
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Figure 4.4 – Activation of GPCRs does not induce GPVI shedding. A(i) Western 
blot for GPVI after platelet stimulation with GPCR agonists, thrombin (1 U/ml), ADP 
(10 µM) and PAR-1 peptide (SFLLRN :100 µM) in the presence of eptifibatide (9 µM) 
and CaCl2 (1 mM) under stirring conditions for 1 h at 37
o
C. Representative figure of at 
least 8 donors. A(ii) Quantitation of GPVI shedding after platelet stimulation with 
GPCR agonists. % of GPVI represents levels of intact GPVI remaining compared to 
unstimulated GPVI levels. Results are shown as mean ±SEM. One way ANOVA with 
Bonferroni post-test was performed to compare shedding to unstimulated platelets, n=8-
12, ***p<0.05 B) GPVI shedding measured by flow cytometry. Washed platelets 
(2x10
8
/ml) were pre-incubated with IG5(Fab’)2-488 (8 µg/ml), an antibody that 
recognises GPVI, before stimulation (static) with A23187 (10 µM), thrombin (1 U/ml), 
ADP (10 µM) and PAR-1 peptide (SFLLRN :100 µM) in the presence of CaCl2 (1 mM) 
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for 45 min at 37
o
C. % of Median intensity fluorescence (MFI) of unstimulated samples 
were compared to stimulated samples. One-way ANOVA performed with Bonferroni 
post-test, n=4, mean shown ±SEM, *p<0.05, **<0.01. 
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the presence of the αIIbβ3 blocker eptifibatide (9 µM) and CaCl2 (1 mM).  The level of 
GPVI was measured using the antibody to the cytosolic tail of GPVI as described above 
and by flow cytometry using mAb 1G5 to the GPVI ectodomain. The GPCR agonists, 
ADP (10 µM) and PAR-1 peptide (SFLLRN; 100 µM), did not induce shedding as 
measured by western blotting (Figure 4.4A) and by flow cytometry (Figure 4.5B). 
A23187 was used as a control and shown to reduce the level of GPVI to 29.8 ± 8.6% of 
controls as measured by flow cytometry (Figure 4.4B).  
 
In contrast to the above results for ADP and PAR-1 peptide, thrombin (1 U/ml) induced 
a similar level of GPVI shedding to that induced by collagen as measured by western 
blotting, 47.6 ± 20.6% and 51.0 ± 22.4% of unstimulated GPVI levels, respectively (± 
SD, n=8-12). The appearance of a band of an ~14 kDa major and 10 kDa minor band 
corresponding to the GPVI remnant was also seen in 50% of donors (Figure 4.4 and 
4.5A). The basis for the variation between donors in formation of the GPVI tail remnant 
is not known, although this could be related to variation of donor responses to thrombin, 
but indicates that in some donors, it may undergo further cleavage.  Thrombin (1 U/ml) 
also induced a similar level of shedding of GPVI when measured by flow cytometry to 
40.0 ± 26.5% of controls (n = 4; Figure 4.4B). These results demonstrate that thrombin 
but neither ADP nor PAR-1 peptide induces shedding of GPVI indicating that shedding 
is not mediated by activation of the Gi- and Gq-coupled GPCRs.  
 
4.2.4 Fibrin stimulation of platelets induces GPVI shedding  
The mechanism of shedding of GPVI by thrombin was further investigated.  Two 
possibilities for thrombin-induced shedding were considered, namely either that   
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Figure 4.5 – Fibrin stimulation of platelets induces GPVI shedding. A(i) Western 
blot for GPVI after washed platelets (5x10
8
/ml) were stimulated with fibrinogen (100 
µg/ml), thrombin (1 U/ml) in the presence of fibrinogen (polymerised fibrin) and fibrin 
formed in the presence of GPRP (10 mM) and under stirring conditions for 1 h at 37
o
C 
in the presence of eptifibatide (9 µM) and CaCl2 (1 mM). GPRP was addded with 
fibrinogen 3 min before thrombin stimulation to prevent fibrin polymerisation. 
Representative figure of stimulations from 5 donors. A(ii) Quantitation analysis of 
GPVI shedding induced by different forms of fibrin. % of GPVI represents levels of 
intact GPVI remaining after stimulation compared to unstimulated GPVI levels. Results 
are shown as mean ±SEM. One-way ANOVA performed with Bonferroni post-test to 
compare fibrin-induced shedding in the presence of GPRP and fibrinogen alone to 
unstimulated samples, *p<0.05 **p<0.01 ***p<0.005, n=5 donors. B(i) Western blot 
for GPVI after stimulation with thrombin (1U/ml) in the presence of fibrinogen (100 
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µg/ml; polymerised fibrin) in the presence of inhibitors under same conditions as 
before. Representative figure of 5 separate donors. GI254023 (2 µM) and GM6001 (10 
µg/ml) were added 5 min before fibrinogen and thrombin stimulation. B(ii) Quantitation 
GPVI shedding analysis of fibrin in the presence of sheaddase inhibitors (GI254023: 2 
µM, GM6001: 10 µg/ml), GPRP (10 mM) and dasatinid (10 µM) and PRT (10 µM). % 
of GPVI represents levels of intact GPVI after stimulation compared to unstimulated 
GPVI levels. Results are shown as mean ±SEM. A two-tailed t-test was performed to 
show significant differnece between fibrin-induced shedding with and with out 
inhibitors. n=3; *p<0.05 **p<0.01 ***p<0.005. 
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thrombin can directly cleave GPVI or that cleavage results from activation of GPVI by 
fibrin. There is however no cleavage site in GPVI for thrombin. Therefore, this favours 
the latter option that fibrin, formed from cleavage of fibrinogen (released from platelets) 
by thrombin, mediated shedding. 
 
To further investigate the mechanism of shedding of GPVI, platelets were stimulated 
with thrombin in the presence of fibrinogen (100 µg/ml) to ensure that a constant 
amount of fibrin was formed between experiments.  In the presence of fibrinogen, 
thrombin induced a marked reduction in GPVI and stimulated formation of a doublet 
corresponding to the GPVI tail remnant, with the lower band being prominent in some 
studies (Figure 4.5Ai).  Fibrinogen alone did not induce GPVI shedding (Figure 4.5Ai). 
In the presence of fibrinogen, thrombin induced a greater level of GPVI shedding than 
in the absence of fibrinogen and was similar to that induced by A23187 (31.4 ± 10.9%, 
47.6 ± 20.6% and 29.5 ± 18.1% of unstimulated GPVI, respectively; Figure 4.5Aii).  
 
Fibrin can be present in a monomeric form and polymerised form. To determine if 
thrombin induces cleavage of GPVI through monomeric or polymerised fibrin, 
polymerisation of fibrin was inhibited by addition of GPRP (10 mM). In the presence of 
GPRP, there was a marked reduction in the level of GPVI cleavage (Figure 4.5A&Bi) 
suggesting monomeric fibrin does not induce GPVI shedding in platelet suspensions. 
 
4.2.5 D-dimers do not induce shedding of GPVI 
Fibrin is degraded through activation of fibrinolytic pathways. D-dimers are a 
degradation product of fibrin breakdown and can be released into the circulation  
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Figure 4.6 – Platelet stimulation with D-dimer does not induce GPVI shedding. 
A(i) Western blot for GPVI after washed platelets (5x10
8
/ml) were stimulated with 
different concentrations of D-dimer (5-10 µg/ml) under stirring conditions for 1 h at 
37
o
C in the presence of eptifibatide (9 µM) and CaCl2 (1 mM). A23187 (10 µM) used 
as positive control. Representative figure of 3 donors. A(ii) Quantitation analysis of 
GPVI shedding induced by D-dimers. % of GPVI represents levels of GPVI remaining 
after stimulation compared to unstimulated GPVI levels. Results are shown as mean 
±SEM, n=3-5. One way ANOVA with Bonferroni post-test was performed to compare 
shedding to unstimulated platelets, ***p<0.005. 
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(Ohlmann et al., 2006). To determine if this fibrin degradation product can also induce 
GPVI shedding, platelets were stimulated with D-dimers (5-10 µg/ml) and blotted for 
GPVI. D-dimers had no effect on GPVI shedding. There was no reduction in GPVI and 
no appearance of the tail remnant (Figure 4.6A), demonstrating that D-dimers do not 
induce shedding of GPVI. 
 
4.2.6 Multiple sheddases are involved in fibrin-induced GPVI shedding 
Collagen-induced GPVI shedding has previously been shown to be predominately 
through the activity of the sheddase ADAM10 (Facey et al., 2016), with a partial role 
for ADAM17 in mice  (Bergmeier et al., 2004).  To determine if this was the case for 
fibrin-induced GPVI shedding various inhibitors known to reduce GPVI shedding, 
including collagen-mediated GPVI shedding were used. GM6001, a general 
metalloproteinase inhibitor, which inhibits ADAM10 and ADAM17, and the specific 
ADAM10 inhibitor, GI254023, were added to fibrinogen before thrombin stimulation. 
GM6001 reduced GPVI shedding by thrombin in the presence of fibrinogen, with less 
reduction in GPVI being observed and less tail remnant expressed (Figure 4.5Bi). To 
determine if ADAM10 was the major contributor to this reduction, GI254023, the 
ADAM10 inhibitor, was added before stimulation. In the presence of GI254023, only 
the upper band of the doublet GPVI tail was observed suggesting that the lower band is 
formed by the action of a second sheddases (Figure 4.5Bi). Fibrin-induced GPVI 
shedding was significantly reduced in the presence of GM6001 (*p<0.05), but there was 
no significant difference in fibrin-induced stimulation in the presence of GI24023 
(Table 4.1 and Figure 4.5Bii). This suggests that other sheddases other than ADAM10 
are involved in fibrin-induced GPVI shedding. DAPT (10µM), a γ-secretase inhibitor, 
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also had no effect on the degree of fibrin-induced GPVI shedding (42.0 ± 15.8% of 
unstimulated GPVI ± SD, data not shown). Overall these results suggest multiple 
sheddases and alternative mechanisms are involved in fibrin-induced shedding.    
 
4.2.7 GPVI signalling does not mediate fibrin-induced GPVI shedding  
Ligand-mediated shedding of GPVI, such as collagen-induced shedding, can be blocked 
in the presence of inhibitors of Src and Syk kinases (Stephens et al., 2005). To 
investigate if this was a similar result in the presence of thrombin and fibrin 
polymerisation, the Src and Syk inhibitors, dasatinib (10µM) and PRT060318 (10µM) 
were added before fibrinogen and thrombin stimulation. There was no difference was 
seen in the amount of GPVI shed by thrombin/fibrinogen in the presence of dasatinib 
and PRT060318 compared to fibrin alone (38.1 ± 12.1% and 21.6 ± 1.25% compared to 
37.3 ± 13.7% respectively, Figure 4.5Bii and table 4.1). This demonstrates that GPVI 
signalling does not mediate shedding by fibrin.  
 
4.2.8 Soluble GPVI is detectable in patients with chronic inflammation including 
rheumatoid arthritis and inflammatory bowel disease  
The results above have shown GPVI shedding occurs after platelet stimulation with 
GPVI ligands including collagen and fibrin. The cleavage of GPVI results in a 55kDa 
soluble fragment, referred to as sGPVI being released into the plasma. An aim of this 
study was to show sGPVI can be detected by sGPVI ELISA (Al-Tamimi et al., 2009) in 
a range of inflammatory conditions, therefore, sGPVI was measured in patients with 
rheumatoid arthritis (RA), inflammatory bowel disease (IBD) and patients that have  
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Table 4.1 – Inhibitors effects on fibrin-induced GPVI shedding. Quantitation 
analysis of GPVI shedding induced by fibrin in the presence of sheaddase inhibitors 
(GI254023: 2 µM, GM6001: 10 µg/ml), GPRP (10 mM) and Src and Syk inhibitors 
(dasatinib: 10 µM, PRT: 10 µM). % of GPVI remaining compared to unstimulated 
samples, mean shown as ±SD.  A two-tailed t-test was performed to compare fibrin-
induced shedding with and without inhibitors to unstimulated platelets. T-test also 
performed to show significant differnece between fibrin-induced shedding with and 
with out inhibitors.  *p<0.05 **p<0.01 ***p<0.005 
  
  
Condition 
% of GPVI 
of 
unstimulated 
samples  
 Mean (± 
SD) 
Significance to 
unstimulated samples 
Significance to Fib + 
Thr samples 
Unstimulated  100 - - <0.0001 ***p<0.001 
Fibrinogen 82.2 (34.3) 0.1270 N.S. 0.0082 **p<0.001 
Fibrinogen + 
Thrombin 
31.4 (10.85) <0.0001 ***p<0.001 - - 
Fibrinogen 
Thrombin + 
GPRP 
61.8 (23.6) 0.0223 *p<0.05 0.0422 *p<0.5 
Fibrinogen 
Thrombin + 
GI254023 
43.2 (32.13) 0.0030 **p<0.01 0.409 N.S. 
Fibrinogen 
Thrombin + 
GM6001 
49.4 (10.75) 0.0005 ***p<0.001 0.040 *p<0.5 
Fibrinogen 
Thrombin + 
Dasatinib 
36.4 (4.59) 0.0020 **p<0.01 0.141 N.S. 
Fibrinogen 
Thrombin + 
PRT060318 
25.1 (6.51) 0.0020 **p<0.01 0.275 N.S. 
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undergone thermal injury and septic patients. RA is a chronic inflammatory condition, 
associated with platelet activation, predominately effecting and causing damage to 
joints (Del Rey et al., 2014). Plasma was obtained from 10 RA patients and compared to 
healthy controls. sGPVI levels were significantly in RA patients compared to HCs 
(***p<0.005; Figure 4.7A).  
 
sGPVI was also measured in IBD patients, another chronic inflammatory condition 
linked with platelet activation.  sGPVI was detected in the plasma of 42 IBD patients 
consisting of either active/inactive Crohn’s disease and active/inactive ulcerative colitis 
(UC). sGPVI levels were not raised in patients with active/inactive Crohn’s disease and 
inactive UC compared to HCs, with a similar distribution of sGPVI levels being 
observed (Figure 4.7B). sGPVI was only significantly elevated in patients with active 
UC, with higher levels then both inactive UC patients and HCs (*p<0.05 and **p<0.01 
respectively; Figure 4.7B). Active UC patients also had a wider distribution range of 
sGPVI levels compared to controls.  
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Figure 4.7 - sGPVI is elevated in patients with chronic inflammatory conditions 
including rheumatiod arthritis (RA) and Ulcerative Colitisis (UC). A) sGPVI levels 
measured by sGPVI ELISA in 10 RA patients compared to 10 HCs. Mann-Whitney 
statistical test was performed to compare sGPVI levels of RA patients and HCs, 
***p<0.005: median shown. B) sGPVI levels of inflammatory bowel disease (IBD) 
patients with inactive, active Crohn’s disease (n=13, n=4), inactive and active UC 
(n=12, n=13), compared to HCs (n=20). Mann-Whitney statistical test was performed to 
compare sGPVI levels of different IBD patient groups and HCs, *p<0.05, **p<0.01: 
median shown. C) sGPVI levels of IBD patients with haemoglobin (Hgb) levels of 
above or below 120 g/l (n=28, 13 respectively) compared to HCs (n=20). A Kruskal-
Wallis statistical test with Dunn’s multiple comparisons was performed to compare the 
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three patient groups (**p<0.01, ***p<0.005). D) Table of statistical values after 
Spearman’s rank correlation performed to examine correlations between sGPVI levels 
and clinical parameters, including age, Hgb levels, platelet count, ferritin levels (CRP 
represents C-Reactive protein levels). Significant correlation is observed when p<0.05. 
A Spearman’s rank value of 0.3 gives weak correlation, 0.5 moderate and above 0.7 
represents strong correlations.  
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Table 4.2 - Patient parameters: Inflammatory Bowel Disease. IBD patient parameters and 
healthy controls (HC). Patients were categorised into the types of IBD, Crohn’s disease or 
ulcerative colitis (UC) and diagnosed with inactive and active inflammatory flares based on 
clinical diagnoses, C-Reactive Protein (CRP) levels and endoscopy results. Results shown as 
mean with inter-quartile range (IQR).  
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sGPVI correlations with other IBD clinical parameters were also investigated. There 
was no correlation between platelet count and sGPVI levels in any of the IBD patient 
groups (Figure 4.7B). When analysing the IBD patients as a whole cohort, C-reactive 
protein levels of the patients also did not correlate with sGPVI levels. There was also no 
significant correlation between age and sGPVI levels in the IBD patients (Figure 4.7B), 
which supports previous findings in other studies (Al-Tamimi et al., 2011a). Iron 
deficiency anaemia (IDA) is commonly associated with IBD cases, with around 17% of 
IBD patients having IDA, increasing in prevalence to around 60% when studying 
hospitalised IBD patients (Guagnozzi and Lucendo, 2014, Bergamaschi et al., 2010). 
Iron deficiency can affect disease severity in IBD patients and chronic gastrointestinal 
bleeding has been proposed as a cause. To establish if there are associations between 
platelet activation and iron deficiency in IBD patients, sGPVI correlations with 
haemoglobin (Hgb) levels and ferritin levels were studied. A weak correlation was seen 
with sGPVI and Hgb levels (Spearman’s rank = -0.3; figure 4.7D) and a moderate 
correlation of sGPVI levels with ferritin levels of patients with a C-Reactive Protein 
level greater than 5 (Spearman’s rank = -0.53). When separating IBD patients into 
groups of low Hgb levels (<120g/l) and high Hgb (>120/l) there was a significant 
difference, with patients with low Hgb have significantly higher levels of sGPVI 
compared to patients with higher Hgb levels and HCs (**p<0.01 ***p<0.005, figure 
4.7C).  
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4.2.9 Soluble GPVI is detectable in patients with thermal injury and raised in 
patients that develop sepsis  
sGPVI was measured in patients who have undergone thermal injury to establish sGPVI 
kinetics in an inflammatory condition over time. Burns patients were recruited as part of 
the Scientific Investigation of the Biological Pathways Following Thermal Injury in 
Adults (SIFTI) study, (Table 4.3; (Hampson et al., 2016)). This was a multi-centre 
prospective observational study which recruited patients with burns of various size from 
1.5-95% total body surface area (TBSA). sGPVI was detected in 99 patients and were 
subdivided into non-septic and septic groups according to whether they met the 
American Burns Association (ABA) sepsis criteria (Greenhalgh et al., 2007) had a 
positive culture and/or an antibiotic response. 
 
In this patient cohort sGPVI levels were measured at regular intervals from Day 1 (D1) 
to Month 12 (M12) in 99 burns patients. There was an increase in sGPVI levels from 
D1 until D14, where levels peaked in the majority of patients before declining back 
down to levels of HCs by M12 (Figure 4.8A and Table 4.4). With each time point there 
was a wide distribution of sGPVI levels, with some patients having significantly high 
levels than average (Figure 4.8A). However, statistical significance above healthy 
controls was only reached at D14 (***p<0.005; Figure 4.8A and Table 4.4). There was 
only weak correlation between sGPVI levels and total body surface area at D1 
(Spearman’s rank = 0.28, ***p<0.005).  
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Table 4.3. Patient parameters: thermal injury patients with and without sepsis. Patient 
parameters listed for thermal injury patients and healthy controls (HC). For patient recruitment 
details see Hampson et al. (2016). Sepsis diagnosis made when at least 3 of the criteria agreed 
in 2007 by the American Burn Association (ABA) were met along with either a positive 
bacterial culture or evidence of clinical antibiotic response. (Hampson et al., 2016, Greenhalgh 
et al., 2007). MOF represents Multiple Organ Failure based on a Denver Post-injury MOF score 
>3 on two consecutive days involving two organ systems (Kraft et al., 2014). %TBSA, 
percentage of total body surface area. IQR, inter-quartile range.  
 
 
  
Parameter HC All  Septic Non-septic  
Number of 
patients 
15 99 57 42 
Age, mean 
(min-max) 
29 (20-47) 49 (16-93) 49 (16-91) 49 (16-93) 
Gender M:F 
9:6 61:38 36:21 25:17 
% TBSA: Mean 
(IQR) 
- 24 (8-38) 34 (16-51) 12 (6-21) 
Survival Y:N 
(%) 
- 78:21 (79) 38:19 (67) 40:2 (95) 
MOF Y:N (%) 
- 25:71 (21) 23:32 (42) 2:39 (5) 
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Figure 4.8 - sGPVI is detectable in patients with thermal injury and raised in 
patients who experience at least one episode of sepsis. A) sGPVI levels of patients 
with thermal injury (n=99) measured in samples taken from Day 1 (D1) to month (M12) 
compared to HCs (n=15). Mann-Whitney statistical test was performed to compare each 
patient time point to HC. ***p<0.005: median shown. B(i) Peak sGPVI levels in septic 
and non-septic patients with thermal injury and HCs. Sepsis diagnoses as meeting at 
least 3 of the American Burn Association (ABA) sepsis criteria and a positive culture. 
Mann-Whitney statistical test was performed to compare sGPVI levels of septic patients 
to non-septic patients and HCs, **p<0.01 ***p<0.005: median shown. B(ii) 
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Comparisons of sGPVI levels of septic patients compared to non-septic patients. Mann-
Whitney statistical test was performed to compare sGPVI levels of septic and non-septic 
***p<0.005: median shown. C(i) Longitudinal analysis using a linear mixed-effects 
model examining the relationship between sGPVI and time according to sepsis status. 
Line represents mean predicted effects and shaded area represents 95% confidence 
interval. B(ii) Table showing the discriminatory performance of GPVI for predicting 
sepsis on different sample days after logistic regression analysis. Discriminatory power 
represented as area under the receiver operator characteristic curve (AUROC) with a 
95% confidence interval. A value of 0.9 represents a strong predictive value. 
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Sepsis was a common complication in thermal injury patients with a 56.7% incidence. 
Separating into septic and non-septic groups revealed a significant elevation in sGPVI 
levels at D7, which is associated with the time point were sepsis manifests in the 
patients (***p<0.005; Figure 4.8Bii).  There is a limited time window in sGPVI 
elevation, which could reflect the different time course of sepsis onset. Peak levels of 
sGPVI were significantly higher in the septic patients compared to those non-septic 
patients and HCs (**p<0.01 ***p<0.005; Figure 4.8Bi).  
 
To establish if sGPVI levels could be a potential diagnostic marker for sepsis 
progression, longitudinal statistical analysis and prediction models were performed, 
showing curves representing sGPVI levels of septic or non-septic patients over time 
(Figure 4.8C). The analysis shows crossovers of sGPVI levels and 95% confidence 
intervals of the septic and non-septic patients and a discriminatory predictive value 
(represented as an area under the receiver operating characteristic (AUROC) curve 
value) of 0.73 (0.61-0.84; 95% confidence interval), whereas a value of 0.9 is a strong 
predicator (Figure 4.8C), therefore suggesting sGPVI is not a good diagnostic predictor 
of sepsis progression. 
 
sGPVI levels could be influenced by platelet count. Previous burn’s studies have 
reported large drops in platelet counts at D3 post injury, which is followed by a rebound 
thrombocytosis phase (Marck et al., 2013). Figure 4.9A shows the platelet kinetics for 
non-septic and septic patients.  The platelet counts reached a nadir at D3 and then 
rebounded to a peak between D14 for non-septic and D21 for septic patients (Figure 4.9 
A&B). To establish there was no masking of low GPVI levels at the earlier time point 
by a low platelet count, sGPVI levels were normalised to platelet count (Figure 4.9C).  
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Figure 4.9 - sGPVI is elevated in patients with thermal injury who develop sepsis 
even when platelet count is taken into effect. Platelet counts of patients with thermal 
injury split into (A) non-septic and (B) septic groups, measured using the Sysmex XN-
1000-Hematology Analyser, over the full time course, from Day 1 (D1) to month 
(M12): median shown with interquartile range. C) sGPVI levels normalised to platelet 
count of septic and non-septic thermal injury patients. Mann-Whitney statistical test was 
performed to compare sGPVI levels of septic patients and non-septic burns patients. 
*p<0.05, **p<0.01 ***p<0.005 and median shown. 
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Table 4.4–sGPVI levels and platelet count at the different time points of patients with thermal injury. Median, mean values (±standard 
error of mean) and inter-quartile (IQR) range of sGPVI levels (ng/ml) and platelet counts (x10
9
/l) of patients at the different time points (Day 
1- Month 12). HC=Healthy control. 
  
Time 
point 
sGPVI levels ng/ml Platelet count x10
9
/l 
N 
number 
Median IQR Mean ±SEM Significance to HC 
N 
number 
Median IQR 
Mean 
±SEM 
Significance to M12 
D1 71 37.6 22.3-52.4 47.7 (4.84) 0.109 N.S. 64 202 182-265 216 (10.4) 0.124 N.S. 
D3 88 29.8 17.2-52.4 39.9 (3.79) 0.430 N.S. 79 137 99-203 149 (6.63) <0.0001 ***p<0.005 
D7 77 32.7 19.9-47.9 42.6 (4.83) 0.237 N.S. 68 202 151-281 223 (13.7) 0.13 N.S. 
D14 74 61.3 34.6-102.7 71.3 (6.52) 0.0005 
***p<0.00
5 
69 469 300-615 481 (27.5) <0.0001 ***p<0.005 
D21 61 50.1 29.0-85.9 60.9 (5.55) 0.0057 *p<0.05 57 501 330-600 507 (32.6) <0.0001 ***p<0.005 
D28 62 38.2 16.7-68.5 47.3 (5.30) 0.148 N.S. 55 367 237-467 366 (24.0) 0.0034 **p<0.005 
M2 44 27.6 18.5-55.5 44.5 (6.90) 0.537 N.S. 35 333 256-424 359 (21.6) 0.0006 ***p<0.005 
M3 34 23.6 12.9-43.9 35.9 (7.37) 0.770 N.S. 22 301 245-388 325 (19.9) 0.0018 **p<0.005 
M6 27 30.8 19.4-45.7 36.4 (3.84) 0.294 N.S. 20 257 227-310 271 (15.6) 0.148 N.S. 
M12 30 29.0 17.3-42.1 36.4 (6.05) 0.622 N.S. 19 228 198-259 251 (19.3) - - 
HC 15 27.2 17.5-37.1 23.0 (5.21) - - - - - - - - - 
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From this there were significantly elevated sGPVI levels in septic patients at D3, D7 
and D14 compared to non-septic patients (**p<0.01, ***p<0.005 and *p<0.05 
respectively: Figure 4.9C). D28 also showed significant elevation in sGPVI between the 
septic groups (*p<0.05). 
 
4.2.10 Soluble GPVI measurements in patients with sepsis  
sGPVI were elevated in thermal injury patients that developed sepsis. To further the 
study of platelet activation in sepsis, sGPVI was measured in different sepsis groups, 
including patients with sepsis, severe sepsis, and patients with acute respiratory distress 
syndrome (ARDS). These patient samples were kindly given by the Dr D. Thickett’s 
respiratory group.  Initially, there seemed to be elevated sGPVI levels in all septic 
groups to the level of the heparin-induced thrombocytopenia (HIT) patient sample, 
which was used as a positive control (Figure 4.10A). However, these patients did not 
show any significant elevation above HCs, which were also much higher than the usual 
sGPVI levels observed with the other HCs. This proposed questions as to why the 
patient groups and HC gave higher levels. It was eventually found that the sepsis patient 
sample preparation differed as different centrifugation speeds were used. Blood was 
then collected from more HCs and spun at the different centrifugation speeds to 
establish any differences. Samples spun at 560 g gave significantly higher levels than 
double spun samples at the usual 2500 g speed (**p<0.01: Figure 4.10B), suggesting 
there was an issue with sample preparation.  
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Figure 4.10 - sGPVI is not elevated in septic patients. A) sGPVI levels measured by 
sGPVI ELISA in septic patients; S=sepsis (n=20), VS= very septic (n=20) and ARDS= 
acute respiratory disease syndrome (n=22) and HCs (n=22). HIT= heparin-induced 
thrombocytopenia patient (n=1: positive control). Mann-Whitney statistical test was 
performed to compare sGPVI levels: median shown. B) sGPVI levels of HC samples 
spun at different centrifugation speeds (n=4). Unpaired T-test statistical test was 
performed to compare speeds, **p<0.01: median shown.  
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4.3 Discussion  
The major platelet receptor for collagen, glycoprotein VI (GPVI) can undergo 
proteolytic cleavage after activation releasing a soluble GPVI fragment (55-kDa), 
known as sGPVI into the plasma (Gardiner et al., 2004). sGPVI is a recognised marker 
of platelet activation in thrombotic conditions (Al-Tamimi et al., 2011a, Wurster et al., 
2013). Previous studies have shown ligand-mediated mechanisms behind GPVI 
shedding in response to platelet stimulation by known GPVI ligands, collagen and CRP 
(Gardiner et al., 2004, Bergmeier et al., 2004, Stephens et al., 2005). Moreover, 
activation of ITAM receptors FcγRIIa and the hemITAM receptor, CLEC-2, can also 
induce GPVI shedding (Gardiner et al., 2008b, Gitz et al., 2014). This study firstly 
wanted to confirm these findings and extend this to investigate if signalling through 
GPCRs also mediates GPVI shedding. GPVI ligands, collagen and CRP did mediate 
GPVI shedding, with increased shedding seen over time, reducing GPVI levels to less 
than half of GPVI in unstimulated samples.  Signalling through GPCRs such as, P2Y1 
and PAR-1 did not induce GPVI shedding after platelet stimulation by ADP or PAR-1 
peptide (SFLLRN). Using more GPCR ligands, such as PAR-4 peptide, arachidonic 
acid or U46619 to stimulate platelets would be required to further confirm that 
signalling through GPCRs do not induce GPVI signalling.  
 
Thrombin was able to induce GPVI shedding to levels observed with the GPVI ligands, 
However, there was marked variation between donors in the thrombin-mediated 
shedding, with reduction in GPVI seen with some and appearance of the 10-17-kDa 
GPVI remnant observed in 50% of donors and others showing little shedding. This 
supports findings from previous studies where some showed thrombin inducing 
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shedding (Stephens et al., 2005) and others showed thrombin is a poor mediator of 
GPVI shedding (Gardiner et al., 2004). There are two potential explanations for the 
variation observed. Firstly, thrombin could directly cleave GPVI or there is wide 
variation in fibrinogen levels released from donor platelets after stimulation, which 
could lead to fibrin formation and shedding. Thrombin-mediated shedding did increase 
over time, suggesting more fibrinogen release and consequent shedding. As GPVI lacks 
of cleavage site for thrombin, which argues against direct cleavage by the protease. 
Overall thrombin-mediated shedding is not a result of signalling through PAR receptors 
and other mechanisms are involved.    
 
Recent work from our lab (including work mentioned before; (Alshehri et al., 2015a) 
and from Jandrot-Perrus group (Mammadova-Bach et al., 2015) have discovered that 
fibrin is now GPVI ligand, which activates GPVI and contributes to thrombus 
stabilisation. It was previously unknown whether fibrin can also induce GPVI shedding. 
This part of the study demonstrated that polymerised fibrin, where platelets were 
stimulated with thrombin in the presence of fibrinogen induced GPVI shedding to a 
similar degree observed with the potent shedder, A23187 and other GPVI ligands. 
Fibrin-induced shedding was independent of the fibrinogen with integrin αIIbβ3 
interaction with shedding still being observed in the presence of the integrin blocker 
eptifibatide.  
 
The different mechanisms behind fibrin-induce shedding were then assessed. GPVI-
shedding usually involves action of sheddases in the metalloendopeptidase family, a 
disintegrin and metalloproteinase (ADAMs)  with shedding mediated by GPVI ligands 
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predominately being ADAM10 (Facey et al., 2016) dependent with a minor role for 
ADAM17 in mice (Bergmeier et al., 2004). Fibrin-induced shedding was shown to be 
dependent on multiple sheddases, presumably ADAM17 among others and not just 
through the activity of ADAM10, as ADAM10 inhibition only partially reduced 
shedding and a broad MMP inhibitor, GM6001 was needed for a greater reduction of 
GPVI shedding, suggesting other sheddases and potential other mechanisms are 
involved.   
 
The conformational state of fibrin formed during stimulation seemed to have a major 
effect on GPVI shedding. The monomeric soluble form of fibrin, which is the 
predominant form when in the presence of GPRP, a peptide which inhibits 
polymerisation, only induced minimal GPVI shedding in comparisons with polymerised 
fibrin. Fibrin-induced shedding in suspension was observed with polymerised fibrin and 
not monomeric. Interestingly monomeric fibrin was shown to bind GPVI and induce 
activation when immobilised (Alshehri et al., 2015a). Fibrin fragments, such as D-
dimers, released after fibrin degradation were also not able to induce GPVI shedding.    
 
Ligand-mediated GPVI shedding by GPVI agonists has previously been shown to be 
dependent on receptor activation and signalling (Stephens et al., 2005).When inhibitors 
such as PP2 were added to inhibit signaling proteins downstream of GPVI, shedding 
was prevented.  To establish if this was the case for fibrin-induced GPVI shedding, 
inhibitors for Src and Syk kinases were added before fibrinogen and thrombin 
stimulation. Fibrin-induced GPVI shedding was not reduced in the presence of src and 
Syk tyrosine kinases inhibitors suggesting that GPVI signaling is not required for 
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shedding to occur and fibrin-induced GPVI shedding is not ligand-mediated shedding. 
Moreover, the GPRP inhibition data showing that only polymeric fibrin induces 
shedding, suggests there is an alternative, yet undiscovered mechanism involved in 
fibrin-induced GPVI shedding, as observed during shear-induced or FXa-induced 
shedding (Al-Tamimi et al., 2011b, Al-Tamimi et al., 2012). Measuring GPVI shedding 
by fibrin under flow conditions at different shear rates and measuring GPVI shedding in 
the presence of Factor Xa inhibitors would give future directions to test whether shear 
and FXa has a role in fibrin-mediated GPVI shedding.  
 
The findings that GPVI can be shed in response to fibrin stimulation of platelets as well 
as collagen provides an alternative physiological agonist that could cause sGPVI to be 
released into the plasma after GPVI shedding. sGPVI has previously been shown to be a 
platelet activation marker in thrombotic associated conditions (Yamashita et al., 2014a, 
Wurster et al., 2013, Al-Tamimi et al., 2011a). This study has extended this to show 
sGPVI can be a platelet activation marker in a range of different inflammatory 
conditions. sGPVI was detected in two chronic inflammatory conditions, rheumatoid 
arthritis (RA) and inflammatory bowel disease (IBD). Both these inflammatory 
conditions have episodes of flare ups followed by remission. sGPVI levels were 
elevated above healthy controls (HCs) in RA patients. As RA is associated with platelet 
activation (Del Rey et al., 2014, Boilard et al., 2010). sGPVI is therefore a potential 
platelet activation marker in patients with inflammatory flare ups.  sGPVI levels were 
also elevated in patients with active ulcerative colitis (UC), but not Crohn’s disease nor 
inactive UC patients. The majority of the Crohn’s patients had lower C Reactive protein 
levels than active UC patients in this cohort, which could be a potential explanation for 
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the wider distribution of sGPVI levels observed and suggests the activate UC patients 
had more severe inflammation than the Crohn’s patients.  
 
sGPVI correlations with various clinical parameters of IBD patients were studied. There 
was no significant correlation with age and sGPVI,  supporting findings of previous 
sGPVI studies (Al-Tamimi et al., 2011a) . Of the other parameters tested, haemoglobin 
levels and ferritin levels of patients with active inflammation gave the strongest 
correlations, with sGPVI levels being negatively correlated to both. These parameters 
suggest there is a potential link between platelet activation and iron deficiency.  Patients 
with C-reactive protein levels greater than 5, had greater levels of inflammation, 
reduced ferritin levels and higher sGPVI, suggesting links between inflammatory status 
causing iron deficiency, which leads to increased platelet activation. Iron deficiency 
anaemia (IDA) is commonly associated with IBD cases, with around 17% of IBD 
patients developing IDA (Guagnozzi and Lucendo, 2014, Bergamaschi et al., 2010) and 
affects disease severity. Elevated sGPVI levels in iron-deficient patients may potentially 
arise from platelet activation during times of chronic gastrointestinal bleeding, where 
blood is lost from inflamed luminal surfaces leading to the development of IDA. GPVI 
plays a critical role in maintaining vascular integrity at sites of inflammation (Gros et 
al., 2015a) and could be cleaved once activated by fibrin at these inflamed areas, 
increasing sGPVI levels. sGPVI may therefore represent a novel marker to predict 
development of IDA in IBD patients. However, more patients with Crohn’s disease and 
UC would need to be recruited and full medical history determined to confirm whether 
the higher sGPVI levels in these patients are a result of iron deficient and not other 
factors such as levels of inflammation, C reactive protein levels or medication taken. 
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The study also looked at sGPVI kinetics longitudinally in patients with thermal injury. 
sGPVI levels were measured in 99 patients from Day 1 post initial injury to Month 12. 
sGPVI was significantly elevated above HCs at Day 14. Surprisingly, sGPVI levels 
were not raised initially at early time points (Day 1-3) post injury, where it would be 
expected that with more tissue damage would occur and presumably more collagen 
exposure to allow platelet activation. This suggests that only a fraction of platelets were 
activated by collagen exposed after damage and other mechanism, potentially fibrin, 
was involved for the platelet activation observed at later time points.  
 
An alternative explanation for low levels of sGPVI initially post injury is that elevations 
may be masked by the low platelet counts observed at Day 3. To address this, sGPVI 
levels were normalised to the platelet count. This then showed that sGPVI levels 
became elevated at Day 3 in septic patients, suggesting that some GPVI shedding is 
mediated through collagen exposed after damage. However, sGPVI levels remained 
elevated in the septic patients at Day 7 and 14.  Collagen exposure at these time points 
would be minimal as the damaged area would undergo recovery.  There was also only 
weak correlation between sGPVI levels and burn injury severity, suggesting sGPVI 
released at these time points was mediated through alternative mechanism associated 
with sepsis development. Overall sGPVI levels were significantly higher in those 
patients that developed sepsis.  sGPVI did only have a moderate predictive value of 
0.73 for predicting sepsis alone, where a strong predictive value would range between 
0.9 and 1.0. The discriminatory power for predicting sepsis is likely to be increased 
when combined with other sepsis markers, such as cell-free DNA, neutrophil function 
or immature granulocytes, which have already been shown to be good prediction 
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markers of sepsis (Hampson et al., 2016). sGPVI elevations observed in the septic 
patients post injury is potentially due to platelet activation through alternative 
mechanisms. The main plausible explanation for elevation of sGPVI, where there is 
minimal activation of platelets by collagen, is that during disseminated intravascular 
coagulation (DIC) seen in sepsis (Semeraro et al., 2010a, Levi et al., 2003), platelets 
become activated by many DIC associated mechanisms, leading to the formation of 
thrombi encompassed by polymerised fibrin networks, which then induce GPVI 
shedding after activation. Correlating plasma fibrinogen levels or d-dimer levels (a 
breakdown product released after fibrinolysis), of patients with thermal injury and 
sepsis with sGPVI levels, would help provide support in the future as to if the elevations 
of sGPVI observed were mediated through fibrin-induced GPVI shedding. sGPVI 
measurements in a other patient cohorts, where increased fibrin formation is clinical 
characteristic such as patients with deep vein thrombosis (DVT), would be helpful in 
supporting the hypothesis that fibrin can mediate GPVI shedding, leading to increased 
sGPVI levels observed in these patients.  
 
sGPVI levels were also measured in the plasma of patients with various forms of sepsis, 
including sepsis, severe sepsis, and acute respiratory distress syndrome (ARDS). No 
elevations were observed in the septic patients compared to HCs, although all samples 
had sGPVI levels raised above all the other samples in the other patient cohorts. 
Unfortunately, this resulted due to the different sample preparation as different 
centrifugation speeds were used. This affected the results as samples spun at 560 g gave 
significantly higher levels than the usual double spun samples at 2500 g when blood 
was collected and spun following this observation. This suggested an artefact produced 
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from the sample preparation, which caused the increase in sGPVI and not elevated 
levels due to sepsis. It would therefore be of great interest to repeat the sGPVI 
measurements in the various sepsis patient plasma cohorts to establish if sepsis 
development can cause platelet activation and elevated sGPVI levels.  
 
Overall the findings in this chapter here provide more support for sGPVI as a platelet 
activation marker in certain inflammatory conditions, including RA, active UC patients 
and patients with thermal injury. sGPVI can be linked to some secondary complications 
such as iron deficiency in IBD patients and sepsis in certain patients following thermal 
injury. The mechanisms behind the GPVI cleavage resulting in the release of the soluble 
GPVI fragment into the plasma were extensively studied. Signalling through GPVI and 
other ITAM containing receptors, but not GPCR activation can induced GPVI shedding. 
Fibrin is a newly discovered GPVI agonist that can also induce GPVI shedding through 
multiple mechanisms, including the activity of multiple sheddases, including ADAM10 
and ADAM17. Ligand-mediated mechanisms behind GPVI shedding by fibrin did not 
seem to have a predominant role, whereas fibrin conformational state having the most 
important role in mediating fibrin-induced GPVI shedding. Polymerised fibrin and not 
monomeric fibrin, or fibrin degradation productions can induce GPVI shedding.  Fibrin 
along with collagen can mediate shedding and be physiological agonists involved in 
platelet activation in inflammatory conditions. 
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CHAPTER 5 
PODOPLANIN UPREGULATION IN 
INFLAMMATORY SETTINGS  
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5.1 Introduction  
The role of platelets is predominately in haemostasis and thrombosis, with emerging 
roles in development, angiogenesis, and maintaining vascular integrity (Bertozzi et al., 
2010, Kisucka et al., 2006, Gros et al., 2015a). The roles of platelets in infection and 
inflammation are now also being extensively studied. This chapter will look at potential 
roles of platelets in inflammation through studying the podoplanin/ C-type lectin-like 
receptor 2 (CLEC-2) axis.  
 
CLEC-2 is an important platelet-activating receptor involved in haemostasis and 
thrombosis (May et al., 2009). CLEC-2 is expressed on platelets with around 2000 
copies per platelet and expressed on subset set of circulating inflammatory dendritic 
cells in mice (DCs; (Gitz et al., 2014, Lowe et al., 2015c)). CLEC-2 was thought to also 
be expressed on subsets of murine myeloid cells, including monocytes, in resting 
conditions, which increased in expression seen in response to inflammatory stimuli 
(Acton et al., 2012a, Mourao-Sa et al., 2011). However, recent studies  have showed 
CLEC-2 with a more restricted expression profile to platelets and activated DCs in mice 
(Lowe et al., 2015c). 
 
Podoplanin, a 36-43-kDa heavily glycosylated type-1 transmembrane sialoglycoprotein, 
is the only known endogenous CLEC-2 ligand. Podoplanin is expressed on kidney 
podocytes, alveolar type-1 epithelial cells lymphatic endothelial cells (LECs) and 
fibroblastic reticular cells (FRCs) from the T-cell zone of lymphoid cells (Breiteneder-
Geleff et al., 1997, Astarita et al., 2015). In inflammatory settings, podoplanin 
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expression can be upregulated on T-helper 17 (TH17 cells), tumour cells and 
inflammatory macrophages (Peters et al., 2015, Kato et al., 2003, Kerrigan et al., 2012). 
Podoplanin and CLEC-2 have important roles in several process including in 
development and maintenance of the lymphatic system. Deletions in podoplanin or 
CLEC-2 lead to similar blood lymphatic mixing, oedema and haemorrhaging observed 
during development, and are unable to properly inflate the lungs at birth, greatly 
effecting survival (Bertozzi et al., 2010, Finney et al., 2012, Turner et al., 1995, Schacht 
et al., 2003, Ramirez et al., 2003).  
 
Podoplanin and CLEC-2 have roles in other processes beyond development. Podoplanin 
upregulation has been described in numerous inflammation settings, with CLEC-2 
interactions also being implicated. Podoplanin upregulation has been observed on FRCs 
during inflammation and interactions with CLEC-2 affects FRC function. FRCs are 
mesenchymal cells found in lymph nodes, which form a dense reticular network, acting 
as a scaffold for lymph, T-cells and DCs to move along (Link et al., 2007, Astarita et 
al., 2015).  In resting conditions, podoplanin regulates the contractility of actomyosin in 
FRCs to maintain FRC contraction and stability of the lymph node microarchitecture 
(Astarita et al., 2015). During inflammation, the contractility of FRCs is reduced due to 
CLEC-2 expressed on DCs interacting with podoplanin. This interaction leads to 
relaxation of FRCs, causing changes in FRC and T cell spacing and expansion of the 
FRC network, allowing greater movement of immune cells through the network (Acton 
et al., 2012a, Astarita et al., 2015). Platelet-CLEC-2 interactions with podoplanin 
expressing FRCs have also been shown to maintain the integrity of high-endothelial 
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venules within the lymph nodes, with blood-filled lymph nodes forming in the absence 
of CLEC-2 (Herzog et al., 2013). 
 
Podoplanin upregulation in other inflammatory settings has also been described. Studies 
into multiple sclerosis (MS), an auto-immune inflammatory disorder, have shown that 
CLEC-2/podoplanin interactions improve the resolution of inflammation (Peters et al., 
2015). Podoplanin expression is upregulated on TH17 cells in inflamed central nervous 
system (CNS) tissue of mice in an autoimmune encephalomyelitis model (Miyamoto et 
al., 2013). Podoplanin on TH17 cells acts to negatively regulate the persistence of T 
effector cells, with enhanced T-cell responses observed in podoplanin-deficient mice 
(Peters et al., 2015).  In rheumatoid arthritis (RA), another chronic inflammatory 
disease, CLEC-2 and podoplanin were proposed to modulate the progression of the 
disease. Podoplanin and CLEC-2 expression have also been shown in tissue sections 
isolated from RA patients (Del Rey et al., 2014, Ekwall et al., 2011). Increased 
podoplanin expression was also detected in synovial arthroscopic biopsies from RA 
patients with lymphoid neogenesis and proposed as an early feature of RA (Del Rey et 
al., 2014). Overall, podoplanin upregulation is increased at sites of inflammation in RA, 
including areas where synovial fibroblast activation occurs (Miyamoto et al., 2013, 
Ekwall et al., 2011, Del Rey et al., 2014). In addition, platelet-CLEC-2 interactions with 
synovial fibroblasts through CLEC-2/podoplanin interactions could lead to release of 
pro-inflammatory cytokines (Del Rey et al., 2014).  
 
Podoplanin upregulation also occurs on multiple tumour cells, including colorectal 
adenocarcinomas and CNS tumours (Kato et al., 2003, Shibahara et al., 2006b). Indeed, 
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tumour cells have been shown to upregulated podoplanin and induce platelet 
aggregation through podoplanin and platelet-CLEC-2 interactions after addition of 
tumour cells to platelets (Kato et al., 2003, Suzuki-Inoue et al., 2007, Kato et al., 2006). 
Some studies suggest podoplanin upregulation on cancer-associated fibroblasts (CAFs) 
in the stroma of areas near tumours can act as barriers to reduce tumour cell invasion 
(Yamanashi et al., 2009). However, other studies have suggested the formation of 
platelet/tumour aggregates protects the tumour from shear stress, helping with evasion 
of the immune system (Gay and Felding-Habermann, 2011, Jain et al., 2009). Targeting 
podoplanin with blocking antibodies has also been shown to reduce platelet aggregation 
and pulmonary metastasis (Takagi et al., 2013). 
 
Podoplanin upregulation has been observed during inflammation in response to 
infection. Podoplanin expression has been described on fibroblastic macrophages (FN), 
a F4/80
+
 subtype macrophage found in the red pulp of the spleen, which is upregulated 
in response to zymosan induced peritonitis (Hou et al., 2010). Podoplanin upregulation 
has also been shown in response to bacterial infection. Hitchcock et al. showed that 
during inflammation of the liver after Salmonella typhimurium infection, podoplanin 
was upregulated on liver macrophages (F4/80+ cells) of infected mice (Hitchcock et al., 
2015). This upregulated podoplanin was shown to trigger CLEC-2-mediated thrombosis 
in the liver (Hitchcock et al., 2015). The absence of platelet CLEC-2 reduced venous 
thrombosis, suggesting platelet CLEC-2/podoplanin interaction mediates the infection-
driven thrombosis.  
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Podoplanin expressed on LECs has also been shown to induce platelet activation 
through interactions with CLEC-2. Studies have shown platelets form aggregates when 
blood is flowed over the surface of LECs; aggregation is CLEC-2 and SLP-76 
dependent (Bertozzi et al., 2010, Pollitt et al., 2014). Platelet activation through 
podoplanin/CLEC-2 interactions has been shown following upregulation of podoplanin 
on RAW264.7 macrophages (a mouse macrophage cell line) following exposure to 
lipopolysaccharide (LPS;  (Kerrigan et al., 2012)). However, this has not been described 
in macrophages in humans.  
 
To mediate platelet activation, podoplanin interacts with CLEC-2 through its O-
glycosylated platelet-aggregation stimulating domain (PLAG domain; (Suzuki-Inoue et 
al., 2007, Pollitt et al., 2014)).  CLEC-2 binding to podoplanin shares a number of 
structural features with binding of CLEC-2 binding with rhodocytin (Nagae et al., 
2014). Additionally, podoplanin can be cleaved at the O-glycosylated Thr52 site (Figure 
5.1) from lymphatic endothelial cells (LECs) after treatment with proteases and 
sialidases (Pan et al., 2014). There is therefore the potential that upregulated podoplanin 
is released into the circulation although, as yet, the presence of podoplanin ectodomain 
in the plasma has not been reported. 
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Figure 5.1 - Schematic of podoplanin. A) Podoplanin consists of a transmembrane 
domain and an O-glycosylated platelet-aggregation stimulating domain (PLAG 
domain), which interacts with the CLEC-2 receptor. B) Architecture of podoplanin. The 
amino acid sequences of the different PLAG domains (PLAG1-3) are listed. The star 
indicates the O-glycosylated Thr52. This area has the potential to undergo cleavage with 
treatment of proteases and sialidases (Pan et al., 2014, Nagae et al., 2014). 
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Podoplanin is upregulated on multiple cell types in several inflammatory settings and is 
therefore a potential biomarker of inflammation. The overall aim of this chapter is to 
determine which cell types in blood upregulate podoplanin when challenged with an 
inflammatory stimulus and to investigate if this upregulation is sufficient enough to 
induce platelet activation. Alongside this a series of pilot studies will be performed to 
measure podoplanin in plasma of patients with inflammatory conditions.  
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5.2 Results  
5.2.1 Podoplanin upregulation on monocytes is not observed after LPS stimulation 
in whole blood 
LPS is potent activator of monocytes and macrophages and a pro-inflammatory 
mediator (Meng and Lowell, 1997). Two serotypes of LPS (E. coli 0111: B4 and 055: 
B5) were added to stimulate monocytes in whole blood to assess if podoplanin could be 
upregulated by 4 and 24 h after stimulation (6 and 8 h were also tested, but didn’t show 
much difference compared to 24h). Whole blood was stained with CD14, a monocyte 
marker, to allow gating for cell interactions and to determine podoplanin upregulation 
on monocytes. Co-staining with CD41, a platelet marker, was used to determine the 
percentages of monocyte/platelet complexes in the blood. In a single pilot experiment, 
there was an approximate 50% increase in levels of CD14+ and CD41+ platelet-
leukocyte complexes after 4 h following stimulation with both types of LPS, which 
remained constant up to 24 h (Figure 5.2A). However, a similar increase in 
platelet/monocyte interactions was observed over time with unstimulated blood (Figure 
5.2A). CD14+ cells were stained with CD69 or CD38 (monocyte activation markers), to 
follow their activation status. Limited activation of monocytes was observed in response 
to serotype 0111 (100 ng/ml) following stimulation after 4 h or 24 h (Figure 5.2B). To 
determine if podoplanin becomes upregulated on stimulated monocytes in whole blood, 
CD14+ cells were stained for podoplanin using the NZ-1.3 anti-podoplanin antibody 
and compared to isotype and unstimulated controls. Podoplanin upregulation was not 
observed after 4 or 24 h with or without LPS (0111) stimulation. (Figure 5.2C).  
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Figure 5.2 – Podoplanin is not upregulated on monocytes after LPS stimulation in 
whole blood. A) Whole blood was stimulated with two serotypes of LPS (E. coli 0111: 
B4 and 055: B5) in the presence of GPRP (10 µM) and integrilin (9 µM) for 4 h and 24 
h at 37
O
C on a shaker (low speed). Blood was stained for CD14 (monocyte marker) and 
CD41 (platelet marker). % of CD14+ CD41+ cells were measured by flow cytometry 
after LPS stimulation. N=1. B) % of cells stained for CD14 and monocyte activation 
markers CD69/38 after whole blood stimulation with LPS (0111; 100 ng/ml). Mean 
shown ±SEM, n=3. C) Median fluorescence Intensity (MFI) of podoplanin (Pdpn) 
staining of CD14+ cells after 4 h and 24 h LPS stimulation compared to unstimulated 
(US) blood and isotype (iso) control. 
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5.2.2 Podoplanin is not upregulated on THP-1 cells after LPS stimulation  
THP-1 cells (a human acute monocytic leukaemia cell line (Auwerx, 1991) were also 
stimulated to test for podoplanin upregulation. Some studies have shown that 
podoplanin is upregulated on neuronal apoptotic cells after LPS injection (Song et al., 
2014). Podoplanin upregulation on apoptotic THP-1 cells was also tested after cells 
were treated two agents that induce apoptosis, staurosporine (1 µM) and cycloheximide 
(25 µg/ml) which are a protein kinase inhibitor and protein synthesis inhibitor, 
respectively and stained with Annexin V (an apoptosis/activation marker). Annexins 
belong to a family of calcium-dependent phospholipid-binding proteins, which bind to 
cells exposing phosphatidylserine (PS). PS is exposed during cell activation and when 
cells are undergoing apoptosis. Cells stained with Annexin V were gated to determine 
whether podoplanin can be upregulated on Annexin V+ and Annexin V- THP-1 cells 
(Figure 5.3A). There was no podoplanin upregulation on Annexin V+ cells after 
stimulation with LPS or staurosporine and cycloheximide treatment compared to 
unstimulated cells (Figure 5.3Bi). Podoplanin upregulation was not observed in 
Annexin V- cells after stimulation with LPS or staurosporine and cycloheximide (Figure 
5.3Bii). Moreover, no differences were seen in podoplanin upregulation in Annexin V+ 
or Annexin V- cells when podoplanin MFI (median) ratio over isotype was calculated 
(Figure 5.3C).  
 
5.2.3 Podoplanin is not upregulated on isolated monocytes after stimulation  
To confirm podoplanin was not upregulated on stimulated monocytes, monocytes were 
isolated from whole blood by negative selection of peripheral blood mononuclear cells  
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Figure 5.3 – Podoplanin is not upregulated on THP-1 cells after LPS stimulation. 
THP-1 cells (acute monocytic leukaemia cell line; 1x10
6
 cells/ml) were stimulated with 
LPS (100 ng/ml) for 24 h at 37
o
C followed by CD14, Annexin V and Pdpn staining. A) 
Gating strategy for determining Annexin V+ and Annexin V- cells that are Pdpn 
positive. Isotype in black, Pdpn in red. B(i) Median fluorescence Intensity (MFI) of 
podoplanin staining of Annexin V+ cells after LPS stimulation and treatment with 
staurosporine (1 µM) and cycloheximide (25 µg/ml) for 24 h compared to isotype 
controls. Mean shown ± SEM, n=4. B(ii) MFI (median) of podoplanin staining of 
Annexin V- cells after LPS stimulation and treatment with staurosporine (1 µM) and 
cycloheximide (25 µg/ml; S+C) for 24 h compared to isotype controls. Mean shown ± 
SEM, n=4. C) Ratio of podoplanin staining over isotype control of Annexin V+ and 
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Annexin V- THP-1 cells after stimulation. Mean shown ± SEM, n=4. One-way 
ANOVA performed with Bonferroni’s post-hoc test. No significant difference observed.  
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Figure 5.4 – Podoplanin is not upregulated on isolated monocytes after stimulation. 
Isolated monocytes (1x10
6
 cells/ml) from donor blood were stimulated with LPS (100 
ng/ml) or staurosporine (1 µM) and cycloheximide (25 µg/ml) for 24 h at 37
o
C. A) 
Gating strategy for determining Annexin V+ and Annexin V- cells that are Pdpn 
positive. Isotype in black, Pdpn in red. B(i) Median fluorescence Intensity (MFI) of 
podoplanin staining of Annexin V+ cells after LPS stimulation and staurosporine (1 
µM) and cycloheximide (25 µg/ml) treatment compared to isotype controls. Mean 
shown ± SEM, n=5. B(ii) MFI (median) of podoplanin staining of Annexin V- cells 
after stimulation compared to isotype controls. Results shown as mean  ± SEM, n=5. C) 
Ratio of podoplanin staining over isotype control of Annexin V+ and Annexin V- 
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monocytes stimulated with LPS and staurosporine and cycloheximide. Mean shown ± 
SEM, n=5. 
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(PBMCs) and stained for CD14, podoplanin and Annexin V after LPS or staurosporine 
and cycloheximide stimulation (Figure 5.4A). There was no podoplanin upregulation on 
CD14+ and Annexin V+ cells after LPS stimulation and treatment with staurosporine 
and cycloheximide (added together; Figure 5.4Bi&C). There was also no upregulation 
seen with CD14+ and Annexin V- cells (Figure 5.4Bii&C). 
 
5.2.4 Absence of upregulation of podoplanin after stimulation of PBMCs 
In order to establish whether other blood cells can upregulate podoplanin following LPS 
stimulation, human PBMCs were isolated and stimulated with LPS. Citrated-human 
whole blood was collected from healthy donors, with no sign of infection or medication, 
and PBMCs were isolated using a ficoll-paque gradient using differential centrifugation. 
PBMCs were stimulated with LPS (100 ng/ml) or treated with staurosporine (1 µM) and 
cycloheximide (25 µg/ml) for 24 h followed by podoplanin and Annexin V staining and 
gated on size scatter and CD45 positivity. Podoplanin was measured on Annexin V+ 
cells and Annexin V- cells as before (Figure 5.5A). As expected, there was no 
upregulation of podoplanin was observed after LPS stimulation or staurosporine and 
cycloheximide treatment on Annexin V+ and Annexin V- cells (Figure 5.5B). There 
was no difference in the ratio of podoplanin staining over isotype with Annexin V+ and 
Annexin V- PBMCs after stimulation (Figure 5.5C).  
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Figure 5.5 – Podoplanin is not upregulated after stimulation of PBMCs. Peripheral 
blood mononuclear cells (PBMCs; 1x10
6
 cells/ml) were isolated from donor blood and 
stimulated with LPS (100 ng/ml) or staurosporine (1 µM) and cycloheximide (25 µg/ml) 
for 24 h at 37
o
C. A) Gating strategy for determining Annexin V+ and Annexin V- cells 
that are Pdpn positive. Isotype in black, Pdpn in red. B(i) Median fluorescence 
Intensity (MFI) of podoplanin staining of Annexin V+ cells after stimulation compared 
to isotype controls. Mean shown ± SEM, n=5. B(ii) MFI (median) of podoplanin 
staining of Annexin V- cells after stimulation compared to isotype controls. Mean 
shown ± SEM, n=5. C) Ratio of podoplanin staining over isotype control of Annexin 
V+ and Annexin V-  after stimulation of PBMCs. Mean shown ± SEM, n=5  
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5.2.5 Podoplanin is upregulated on M-CSF treated monocyte-derived macrophages 
but not GM-CSF treated cells after stimulation  
Podoplanin was not upregulated on PBMCs or monocytes after LPS stimulation. 
Studies have shown that podoplanin can be upregulated on cultured RAW264.7 cells 
(inflammatory macrophages from a mouse cell line) after LPS stimulation (Kerrigan et 
al., 2012). To test whether this was the case for human macrophages, monocyte-derived 
macrophages were produced as an alternative, as macrophages are very difficult to 
isolate and there are very few reliable macrophage cell lines. Monocytes were isolated 
from the blood and treated with granulocyte-macrophage colony-stimulating factor 
(GM-CSF) or macrophage colony-stimulating factor (M-CSF) for 5-6 days to produce 
monocyte-derived macrophages, which were initially confirmed by CD68, CD14 (low), 
CD16 (high) expression by flow cytometry. Treatment with these cytokines was used to 
polarize monocyte into macrophage-like cells with ‘M1 and M2’ macrophage 
phenotype, respectively, resulting in profound differences in morphology (Figure 5.6). 
Untreated monocytes adhered to the plate wells and most cells had uniformed circular 
appearance after 6 days. GM-CSF treatment causes differentiation of monocytes into the 
‘M1’ phenotype, which are cells with a pro-inflammatory phenotype and DC antigen-
presenting properties (Masurier et al., 1999). M-CSF treatment of monocytes causes 
differentiation into the ‘M2’ macrophage phenotype with anti-inflammatory properties 
(Verreck et al., 2004, Lacey et al., 2012). Most cells had long thin extrusions when 
spreading on the plate well. M-CSF treatment cells had a different appearance with 
fewer extrusions. A CD206 marker was used initially to determine differences between 
M2 phenotype compared to M1 by flow cytometry, which then allowed consequent 
gating based on size and characteristics for future experiments.  
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Figure 5.6 – Differentiation of monocyte-derived macrophages after GM-CSF and 
M-CSF treatment of isolated monocytes. Isolated monocytes (1x10
6
 cells/ml) were 
incubated in a well of a 6-well plate added to wells and treated with GM-CSF (50 
ng/ml) or M-CSF (100 ng/ml) to differentiate into ‘M1’ and ‘M2’ macrophages. For 
some conditions macrophages were treated with LPS (0111: B5 100 ng/ml) or 
staurosporine (1 µM) and cycloheximide (25 µg/ml). Brightfield images taken with the 
EVOS FL Cell imaging system. Scale bar represents 400 µm. 
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Figure 5.7 – Podoplanin is upregulated on LPS treated monocyte-derived 
macrophages treated with M-CSF. Isolated monocytes (1x10
6
/ml) were treated with 
GM-CSF (50 ng/ml) or M-CSF (100 ng/ml) for 6 days to allow for macrophage 
differentiation. Cells were then stimulated with LPS (100 ng/ml) or staurosporine (1 
µM) and cycloheximide (25 µg/ml) for a further 24 h. A) Gating strategy for 
determining Annexin V+ and Annexin V- cells that are Pdpn positive. Isotype in black, 
Pdpn in red. B) Ratio of podoplanin staining over isotype control of Annexin V+ and 
Annexin V- GM-CSF treated cells stimulated with LPS and staurosporine (1 µM) and 
cycloheximide (25 µg/ml). Mean shown ± SEM, n=5. C) Ratio of podoplanin staining 
over isotype control of Annexin V+ and Annexin V- M-CSF treated cells stimulated 
with LPS. Mean shown ± SEM, n=5. Unpaired T-test performed to determine difference 
between untreated cells, **p<0.0.1.  
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LPS (100 ng/ml) stimulation of both types of treated cells resulted in cell accumulation. 
Some extrusions were seen with the GM-CSF treated cells but not as many as with 
unstimulated GM-CSF treated cells. LPS stimulation of the M-CSF treated cells also 
lead to accumulation of cells, however, more extrusions were seen and some cells had 
expanded surface areas. The addition of staurosporine (1 µM) and cycloheximide (25 
µg/ml) to both GM-CSF and M-CSF treated cells lead to cell disruption and apoptosis. 
(100 ng/ml) stimulation of both types of treated cells resulted in cell accumulation. 
Some extrusions were seen with the GM-CSF treated cells but not as many as with 
unstimulated GM-CSF treated cells. LPS stimulation of the M-CSF treated cells also 
lead to accumulation of cells, however, more extrusions were seen and some cells had 
expanded surface areas. The addition of staurosporine (1 µM) and cycloheximide (25 
µg/ml) to both GM-CSF and M-CSF treated cells lead to cell disruption and apoptosis. 
GM-CSF and M-CSF treated monocytes were stimulated with LPS (100 ng/ml) and 
treated with staurosporine (1 µM) and cycloheximide (25 µg/m) for 24 h and then 
stained for podoplanin. Cells were gated on size and CD68 positivity (CD68 is a 
macrophage marker). Podoplanin upregulation was measured on Annexin V+ cells and 
Annexin V- cells (Figure 5.7A). There was a marginal increase in the MFI ratio of 
podoplanin staining over the isotype controls in Annexin V+ cells compared to 
untreated GM-CSF cells (Figure 5.7B) which however did not reach significance. There 
was no upregulation observed with GM-CSF treated cells which were stimulated with 
staurosporine and cycloheximide. There was no increase in podoplanin upregulation of 
GM-CSF treated cells that were Annexin V- (Figure 5.7B). Podoplanin was 
significantly upregulated on Annexin V+ M-CSF treated cells stimulated with LPS 
(Figure 5.7C). This suggests that only M2 macrophages have the capacity to upregulate 
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podoplanin once stimulated with LPS. M-CSF treated cells stimulated with 
staurosporine and cycloheximide did not show podoplanin upregulation.  Podoplanin 
was not upregulated on Annexin V- M-CSF treated cells (Figure 5.7C). 
 
5.2.6 Upregulated podoplanin on macrophages is unable to activate platelets  
M-CSF treated monocytes (M2 macrophages) were the only blood cell type where 
podoplanin was upregulated after LPS stimulation. The ability of these macrophages to 
cause platelet activation was therefore studied. Monocytes were isolated from the blood, 
treated with M-CSF for 6 days before being stimulated with LPS for a further 24 h. 
These inflammatory macrophages were added to washed platelets from the same donor 
at 37
o
C under stirring conditions (1200 rpm). Platelet interactions with macrophages 
were measured using anti-CD41 and -CD68 antibodies by flow cytometry. Activation of 
the platelets was measured by P-selectin expression, shown as increased MFI (median; 
Figure 5.8A). Positive CD68 and P-selectin staining represented the activated platelets 
on CD68 cells. P-selectin on CD68+ gated cells was measured in GM-CSF and M-CSF 
treated cells that were stimulated with LPS (Figure 5.8C). There were no increases in P-
selectin expression on LPS treated monocyte-derived macrophages compared to 
unstimulated cells in the absence of platelets, suggesting the increases in P-selectin 
observed is through activation of the platelets.  NZ-1.3 antibody was used to bind to and 
block podoplanin expressed on the macrophages, before the addition of macrophages to 
platelets, to investigate whether blocking podoplanin reduced any platelet-macrophage 
interactions. There were no increases in P-selectin expression on platelets added to the 
GM-CSF treated cells after stimulation (Figure 5.8Ci). 
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Figure 5.8 – Upregulated podoplanin on macrophages is not sufficient enough to 
induce platelet activation. GM-CSF (50 ng/ml) and M-CSF (100 ng/ml) treated cells 
were stimulated with LPS (0111; 100 ng/ml) for 24 h. Washed platelets (2x10
7
 cells/ml) 
from same donor were mixed with macrophages (0.3 x10
6
 cells/ml) in the presence of 
integrilin (9 µM) under stirring conditions (1200 rpm) at 37
o
C for 10 min. Samples were 
then stained for CD68, CD41 and CD62P (P-selectin antibody) for 20 min before 
fluorescence signals were measured by flow cytometry. A) Gating strategy for 
determining CD68+ and CD62P+ cells. B) Shift of P-selectin on CD68+ cells after 
platelets were added to LPS stimulated M-CSF treated cells with and without NZ-1.3 
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antibody. C(i) MFI (median) of P-selectin staining of CD68+ cells (in M6) after 
platelets were mixed with unstimulated and LPS stimulated GM-CSF treated cells. NZ-
1.3 antibody was added before mixing in some conditions. Mean shown ± SEM, n=6. 
One-way ANOVA performed with Bonferroni’s post-hoc test; N.S: no significance 
shown. C(ii) MFI (median) of P-selectin staining of CD68+ cells (in M6) after platelets 
were mixed with unstimulated and LPS stimulated M-CSF treated cells were mixed. 
NZ-1.3 antibody was added before mixing in some conditions Mean shown ± SEM, 
n=5. One-way ANOVA performed with Bonferroni’s post-hoc test; N.S: no significance 
shown. 
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There were no significant increases in P-selectin expression on platelets on M-CSF 
treated monocyte-derived macrophages stimulated with LPS (5042 ± 2492 MFI ± SEM, 
compared to 2294 ± 1383 MFI respectively; Figure 5.8B). There were also no 
significant increase when measuring the percentage of CD68+ CD62P+ cells (instead of 
MFI), with LPS stimulated monocyte-derived macrophages treated with M-CSF and 
GM-CSF. Unstimulated M-CSF cells and untreated cells also did not increase the P-
selectin expression or induce platelet activation (Figure 5.8Cii). Interestingly, the 
addition of the anti-podoplanin antibody NZ1.3, previously shown to neutralise tumour-
induced platelet aggregation (Kato et al., 2006), seemed to increase P-selectin 
expression on LPS-treated M-CSF differentiated cells following platelets addition (7529 
± 2925 MFI), but again this did not reach significance. It would be expected however 
that the NZ-1.3 antibody would reduce activation and P-selectin expression through 
blocking the podoplanin/CLEC-2 interactions, therefore the antibody might cause some 
off-target platelet activation, possibly through the low affinity FcγRIIA receptor.  
 
5.2.7 Podoplanin is not upregulated on microvesicles of IBD or septic patients  
Podoplanin is upregulated on a sub-set of human macrophages and on other cells in a 
range of inflammatory conditions, such as RA (Del Rey et al., 2014). Podoplanin has 
previously been shown in our lab to be upregulated on microvesicles derived from 
leukocytes in patients with RA (unpublished data). To further test this, podoplanin 
upregulation was measured on CD45+ microvesicles from two inflammatory cohorts, 
inflammatory bowel disease (IBD) and septic-patents. There was no difference in the 
number of microvesicles in IBD patients compared to healthy controls (HCs) and no 
podoplanin upregulation on CD45+ microvesicles (Figure 5.9A). There was only a 
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significant increase in the number of microvesicle compared to HCs in very septic 
patients (*p<0.05: Figure 5.9 Bi). However no significant podoplanin upregulation on 
the microvesicles in any patient group compared to HCs and isotype controls was 
observed (Figure 5.9 Bii). 
 
5.2.8 Podoplanin detection by ELISA  
Podoplanin has been shown to be cleaved after sialadase treatment (Pan et al., 2014). 
This study set out to confirm cleavage of podoplanin and to develop an ELISA for 
podoplanin detection in order to measure the cleaved form or microvesicle-associated 
form in patients with inflammatory conditions. Podoplanin cleavage and the use of 
suitable antibodies for detection were first established. Anti-human podoplanin 
antibodies, NZ-1.3 and 18H5 were tested. Both recognised podoplanin expression on 
human 293T cells, a cell line which constitutively expresses podoplanin, with the NZ-
1.3 clone being preferred due to reduced background relative to the isotype control 
(Figure 5.10Ai).  To test for cleavage of podoplanin, 293T cells were treated with 
trypsin (10%) for 15 min and 1 h.  Podoplanin expression on cells and levels in the 
supernatant after centrifugation were then measured by flow cytometry (Figure 
5.10Aii). Podoplanin expression on 293T cells decrease over following exposure to 
trypsin, with podoplanin levels in the supernatant increasing over time (74.3 ± 32.5% 
and 34.9 ± 17.1% of unstimulated MFI respectively, n=2; Figure 5.10B), suggesting 
cleavage; however, this could not be tested statistically due to the low n value. 
Podoplanin was also detected in the supernatant post trypsin treatment after western 
blotting using the anti-podoplanin (NZ1.3) antibody (Figure 5.10C).   
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Figure 5.9 – Podoplanin is not upregulated on microvesicles in patients with IBD 
or in septic patients. A(i) average number of microvesicles counted/ml in plasma 
samples of IBD patients with inactive, active Crohn’s disease (n=13, n=4), inactive and 
active UC (n=12, n=13), compared to HCs (n=20), Mean shown ±SD. A(ii) Median 
intensity fluorescence (MFI) of microvesicles gated on size and CD45+ of IBD patient 
groups and HCs. – and + represents presence of isotype or podoplanin (PDPN) 
antibody. Mean shown ±SD B(i) average number of microvesicles counted/ml in plasma 
samples of septic patient groups compared to HCs. Mean shown ±SD. Unpaired t-test 
was performed to compare microvesicle count between septic patients and HC. 
*p<0.05. B(ii) Median intensity fluorescence (MFI) of microvesicles gated on size and 
CD45+ of septic patient groups and HCs. – and + represents presence of isotype or 
PDPN antibody. Results are shown as mean shown ±SD.  
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The presence of podoplanin in the supernatant from trypsin-treated cells facilitated the 
development of the podoplanin ELISA. A sandwich ELISA, using the two anti-
podoplanin antibodies (18H5 and NZ-1.3) as a capture and detection antibodies 
respectively was first tested (Figure 5.11A). Human recombinant podoplanin, with the 
Fc region attached, was used to generate a standard curve for extrapolation of test 
podoplanin concentrations (Figure 5.11Bi). The best standard curve generated using the 
recombinant podoplanin gave a R-square value of 0.747 (Figure 5.11Bi). The standard 
curve gave values in the µg/ml range, instead of the ng/ml range expected. There were 
also a number of inconsistencies using the sandwich ELISA method, with spiking of 
HC plasma samples with recombinant podoplanin reducing detection levels (Figure 
5.11Bii).  
 
Further assessment of podoplanin antibodies used revealed a potential overlap in 
binding sequences of the podoplanin epitopes. Therefore, a competitive podoplanin 
ELISA was developed, which used only the NZ-1.3 podoplanin antibody (Figure 
5.12A). Varying amounts of recombinant podoplanin were pre-incubated with the NZ-
1.3 antibody separately. Samples were incubated on a recombinant podoplanin (3 
µg/ml) pre-coated plate to assess for antibody competition. With increased podoplanin 
in the samples, less antibody would be available to bind to recombinant podoplanin on 
the plate, giving a reduced signal (Figure 5.12B). The R-square value generated from 
the recombinant podoplanin standard curve was a respectable 0.96, in line with values 
observed with the sGPVI ELISA. The signal did decrease when the sample was spiked 
with recombinant podoplanin (3 µg/ml) as expected.  
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Figure 5.10– Podoplanin levels are reduced after trypsin treatment of 293T cells. 
A(i) Gating strategy for podoplanin staining of 293T cells by flow cytometry. Shift to 
right of unstained cells shows expression of podoplanin by the anti-podoplanin antibody 
(NZ-1.3). A(ii) Shifts of podoplanin expression of trypsin treated cells compare to 
unstimulated cells over time. B) Median intensity fluorescence (MFI) of cells and 
supernatant stained for podoplanin over various time points after trypsin treatment. 
Results are shown as mean shown ±SD. C) Detection of podoplanin in lysed 293T cells 
and in the supernatant post trypsin treatment using a dot plot with the NZ-1.3 antibody. 
Representative of 2 experiments.  
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Figure 5.11 – Podoplanin sandwich ELISA development. A) Schematic of the 
podoplanin sandwich ELISA developed including capture, detection and signal 
antibody details. B(i) Best standard curve generated from measurements of a serial 
dilution of rPdpn containing FC region in ddH2O. RLU represents relative luminescence 
units. B(ii) Podoplanin concentrations extrapolated from the standard curve in the 
difference conditions tested.  Average values of 3 readings.  
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Figure 5.12 – Podoplanin competitive ELISA development and commercial 
podoplanin ELISA results. A) Schematic of the podoplanin competitive ELISA 
developed including capture, detection and signal antibody details. B) Standard curve 
generated from measurements of a serial dilution of rPdpn incubated with NZ-1.3 
antibody added to a pre-coated rpdpn plate, with and without extra rPdpn spike. RLU 
represents relative luminescence units. C(i) Standard curve generated using the 
commercial podoplanin ELISA kit (Biomatik) showing optical density increases with 
increased podoplanin concentrations. C(ii) Podoplanin concentrations of the rPdpn 
serial dilution extrapolated from the standard curve. C(iii) Podoplanin concentrations 
detected by commercial ELISA in plasma samples of septic patients (n=4) and HCs 
(n=3). Results are shown as mean shown ±SD.  
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However, the generated standard curve was in the µg/ml range and the ELISA was not 
able to detect podoplanin in the plasma. 
 
A commercial podoplanin ELISA (Biomatik) was the obtained and tested for 
podoplanin detection in patient samples. The standard curve generated using the 
manufacture’s agonists, gave a reasonable R-square value of 0.93 (Figure 5.12Ci). 
However, the commercial podoplanin ELISA was unable to detect any human 
recombinant podoplanin (0-3 µg/ml; Figure 5.12Cii) thereby questioning its validity. 
When detecting podoplanin in the plasma samples of HCs and patients, no significant 
difference between podoplanin concentrations in the plasma of HCs compared to the 
septic patients  was observed (very septic; Figure 5.12Cii).  
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5.3 Discussion 
Podoplanin upregulation on different cells, including fibroblasts, LECs and a subset of 
liver macrophages has been described in several inflammatory settings (Astarita et al., 
2015, Bertozzi et al., 2010, Hitchcock et al., 2015). Podoplanin upregulation has also 
been shown after LPS stimulation of mouse macrophages from the RAW264.7 cell line 
(Kerrigan et al., 2012). This chapter aimed to establish which cells, if any in human 
blood can upregulate podoplanin in response to inflammatory stimulus, in order to 
provide a route for podoplanin/CLEC-2 interactions, potentially leading to platelet 
activation.   
 
LPS is potent pro-inflammatory mediator, used in many studies to induce inflammation. 
LPS stimulates myeloid cells, including monocytes and macrophages, triggering 
secretion of multiple cytokines including IL-1, IL-6 and TNF-α, leading to pro-
inflammatory responses (Meng and Lowell, 1997). LPS is proposed to bind to TLR4 
and CD14 to induce responses leading to the production and release of cytokines and 
chemokines (Tan and Kagan, 2014). Genomic analysis of LPS-mediated response has 
shown pro-inflammatory responses are similar across all myeloid cells after stimulation 
(Hutchins et al., 2015). In this study, LPS was used to stimulate a range of isolate blood 
cells to test for podoplanin upregulation in response to the inflammatory stimulus. 
Different serotypes of LPS (0111 and 055) were first tested to see which affect the cells 
the most. There was no difference observed with the LPS serotypes used.  As LPS 0111 
was used at lower concentrations to give the same potency of 055 serotype, this was 
used for further studies.  
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Stimulation of whole blood with LPS showed a small increase in CD14+ CD41+ 
complexes as measured by flow cytometry. This increase was also seen in the 
unstimulated blood samples, suggesting the blood incubation process could have 
affected the results, with platelets and monocytes forming more complexes over time.  
There was no significant increase in CD14+ CD69/38+ cells after time or with LPS 
stimulation, suggesting there was no activation of monocytes. The reduced monocyte 
activation may have potentially resulted from the ‘resting’ monocytes in the 
unstimulated samples being already slightly activated, so further increases in activity 
could not be detected. When staining CD14+ monocytes for podoplanin, there was no 
podoplanin upregulation observed after LPS stimulation for 4 h or 24 h after 
stimulation, suggesting monocytes do not express podoplanin. An alternative 
explanation is that the LPS stimulation of monocytes in whole blood is not sufficient 
enough to cause activation or podoplanin upregulation. To confirm there was no 
podoplanin upregulation on stimulated monocytes, both isolated monocytes from whole 
blood and THP-1 monocytes from the human acute monocytic leukaemia cell line 
(Auwerx, 1991), were stimulated with LPS for 24 h. THP-1 cells were used to give a 
good yield of monocytes to stimulate with LPS and look for podoplanin upregulation. 
The monocytes from the THP-1 cell line would give slightly different characteristics to 
isolated monocytes, however, with both types of monocytes, there was no podoplanin 
upregulation was observed after stimulation. Podoplanin upregulation on other blood 
cells, such as PBMCs and neutrophils were assessed after LPS stimulation for 24 h but 
again no podoplanin expression was seen.  
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Studies have shown upregulation of podoplanin on apoptotic cells. Podoplanin is 
upregulated on neuronal apoptotic cells after LPS infection into the CNS (Song et al., 
2014). In this study, apoptosis was induced on monocytes, PMBCs and monocyte-
derived macrophages after treatment with staurosporine and cycloheximide for 24 h, 
before being stained for Annexin and podoplanin. There was no increase in podoplanin 
upregulation of both apoptotic monocytes and PBMCs. Propidium iodide was also used 
to show cells were apoptotic, however, no podoplanin upregulation was seen either, 
confirming that both apoptotic and non-apoptotic monocytes and PBMCs do not 
upregulate podoplanin after LPS stimulation.   
 
Podoplanin expression has previously been described on a subset of macrophages. 
Indeed, a population of macrophages F4/80+ in the red pulp of the spleen and in 
inflamed livers were shown to express podoplanin (Hou et al., 2010, Hitchcock et al., 
2015). The macrophages found in the spleen have been termed as fibroblastic 
macrophages, which upregulate podoplanin in response to zymosan induced peritonitis 
(Hou et al., 2010). On the other hand, liver macrophages were shown upregulated 
podoplanin in response to Salmonella typhimurium driven inflammatory response to 
infection of mice. Podoplanin upregulation in response to an inflammatory stimulus has 
also previously been shown in vitro after LPS stimulation of mouse RAW264.7 cells 
(macrophage cell line; (Kerrigan et al., 2012). A main aim of this work is to study 
podoplanin upregulation in human macrophages in response to an inflammatory 
stimulus, such as LPS. To test these macrophages were derived from isolated 
monocytes with the addition of growth factors. These monocyte-derived macrophages 
will have some differences in characterises compared to isolated macrophages 
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(Ohradanova-Repic et al., 2016); however macrophage isolation is very difficult and 
there is a very limited availability of a reliable immortalised human macrophage cell 
line, therefore was the alternative option avaliable. THP-1 cells were also used for 
macrophage differentiation but did not produce a high yield of CD68+ macrophages. 
Therefore, monocytes isolated from human blood were differentiated into macrophages 
after GM-CSF and M-CSF treatment. GM-CSF addition leads to the formation of ‘M1 
macrophages’ with a pro-inflammatory phenotype and DC antigen-presenting properties 
(Masurier et al., 1999). M-CSF addition leads to the formation of ‘M2’ macrophages 
with an anti-inflammatory phenotype (Verreck et al., 2004, Lacey et al., 2012). 
Macrophages have great heterogeneity during inflammation depending on the tissue in 
which they reside (Gordon and Taylor, 2005). Monocyte-derived macrophages were 
treated with GM-CSF or M-CSF for 5-6 days. This was a sufficient number of days to 
give reasonable yields of monocyte-derived macrophages, without increasing the levels 
of cell death. The GM-CSF and M-CSF treated monocyte-derived macrophages were 
both stimulated with LPS for 24 h before podoplanin expression was determined. It was 
initially expected that both types of monocyte-derived macrophages would be converted 
into an inflammatory macrophage after LPS stimulation. However, differences were 
seen between the two, both phenotypically and functionally. LPS stimulation lead to 
different morphological appearances. There was no major podoplanin upregulation with 
GM-CSF treated cells after LPS stimulation. M-CSF treated monocyte-derived 
macrophages did significantly upregulated podoplanin after LPS stimulation, which is 
interesting as M-CSF treatment is proposed to give a M2, anti-inflammatory phenotype. 
LPS stimulation is thought to switch the M2 phenotype to an M1 like, pro-inflammatory 
phenotype; however reasons why the LPS stimulated GM-CSF treated monocyte-
204 
 
derived macrophages did not induce podoplanin upregulation are uncertain and suggests 
a preferential role for the M2 macrophages leading to the upregulation of podoplanin 
after an inflammatory stimulus. Interestingly however, podoplanin was upregulated in 
both bone-marrow derived macrophages and macrophages from the RAW 264.7 cell 
line, stimulated with LPS and when treated with staurosporine and cycloheximide to 
induce apoptosis (unpublished results in the laboratory; (Rayes et al., 2015)). Therefore, 
this suggests that the expression profile for podoplanin and upregulation in response to 
inflammatory stimulus is limited to inflammatory and apoptotic macrophages in mice 
and limited further to a few sub-types of inflammatory macrophages in humans. 
 
Importantly in the context of platelets, podoplanin can interact with CLEC-2, leading to 
platelet activation. Platelet activation through CLEC-2 has been shown in response to 
up-regulation of podoplanin on inflammatory mouse macrophages (RAW264.7 cells), 
tumour cells and LECs (Kerrigan et al., 2012, Kato et al., 2003, Bertozzi et al., 2010).  
Podoplanin upregulation on liver macrophages in response to Salmonella typhimurium 
infection in vivo triggers a long-lasting, CLEC-2-dependent venous thrombosis in the 
liver (Hitchcock et al., 2015). My results show for the first time that a subset of human 
macrophages (monocyte-derived) upregulate podoplanin in vitro following LPS 
treatment. Podoplanin-upregulation on the M-CSF treated monocyte-derived 
macrophages was not sufficient to induce platelet activation, as measured by P-selectin 
expression on gated CD68+ cells. A small shift in P-selectin expression was seen with 
M-CSF derived macrophages stimulated with LPS, although this did not reach 
significance, which may have result from the cell ratio of platelets to macrophages. 
There was also no increase in P-selectin after platelets were added to GM-CSF treated 
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cells.  The differentiation process of macrophages derived from treated monocytes only 
yielded a limit number of macrophages, therefore increased numbers may be required 
for significant platelet activation to occur. Therefore this part of the study was 
underpowered and would require increased sample size to conclude if the upregulated 
podoplanin can mediate platelet activation. In vivo studies may also be required to see if 
human macrophages can upregulate podoplanin in response to an inflammatory 
stimulus and if platelet activation consequently occurs.  
 
In order to investigate whether blocking podoplanin could reduce the platelet activation 
by interactions with macrophages, the podoplanin antibody NZ-1.3 was added and 
platelet interaction with macrophages was assessed The anti-podoplanin antibody NZ-
1.3 has previously been shown to neutralise and prevent tumour cell mediated platelet 
aggregation through blocking podoplanin (Kato et al., 2006). P-selectin expression, 
representing platelet activation, however did not decrease in the presence of NZ-1.3, 
possibly because of the limited (non-significant increase in expression). Surprisingly, 
the NZ-1.3 antibody caused a small increase in P-selectin expression and in the number 
of platelets in complex with macrophages. There are two possible explanations for these 
results; firstly, the anti-podoplanin antibody had some off target effects through 
FcγRIIA inducing platelet activation or secondly, the blocking podoplanin induces the 
expression of new receptors on macrophages and their interaction with another receptor 
on platelets leads to platelet activation. Using another podoplanin blocking antibody, or 
only using the fab fragment of a podoplanin antibody would establish if the antibody 
caused platelet activation. The NZ-1.3 anti-podoplanin antibody however, was the best 
anti-podoplanin antibody tested in these studies, with the least background given 
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compared to the isotype control. Therefore, a CLEC-2 blocking antibody in future 
studies would be more useful to establish if the platelet activation induced by 
inflammatory macrophages is mediated through podoplanin-CLEC-2 interactions.  
 
Many studies showing podoplanin upregulation of fibroblasts and inflammatory 
macrophages in inflammatory settings have been limited to the study of mice. The 
results of this chapter have shown only a limited number of cells in the blood that have 
the capacity to upregulate podoplanin in response to an inflammatory stimulus. PBMCs 
and monocytes are unable to upregulate podoplanin after LPS stimulation. Monocyte-
derived macrophages treated with M-CSF were the only cells able to sufficiently 
upregulated podoplanin in response to LPS stimulation, confirming findings that only a 
sub-set of inflammatory macrophages can upregulate podoplanin. However, monocyte-
derived macrophages will have different morphology to human inflammatory 
macrophages and therefore further in vivo studies looking into podoplanin upregulation 
on macrophages after LPS stimulation would be required.  Furthermore, the functional 
consequence of the finding that a subset of human macrophages can upregulate 
podoplanin and activate platelets in inflammatory setting remains to be determined. 
 
Following a previous study in our laboratory of upregulation of podoplanin on CD45+ 
microvesicles, podoplanin has been proposed as potential candidate as an inflammatory 
marker. However, there was no significant upregulation of podoplanin on CD45+ 
microvesicles from IBD patients. Although some very septic patients had increased 
numbers of microvesicles compared to HCs, there was no increase in podoplanin on the 
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CD45+ microvesicles compared to HCs and isotype controls. Therefore, these results 
indicate that podoplanin is not upregulated on microvesicles in inflammatory settings.  
 
Podoplanin has previously been shown to be cleaved after sialadase treatment (Pan et 
al., 2014). Podoplanin cleavage was also observed after 1 h trypsin treatment of 293T 
cells.  Podoplanin could be detected in the cell supernatant by flow cytometry and by 
Western blotting. A podoplanin ELISA to measure microvesicle-bound podoplanin was 
developed. After various trials and development, it was found that a podoplanin 
sandwich ELISA could not be developed due to overlapping binding sequences of the 
podoplanin epitope in different podoplanin antibodies tested. Because of the lack of 
efficacy with the sandwich ELISA, a competitive ELISA was developed, using only the 
NZ-1.3 anti-podoplanin antibody. With the competitive ELISA, recombinant 
podoplanin was shown to generate a reasonable standard podoplanin curves although 
this fell in µg/ml range, reducing the sensitivity of the ELISA.  This was unable to 
detect podoplanin in plasma of controls or patients.  A similar sensitivity was seen with 
a commercial podoplanin ELISA. Further development is needed to increase the 
podoplanin ELISA sensitivity to establish if podoplanin is present in plasma at 
physiological levels.  
 
Although podoplanin has been shown to be cleaved and can potentially be measured in 
the plasma of patients, its reliability as a marker of inflammation is of doubt. CLEC-2 
has also been shown to be shed (Xie et al., 2008, Fei et al., 2012), making sCLEC-2 
another potential marker for platelet activation in inflammation. However, other studies 
from our laboratory have shown that CLEC-2 does not undergo cleavage after activation 
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and is instead be internalised (Lorenz et al., 2015, Gitz et al., 2014). sCLEC-2 is also 
not yet a reputable marker for platelet activation in inflammation. The results of the 
studies showed that podoplanin can be upregulated on a subset of human macrophages 
in response to an inflammatory stimulus. Although this upregulation in vitro was not 
sufficient to mediate platelet activation, this may not be the case in vivo. Therefore 
further in vivo experiments exploring whether podoplanin upregulation in response to 
inflammatory stimuli can lead to platelet activation would be required to determine if 
the CLEC-2/podoplanin interaction between platelets and podoplanin expressing cells, 
could provide a potential therapeutic target for resolving excess inflammatory-driven 
disease.  
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CHAPTER 6 
THE ROLE OF PLATELETS IN 
WOUND HEALING 
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6.1 Introduction  
Wound healing is an important process in response to trauma, thermal injury and in the 
fight against infection. In a trauma context, where substantial tissue damage will occur 
including to the skin, there is the potential of chronic wound development, scarring, 
infection and mortality with impaired healing. Thermal injury can also result in 
significant damage of the skin at varying depths, depending on burn type and thickness, 
with full thickness burns disrupting all skin layers. Thermal injury can increase the risk 
of mortality, with around 265,000 deaths resulting from thermal injury per year 
according to the World Health Organisation (Mock et al., 2008). In addition, damage to 
the skin results in the loss of integrity of the protective barrier against the environment 
and infection (Singer and Clark, 1999). Cutaneous wound healing is therefore a vital 
process for repairing damaged tissue and maintaining the barrier against infection. 
Studying the roles of platelets in the process of cutaneous wound healing acts as a 
model for healing and gives further insight into the role of platelets in vascular integrity. 
 
6.1.1 Structure of the skin  
The skin is made up of different layers containing extracellular matrix proteins and 
various cell types. Figure 6.1 shows a schematic of mouse and human skin, illustrating 
the basic components of the two main skin layers, the epidermis and dermis of both 
mice and humans. In general, the epidermis is made up of several stratum layers and a 
uniform layer of basal keratinocytes attached to the basement membrane.  Keratinocytes 
are specialised epithelial cells found abundantly in the epidermis, which can synthesise 
structural components of the epithelial barrier and can undergo differentiation-
dependent structural changes when required (Eckert and Rorke, 1989). Basal 
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keratinocytes can process environmental signals, leading to the production of cytokines 
and chemokines to attract and recruit immune cells. Keratinocyte-intrinsic pathways are 
proposed to have a major role in the regulation of immune homeostasis and 
inflammation in the skin (Pasparakis et al., 2014). The dermis is beneath the epidermis 
and is the location of lymphatic vessels, immune cells, extracellular matrix proteins, 
including elastin and collagen, and fibroblasts. Fibroblasts are heterogeneous and 
dynamic stromal cells, with essential roles in skin maintenance (Sorrell and Caplan, 
2004). Fibroblasts have several roles from synthesising granulation tissue and 
extracellular matrix components, such as collagen, to releasing cytokines in response to 
wound injury (Tracy et al., 2016). Fibroblasts are crucial at most stages of wound 
healing; they are attracted to the wound edge at initial stages of injury, involved in the 
deposition of extracellular matrices and differentiate into myofibroblasts during the 
latter remodelling stage (Li et al., 2007, Darby et al., 2014, Singer and Clark, 1999). 
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Figure 6.1 – Structure of skin in mice and humans taken from (Pasparakis et al., 
2014). Structure of mouse and human skin and components of the epidermis and 
dermis. A) Model of mouse skin. A layer of basal keratinocytes lies above the basement 
membrane in the epidermis.  Mouse skin contains densely packed hair follicles 
compared to human skin. Mouse epidermis contains Vγ5+ dendritic epidermal T cells 
(DETCs), which are not found in the epidermis of humans. Mouse dermis consists of 
macrophages, mast cells, conventional αβ T cells, innate lymphoid cells (ILCs) and 
dendritic cells (DCs) (Pasparakis et al., 2014). B) Model of human skin with less 
densely packed hair follicles and a thicker multi-layered epidermis. Human epidermis 
contains mainly Langerhans cells and CD8+ T cells in relation to other immune cells.  
Human dermis contains similar cells as mice dermis, however there is no major 
contribution of recruited γδ T cells, as seen with mouse skin (Pasparakis et al., 2014).  
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6.1.2 Process of wound healing 
There are three main stages of wound healing which take place after injury; 
inflammatory, proliferation and remodelling. These phases do not occur in a linear 
fashion but overlap in time, with strong regulation in place by the release of multiple 
growth factors and cytokines (Li et al., 2007). Tissue injury can often result in damage 
of both the epidermis, the dermis and underlying blood vessels. In the initial stage after 
tissue damage, keratinocytes in the epidermis become activated and depending on the 
nature of the injury can become damaged, causing disruption to the basement 
membrane. Haemostasis will initially occur to prevent excess blood loss. Platelets will 
become activated and aggregate to form fibrin rich clots, sealing off the damaged areas. 
Granular contents from platelets will be released, including several chemokines and 
growth factors, such as platelet-derived growth factor (PDGF) for initiation of wound 
healing and immune cell and fibroblast recruitment (Singer and Clark, 1999, Werner 
and Grose, 2003).    
Inflammatory phase  
Circulating leukocytes, such as neutrophils, monocytes and macrophages, will be 
recruited to the damaged areas through chemokine gradients. These cells will release 
further chemokines and growth factors to enhance the immune response. Neutrophils 
and macrophages will kill and phagocytose infectious agents along with any cell 
damage debris (Li et al., 2007).  Monocytes also infiltrate the wounded area and 
differentiate into macrophages, which go on to release PDGF and vascular endothelial 
growth factor (VEGF), leading to the formation of granulation tissue and the start of the 
proliferation stage (Singer and Clark, 1999). Granulation tissue formation involves 
fibroblast proliferation, deposition of extracellular matrix (ECM) proteins and the start 
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of the formation of new blood vessel (Li et al., 2007). Macrophages also promote 
keratinocyte migration and proliferation to reseal the epidermis and release mediators to 
promote dermal regeneration via activities of fibroblasts, including deposition of ECM 
proteins and myofibroblast differentiation (Shook et al., 2016, Lucas et al., 2010). This 
depletion of macrophages leads to defective wound repair through reducing granulation 
tissue and impaired re-epithelisation (Lucas et al., 2010, Singer and Clark, 1999).  
Resident cells, such as mast cells, located in the dermis, will also becoming activated 
post injury. This robust inflammatory response usually occurs around day 3 post wound 
injury in mice (Singer and Clark, 1999) and generally lasts for 24 to 48 hours. A similar 
time frame is observed in humans, however in some cases this stage can persist for up to 
2 weeks (Li et al., 2007). 
Proliferation phase  
Recruited cells migrate to the wound edge, along with the basal keratinocytes to start 
rebuilding the disrupted epidermis. These will eventually cover the surface of the whole 
wound, a process termed re-epithelisation (Li et al., 2007). First, keratinocytes 
proliferate at the wound edge to ensure there are sufficient number of cells to fully 
cover the wound (Li et al., 2007, Singer and Clark, 1999). During this re-
epithelialisation period, basement membrane proteins start to form a uniformed 
sequence (Singer and Clark, 1999) and fibroblasts from the dermis and monocyte-
derived fibroblasts from the circulation move towards the wounded edge. At the same 
time in the dermis, fibroblasts differentiate into contractile myofibroblasts, characterised 
by large bundles of actin-containing microfilaments, which contract to reduced wound 
size (Tracy et al., 2016, Desmouliere et al., 2005).  
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Remodelling phase  
The resolution and remodelling phase then follows to restore integrity of the wounded 
tissue. During this phase the epidermis thickens and the basement membrane is fully 
sealed. The dermal reconstruction occurs during this stage, which is characterised by 
granulation tissue formation and new blood vessel formation (Li et al., 2007). Blood 
vessels that have also undergone angiogenesis will mature to re-vascularise the 
damaged area. Fibroblasts, which have accumulated in the previous phases undergo 
proliferation and produce new collagen and extracellular matrix proteins (Li et al., 2007, 
Tracy et al., 2016).  Wounds continue to undergo contraction mediated through 
myofibroblast activity (Young and McNaught, 2011, Desmouliere et al., 2005), and 
when near completion of the wound healing process, the immune cells recruited during 
the inflammatory phase and the contracted myofibroblasts will undergo apoptosis. This 
remodelling process and wound contraction by the myofibroblasts can last for around 2 
weeks in mice, depending on size, depth and thickness of wound (Li et al., 2007). 
Remodelling in human wounds however can take much longer, up to two years. Scar 
tissue is formed if there is not a correct balance between synthesis and degradation of 
matrix proteins, such as collagen and fibronectin, deposited in the wound (Young and 
McNaught, 2011, Xue and Jackson, 2015). 
 
6.1.3 Role of platelets in wound healing 
Platelets have numerous roles at different stages of wound healing. The predominate 
role is during the immediate response after wound injury to maintain haemostasis by 
stopping blood loss. The clot formed to seal the wound also provides a matrix scaffold 
for recruited cells to infiltrate the damaged area (Li et al., 2007). Another important 
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function of platelets is in the release of chemoattractant and growth factors to recruit 
immune cells to initiate the healing process (Li et al., 2007). A range of pro-angiogenic 
and protein factors that promote differentiation, including, PDGF, transforming-growth 
factor-β (TGF-β), platelet factor 4 (PF4) are all released from platelets. These have all 
been implicated in wound healing, helping to increase the rate of granulation and 
promote tissue granulation formation (Ksander et al., 1990b, Li et al., 2007). Studies 
have looked into the roles of platelet releasate in the wound healing response; they show 
that platelet releasate, containing PDGF and TGF-β, can promote connective tissue 
deposition and improve wound healing in several animal models (Ksander et al., 1990b, 
Moulin et al., 1998, Margolis et al., 2001, Eppley et al., 2004). Furthermore, platelet 
releasate has been proposed to be an effective treatment in improving wound healing in 
large wounds caused by foot ulcers in diabetic neuropathic foot ulcers (Margolis et al., 
2001). In similar studies, growth factors released from platelets have also been found in 
platelet-rich-plasma (PRP), which is used to prepare platelet gels and concentrates to 
also help improve wound healing. This has therefore been suggested to be a potential 
therapeutic treatment (Eppley et al., 2004, Crovetti et al., 2004). Indeed, a recent study 
reported that co-culture of PRP with keratinocytes and fibroblasts modulated wound 
healing by promoting remodelling and increasing collagen deposition (Xian et al., 
2015). In addition, studies have proposed that platelets can modulate PBMCs directly to 
release growth factors and cytokines which help in wound healing when scratch wounds 
were performed (Nami et al., 2016). 
 
There are limited studies to show the effects of wound healing after platelet depletion to 
confirm the role of platelets. This is presumably due to issues with the requirement of 
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haemostasis immediately after wound injury. However, a study has looked at the effects 
of platelets in acute immune complex–mediated inflammation in the mouse skin using 
the reverse passive Arthus (rpA) reaction model. These data suggest that there is a loss 
of vascular integrity with platelet depletion (using the JAQ1 anti-GPVI antibody). In 
addition, they show that the (hem)ITAM receptor CLEC-2 and GPVI are required for 
the maintenance of vascular integrity in the rpA model and at other sites of 
inflammation (Boulaftali et al., 2013). More recently, the platelet receptor CLEC-2 has 
been investigated in cutaneous wound healing; here it was shown that CLEC-2 on 
platelets regulate the migration of keratinocytes via interaction with podoplanin 
primarily on expressed keratinocytes (Asai et al., 2016). The contribution of podoplanin 
will be discussed further below. 
 
6.1.4 Role of podoplanin in wound healing  
Podoplanin, the only reported endogenous ligand for CLEC-2 has been shown to have 
multiple roles in wound healing, at different stages. Podoplanin signalling generally 
leads to effects on cell motility and migration (Astarita et al., 2012a, Baars et al., 2015). 
In the context of wound healing, it has been reported to promote the migration of 
fibroblasts to the disrupted epidermis. In addition, Baars et al., suggest that podoplanin 
is absent during normal epidermal homeostasis but is significantly upregulated to high 
levels on basal keratinocytes during wound healing (Baars et al., 2015). Other studies 
have assessed the timing of expression of podoplanin during wound healing; together 
these investigations show that upregulation starts at day 1 during the inflammatory 
phase, with high expression and upregulation being observed between day 3 and 7.  
Levels then decrease to nearly negligible levels at day 10 post injury, when the wound 
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is closed (Asai et al., 2016, Honma et al., 2012). As with fibroblasts, podoplanin 
upregulation is proposed to be important for keratinocyte migration as reductions in 
expression of podoplanin using siRNA in normal human epidermal keratinocytes 
(NHEKs) cause significant reductions in keratinocyte motility (Asai et al., 2016). 
Podoplanin is proposed to mediate keratinocyte motility through the RhoA signalling 
pathway, by downregulating E-cadherin, leading to the upregulation of N-cadherin 
which then promotes cell motility (Asai et al., 2016). Asai et al. hypothesise that 
platelets, via CLEC-2 interaction, downregulate podoplanin expression, leading to the 
reduction of keratinocyte motility once re-epithelisation has occurred (Asai et al., 2016). 
However, other studies using conditional genetic deletion of podoplanin in K14-basal 
keratinocytes have suggest there are no defects in wound healing (Baars et al., 2015). 
Therefore, the importance of podoplanin in wound healing has yet to be fully 
established.  
 
In this chapter, a mouse model of wound healing will be used in conjunction with GPVI 
or platelet-specific CLEC-2 deficient mouse strains to determine the effects of ITAM 
receptors on wound healing.  In addition, a haematopoietic-specific podoplanin-
deficient strain will be used to assess the effects of podoplanin deficiency on wound 
healing. Together these mouse models will establish whether the platelet ITAM 
receptors contribute to wound healing, and/or whether podoplanin expressed on T cell 
and/or myeloid populations is required for appropriate wound closure.   
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6.2 Results  
 provided help in anaesthesia administration, mouse monitoring, 
mouse restraint for wound healing measurements and in the immunohistochemistry 
staining, in particular in the podoplanin staining as stated.   
 
6.2.1 Wounds of wild-type mice start to heal by day 5 post biopsy and are almost 
completely healed by day 10.  
Wound closure kinetics in wild-type mice (WT) were assessed after 4 mm full thickness 
punch biopsies taken from the flanks of WT mice aged 8-10 weeks. The primary 
outcome measurement was to measure the extent of wound closure at different time 
points post biopsy. Images of the wound were taken daily, as well as measurements of 
the horizontal and vertical length of the wound to calculate wound area, giving an 
overall indication of wound size. There were no significant adverse effects to the mice 
post biopsy. A small drop in weight was observed initially post biopsy but increased to 
normal levels between day 2 and 3, remaining consistent through the rest of the time 
course. The wounds generally increased in diameter between 4 hours (h) and 2 days 
post biopsy, due to the initial movement of mice causing the wound to open up to some 
extent. From day 2 onwards the wound reduced in size, with a significant reduction 
from the original wound being observed at day 5 (Figure 6.2B). By day 9 post injury the 
wound was greatly reduced to fully healed levels (Figure 6.2A&B).  
 
Platelet counts were measured in blood taken before mice were sacrificed for tissue 
extraction at day 10. There were no significant reductions in platelet counts between,  
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Figure 6.2 – Wound closure kinetics of wild-type (WT) mice. A) 4 mm punch 
biopsies were taken from the flank of WT mice. Wound diameters were imaged and 
measured daily for 10 Days to establish rate of wound closure, n=7. B) Percentage of 
wound closure was calculated compared to the original wound area at t=0. Mean shown 
±SEM. Individual points represents one individual mouse. One-way ANOVA 
performed with Bonferroni post-test to test to compare % of wound closure at the 
different time points to original wound. **p<0.01. ***p<0.005. C) Platelet counts of 
mice at Day 10; individual points represent one mouse. Mean ±SEM shown. 
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Figure 6.3 – Wound structure of WT mice during healing. Representative images of 
Haematoxylin and Eosin (H&E) staining of histology sections taken from WT mice at 
Day 3 (D3) and Day 10 (D10) post biopsy compared to skin tissue prior to biopsy. A) 
Normal undisrupted tissue showing the structure of the skin. Representative image of 
three wounds from three separate mice. B) Section of wounded area of skin from WT 
mice at Day 3. Representative wound image from seven separate mice C) Section of 
wounded area of skin at Day 10 post biopsy. Representative image of a wound from 
seven separate mice. BK = basal keratinocyte, Fb = fibroblast, LV = lymphatic vessel, V 
= blood vessel. Scale bar represents 200 µm and 50 µm, in small and large images, 
respectively.  
222 
 
GPVI
-/- 
and CLEC-2
-/- 
and WT mice, supporting the theory that it is the platelet 
receptors that potentially have a role in wound healing and not a result of reductions in 
overall platelet count (Figure 6.2C). Variations in platelet count were observed with the 
Pdpn
-/-
 mice, with one mouse having a reduced platelet count compared to the other.  
 
Wound structure of WT wounds were analysed after Haematoxylin and Eosin 
(H&E) staining of wound tissue extracted (Figure 6.3). At day 3 post biopsy, near the 
start of the proliferation phase and re-epithelialisation process, basal keratinocytes start 
to reform the epidermis layer and recruit other cells, including fibroblasts to the wound 
edge (Figure 6.3B). Red blood cells (RBCs) were observed at the wound edge, where 
bleeding potentially occurred in response to the punch biopsy. At day 10 post biopsy the 
re-epithelisation process had successfully sealed the wound, with the formation of 
granulation tissue and multiple layers of basal keratinocytes in the epidermis being 
observed (Figure 6.3C). 
 
6.2.2 Wound closure did not vary between Pdpn
fl/fl 
Vav-1-Cre and Clec1b
fl/fl
 PF4-
Cre mice compared to WT.   
To establish if the podoplanin/CLEC-2 axis has a role in wound healing, punch biopsies 
were taken from Pdpn
fl/fl 
Vav-1-Cre and Clec1b
fl/fl
 PF4-Cre mice and wound closure 
compared to WT littermate controls. There were no significant differences in wound 
healing observed visually, including no signs of excess bleeding with the Pdpn
-/- 
and 
CLEC-2
-/-
 mice compared to WT controls (Figure 6.4A). Wound closure kinetics of the 
CLEC-2
-/-
  mice were similar to those observed to WT, with an increase in size seen at 4 
h to day 2 post biopsy (Figure 6.4B). A marginal increase in wound size compared to  
223 
 
 
Figure 6.4 -  No difference in wound closure kinetics with Pdpn
fl/fl 
Vav-1
-Cre
and 
CLEC-2
-/- 
mice compared to WT.  4 mm punch biopsies were taken from the flank of 
Pdpn
fl/fl 
Vav-1-Cre and Clec1b
fl/fl
 PF4-Cre mice. A) Wound diameters were imaged and 
measured daily for 10 Days to establish rate of wound closure. Representative image of 
two separate mice per strain. B) Percentage (%) of wound closure calculated compared 
to the original wound area over time after biopsies were taken from Pdpn
fl/fl 
Vav-1-Cre 
and Clec1b
fl/fl
 PF4-Cre mice and compare to mice. (n=2 per strain).  
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Figure 6.5 – No major structural difference with wounds taken from Pdpnfl/fl Vav-
1-Cre and Clec1b
fl/fl
 PF4-Cre mice compared to WT mice. Representative images of 
H&E staining of histology sections taken from WT, Pdpn
fl/fl 
Vav-1-Cre and Clec1b
fl/fl
 
PF4-Cre mice 10 Days post biopsy. A) Section of wounded area of skin from WT mice 
Day 10 post biopsy. Representative image of a wound from seven separate mice. B) 
Section of wounded area of skin from Pdpn
fl/fl 
Vav-1-Cre at Day 10. Representative 
image of two wounds C) Section of wounded area of skin at Day 10 post biopsy of 
Clec1b
fl/fl
 PF4-Cre mice. Representative wound image from two separate mice. Scale 
bar represents 200 µm. 
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WT was observed at day 2, but did not reach significance and the overall rate of wound 
closure phenocopied WT from day 3 onwards (Figure 6.5 B). Moreover, Pdpn
fl/fl 
Vav-1-
Cre mice did not vary greatly in wound closure time of size compared to WT controls 
(Figure 6.4B). H&E staining of day 10 wound tissue to determine structural differences 
also showed no major differences, with the re-epithelisation process completed and 
intact epidermis observed in all wound sections from Pdpn
fl/fl 
Vav-1-Cre Clec1b
fl/fl
 PF4-
Cre and WT mice (Figure 6.5). 
 
6.2.3 Wound closure was slower with GPVI
-/- 
mice compared to WT.   
To assess whether GPVI, a major platelet receptor for collagen and fibrin, had a role in 
wound healing, wound closure was measured in GPVI
-/-  
mice and compared to WT 
controls after punch biopsy. When assessing the wounds visually, GPVI
-/- 
wounds 
seemed to be more pigmented and showed more signs of bleeding at early time points 
compared to WT controls (Figure 6.6). Furthermore, from observations only, the closed 
wound at day 10 in GPVI
-/-
 mice was also more pigmented. Wounds in GPVI
-/- 
mice did 
increase in size at 4 h post biopsy, as seen the WT controls. However, the wounds 
remained larger and took longer to reduce in size, as the percentage of original wound 
size remained higher in GPVI
-/-
 until day 5 post biopsy (Figure 6.7A). Observationally, 
GPVI
-/- 
wounds seemed to heal slower and the GPVI
-/- 
wounds remained a similar size 
to the original wound at day 3 compared to WT wounds (95.4 ± 35.0% and 77.7 ± 
16.5% of original wound respectively), however this did not reach significance (Figure 
6.7B). Two populations of GPVI
-/-
 mice also seemed to present, with one group having 
slower wound healing (Figure 6.7B).  
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Figure 6.6 – Wound closure kinetics with GPVI-/- mice compared to WT.  4 mm 
punch biopsies were taken from the flank of WT and GPVI
-/- 
mice. Wound diameters 
were imaged and measured daily up to 10 days post to establish rate of wound closure. 
Representative images of three nine separate mice. 
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Figure 6.7 – Wound closure kinetics with GPVI-/- mice compared to WT. A) 
Percentage (%) of wound closure calculated compared to the original wound area over 
time after biopsies were taken from WT and GPVI
-/-
 mice. Mean shown ±SEM. B) 
Percentage of original wound remaining with GPVI
-/-
 and WT wounds at Day 3 and 
Day 10. Individual points represent individual mice. Mean ±SEM shown. One-way 
ANOVA performed with Bonferroni’s post-hoc test to compare Day 3 and Day 10 
wounds to original wound and to compare WT and GPVI
-/-
 mice, ***p<0.005. N.S; not 
significant (n=9 (D0 and D3): n=7 (D10).  
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Wound structure after biopsy in WT and GPVI
-/-
 mice were also examined on day 3, 
and at day 10, to see if absence of GPVI had an effect on healing of the wound and if 
any subtle differences in structure of the healing wound could be observed. The re- 
epithelisation process seemed delayed with GPVI
-/-
 mice wounds compared to WT, with 
less granulation tissue formed (Figure 6.8A&B). 
 
6.2.4 Podoplanin expression is normal in WT and GPVI
-/-
 skin during wound 
healing 
GPVI
-/-
 and WT wound sections were assessed for podoplanin expression to establish 
any effects on podoplanin upregulation during wound healing. There was some 
difference in podoplanin staining of the wounds observed at day 3 and day 10 of GPVI
-/-
 
mice compared to WT mice, with podoplanin positive cells being located at the wound 
edge (keratinocytes) and in the dermis (primarily fibroblasts, but other immune cells 
cannot be ruled out; Figure 6.8A&B). Similar levels of podoplanin staining of the basal 
keratinocytes in the epidermis was observed near the wound edges in both GPVI
-/- 
and 
WT mice (Figure 6.8A&B). However, podoplanin staining appeared more intense in the 
dermis of WT mice compared to GPVI
-/-
 in day 3 tissue. This could represent more 
fibroblasts and immune cells being recruited and increased granulation tissue formation 
compared to GPVI
-/-
 mice (Figure 6.8A&B). However, further staining of tissues from 
multiple wound sections from more mice are needed to confirm this. By day 10 the 
epidermal layer at the wound edge was sealed, with an intact layer of basal 
keratinocytes being present in both WT and GPVI
-/-
 mice (Figure 6.8C&D). As 
expected, less podoplanin staining was observed in epidermal keratinocytes and dermal 
layers in day 10 wounds compared to day 3 wounds of both WT and GPVI
-/-
.  
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Figure 6.8 – Podoplanin staining and structure of wounds at Day 3 and Day 10 
post biopsy of GPVI
 -/- 
mice compared to WT mice. Representative images of 
podoplanin (brown colour) staining of histology sections taken from WT and GPVI
-/-
 
mice at Day 3 and Day 10 post biopsy. A) Section of wounded area of skin from WT 
mice at Day 3. Representative wound image from three separate mice. B) Section of 
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wounded area of skin at Day 3 post biopsy of a GPVI
-/-
 mouse. Representative wound 
image from three separate mice. C) Section of wounded area of skin from WT mice at 
Day 10. Representative wound image of three separate mice. D) Section of wounded 
area of skin of a GPVI
-/- 
mouse at Day 10. Representative wound image from three 
separate mice.  BK = basal keratinocyte, Fb = fibroblast, LV = lymphatic vessel, V = 
blood vessel. Scale bar represents 200 µm and 50 µm. All podoplanin staining was 
performed by  . 
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6.3 Discussion  
The main aim of this chapter was to establish whether the platelet ITAM receptors 
CLEC-2 or GPVI, and the endogenous CLEC-2 ligand podoplanin could affect wound 
healing. Wound biopsies were taken from mice deficient in GPVI or deficient in CLEC-
2 or podoplanin from haematopoietic cells to determine if any differences in wound 
healing compared to WT mice.  
 
The wound healing kinetics in WT mice were first established after punch biopsies 
taken, which showed wounds generally increased in size initially from 4 hours to day 2 
after biopsy, potentially due to movement of the mice to some extent. Wounds started to 
decrease in size from day 2 post biopsy, with significant reductions in size being 
observed at day 5. The reduction in wound size at day 2 would correspond to the end of 
the inflammatory phase and start of the proliferation stage of wound healing (Li et al., 
2007, Singer and Clark, 1999). When analysing wound structure by histology, at day 3 
the epidermal layer of basal keratinocyte started to reform following the disruption 
caused from the punch biopsy, representing the start of re-epithelisation. Cells, 
including fibroblasts appeared to be recruited near to the wound edge. RBCs were 
observed in wound sections at day 3, presumably a result of initial bleeding occurring 
when punch biopsy was taken. Wound structure at day 10 showed that wounds were 
mostly healed with re-epithelisation process completed and fully intact epidermis being 
observed.  
 
Platelet CLEC-2 and podoplanin have been shown to have crucial roles in migration and 
proliferation of keratinocytes and fibroblasts (Asai et al., 2016). To determine whether 
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there was a role for the CLEC-2/podoplanin axis in wound healing, biopsies were taken 
from Pdpn
fl/fl 
Vav-1-Cre and Clec1b
fl/fl
 PF4-Cre mice and compared to WT mice. 
Pdpn
fl/fl 
Vav-1-Cre are mice with haematopoietic cells deficient in podoplanin, as global 
podoplanin knockouts die at birth (Schacht et al., 2003). Clec1b
fl/fl
 PF4-Cre are mice 
with CLEC-2 knocked out of all CLEC-2 expressing cells, including platelets and 
dendritic cells. There were no structural differences in wounds of Pdpn
fl/fl 
Vav-1-Cre 
and Clec1b
fl/fl
 PF4-Cre mice, with wound closure similar to WT wounds for the full 
time course, and being healed between day 9 and 10.  Overall this suggests that 
deficiencies in podoplanin or CLEC-2 have little effect on wound closure, supporting 
findings by Baars et al. (2015), who showed that podoplanin function was not rate-
limiting in the re-epithelisation process in wound healing (Baars et al., 2015). However, 
to confirm this finding it would require increased sample number of mice to undergo 
biopsies. This study was a pilot study to give preliminary findings, as only two mice 
were used per condition, so therefore under-powered. The aim of the pilot study was to 
see which platelet receptors/ligands appeared to have roles in wound healing to pursuit 
further. The Pdpn
fl/fl 
Vav-1-Cre mice seemed to have varying phenotypes as one had a 
lower platelet count than the other and bleeding in the guts, suggesting varying severity. 
Therefore, increasing the sample number would confirm if podoplanin deficiencies 
effected wound healing. Other strains of mice with deficiencies in podoplanin, such as 
an epithelial specific deletion of podoplanin or strains with fibroblasts deficient in 
podoplanin may be a useful to determine if podoplanin can modulate the wound healing 
response. CLEC-2 deficient mice also showed no signs of impaired healing. However, 
again only a small number of mice were used for the pilot study and using another 
CLEC-2 deficient mouse model such as the tamoxifen induced global CLEC-2 
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knockout model, where CLEC-2 is removed from all CLEC-2 expressing cells may help 
to confirm whether there is a role for CLEC-2 in wound healing.  
 
GPVI and other ITAM receptors are important in maintain vascular integrity in the skin 
with acute immune complex–mediated inflammation (Boulaftali et al., 2013). Punch 
biopsies were taken from GPVI
-/- 
mice in these preliminary studies to assess effects on 
cutaneous wound healing. GPVI
-/-
 mice used were mice with GPVI knocked out from 
platelets and megakaryocytes (platelet precursor).  Wounds from GPVI
-/- 
mice did show 
visually differences in structure, size and composition at early time points (day 2 to day 
5) compared to WT wounds, when looking visually at the wounds compared to WT. 
GPVI
-/-
 mice tended to show more signs of bleeding, initially at the time of biopsy taken 
and through the ten-day time course. However, based on the wound healing 
measurements, the wound closure of GPVI
-/- 
mice was not significantly different to WT 
at day 3. There was a split in the population of GPVI
-/-
 mice on day 3 with some GPVI
-/-
 
mice having slower wound healing to the others. Explanations for this could be due to 
age of the mice, size of initial wound, sex or litter. However, most of the mice were 
aged between 8-10 weeks due to licence protocol and established methods, there was 
variation in the sex, with both males and females being used, which didn’t associate 
with the split in the groups and the initial size of the wounds were similar. Mice used 
were also from different litters, but this can not be fully ruled out as a possible 
explanation as this study was only able to use a small number of GPVI
-/-
 mice for this 
time point, therefore this could affect wound closure. Another limitation may arise due 
to the accuracy of the wound measurements. Due to animal licence restrictions and 
animal housing issues, only callipers were allowed for measuring the wounds whilst the 
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mice were awake, therefore potentially giving less accurate measurements. Future 
measurements could involve anaesthetising the mice to get exact wound measurements 
or using the appropriate cameras and software, which will accurately measure the 
wound lengths.  Further exploration with the methods and increasing the number of 
mice undergoing the biopsy procedure could provide more information as to the reasons 
for the split population and also potentially increase the significance to show whether 
there is a delay in wound healing in GPVI
-/-
 at day 3 post biopsy. By day 6 the wound 
healing processes of the GPVI
-/-
 mice appeared to have reached the same levels of WT 
wound healing with the wounds being healed at day 10, suggesting that GPVI 
deficiency may delay wound healing but not prevent full wound closure. The re-
epithelialisation process looked delayed when assessing wound structure using 
immunohistochemistry. There seemed to be less granulation tissue formed at day 3 in 
GPVI
-/-
 mice wounds compared to WT. However, at day 10, there was a uniformed 
layer of basal keratinocytes and intact epidermis being present in both WT and GPVI
-/-
 
mice. 
 
Wound sections were then co-stained for podoplanin to see if podoplanin staining could 
show more subtle differences in wound closure. Podoplanin upregulation during wound 
healing is regulated to modulate the migration of keratinocytes and fibroblasts at certain 
stages of healing (Asai et al., 2016). General podoplanin staining was similar at day 3 
and day 10 in wounds of GPVI
-/-
 and WT mice. Podoplanin positive cells were located 
at the wound edge, representing keratinocytes and the number of podoplanin positive 
cells, most likely fibroblasts, were located in the dermal layer at day 3, consistent with 
findings of previous studies (Asai et al., 2016). There was however denser podoplanin 
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staining observed in the dermis of WT mice compared to GPVI
-/-
, which could represent 
less fibroblasts and keratinocytes being recruited and reduced granulation tissue 
formation at this stage in GPVI
-/-
 mice, consistent with our findings that the 
proliferation phase may be delayed in these mice. More tissue sections would need to be 
performed to fully establish this, along with using other epithelialisation markers to 
stain sections to look for delayed wound healing and effects on re-epithelisation. The 
podoplanin positive cells are thought to be fibroblast however it would also be of use to 
stain for inflammatory macrophages (CD45
+
 or F4/80
+
 together) to confirm which cell 
type is present and expressing podoplanin. Co-staining with CD41 could also determine 
if are platelets are present at the different stages of wound healing. To determine 
whether there is a reduction in podoplanin positive cells in the dermis of GPVI
-/-
 
wounds at the earlier time points, flow cytometry, real-time QT-PCR and Western blots 
could all be used to measure podoplanin upregulation in cell suspensions from isolated 
dermis and epidermis of the wounds. Overall, further studies are needed to determine in 
GPVI has a role in cutaneous wound healing.  
 
The findings of these preliminary wound healing experiments suggest that deficiencies 
of podoplanin in haematopoietic cells and CLEC-2 deficiencies do not affect wound 
healing, supporting findings of Baars et al. (2015), which showed podoplanin deletion 
in keratinocytes did not affect migration or ability of wounds to heal (Baars et al., 
2015). Overall this suggests podoplanin mainly as an inflammatory maker or an 
alternative explanation is that there is a compensatory mechanism in place to maintain 
keratinocyte function in the absence of podoplanin (Baars et al., 2015). An important 
aim of this chapter was to establish if platelet ITAM receptors had any part in wound 
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healing. The results suggest that GPVI does not have a major role in wound healing, as 
the wounds did not significantly heal different in the GPVI
-/-
 mice compared to WT. 
However, based on some of the observations, the wounds did seem more pigmented, 
suggest a slight healing impairment. Further studies looking at healing in GPVI
-/-
 mice, 
including having more accurate ways of measuring wound closure, increasing the 
number of mice to increase power of the study and more H&E staining of the wounds to 
show subtle differences, will be required to confirm if there is a role for GPVI in wound 
healing. 
 
The potential role of GPVI in wound healing could be due to delays in proliferation and 
re-epithelisation, which may result from immediate haemostasis that occurs post injury. 
It is at this stage that platelet GPVI activation may be important for aggregate formation 
and release of chemokines and growth factors for the initiation of the inflammation 
phase for wound healing. The absence of GPVI may result in delayed immune cell 
recruitment, which only then occurs once the neutrophils and monocytes infiltrate the 
wound to the release the important mediations and growth factors needed to drive the 
wound healing process. However, further studies are required to determine the full role 
of platelet GPVI in all the different stages of the wound healing process. 
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CHAPTER 7 
 
GENERAL DISCUSSION 
  
238 
 
7.1 Summary of results  
Platelets play critical roles in thrombosis, inflammation and wound healing, which are 
essential processes needed in the response to trauma and have been fundamental to the 
work performed in this thesis. The following have driven the work in this thesis; (i) 
identifying which of the endogenous mediators released following trauma and during 
inflammation induce platelet activation; (ii) the molecular basis of activation; (iii) the 
consequences of platelet activation in disease as indicated using molecular biomarkers; 
and (iv) investigating the role of platelets in wound healing. 
7.1.1 Platelet activation in response to trauma and inflammation  
I have assessed several different types of Alarmins and other endogenous mediators 
released after trauma and have shown histones to be one of the most potent Alarmins in 
mediating robust platelet activation both in vitro and in vivo. Histone-mediated platelet 
activation in vitro was shown to be through the ITAM receptor, GPVI, providing an 
alternative mechanism to the toll-like receptor mechanism previously described 
(Semeraro et al., 2011, Fuchs et al., 2011a). However, histone-mediated platelet 
activation was shown to be independent of GPVI in vivo by measurement of 
thrombocytopenia after injection into mice, as this was not reduced in GPVI
-/-
 mice 
(even in the presence of a direct thrombin inhibitor, hirudin), suggesting an alternative 
in vivo mechanism(s) for histone-mediated platelet activation, such as endothelial 
damage and release of mediators or through activation of multiple platelet receptors. 
Histones are highly positive charged proteins, which have multiple effects on several 
different cells, suggesting that targeting or neutralising histones directly, such as heparin 
treatment, may have the greatest potential for preventing their cytotoxic effects. 
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Other mechanisms for platelet activation as a result of inflammation were also studied. 
Podoplanin, the endogenous ligand for the hemITAM receptor, CLEC-2, has been 
shown to be upregulated on several cells under inflammatory conditions (Astarita et al., 
2012b, Ekwall et al., 2011), including on inflammatory macrophages in mice (Mourao-
Sa et al., 2011, Kerrigan et al., 2012). I extended this to show an important difference 
with podoplanin upregulation on human blood cells, with podoplanin only being 
upregulated on inflammatory macrophages (monocyte-derived macrophages) in 
response to the inflammatory stimulus LPS.  Surprisingly, podoplanin upregulation was 
not sufficient to induce platelet activation. However, due to the low sample size for 
these sets of experiments, further studies looking to alter the platelet – macrophage ratio 
would be required to confirm whether the podoplanin upregulation can induce platelet 
activation.  In vivo studies would also be beneficial to determine precisely which cells 
can upregulate podoplanin in response to an inflammatory challenge and establish if this 
would be sufficient to induce platelet activation. 
7.1.2 Consequences of platelet activation  
It is known that soluble GPVI (sGPVI) is released into the circulation after GPVI 
cleavage following activation of the predominate sheddase ADAM10, in response to 
numerous stimuli including collagen, other ITAM ligand, shear and FXa (Facey et al., 
2016). In this study, I have confirmed that activation of GPCRs by ADP and PAR-1 did 
not induce GPVI shedding. Thrombin stimulation did however induce GPVI shedding 
in 50% of the donors, presumably as a result of fibrin formation. Fibrin-mediated GPVI 
shedding was found to be mainly dependent on the confirmation of fibrin, with only 
polymeric and not monomeric fibrin mediating shedding. There were limited roles for 
matrix metalloproteinases, including ADAM10 and ADAM17 in the fibrin-mediated 
240 
 
shedding.  Fibrin-mediated shedding did not appear to dependent on GPVI signalling, as 
inhibitors to key signalling proteins Src and Syk did not reduce fibrin-induced GPVI 
shedding. This is in contrast to activation by GPVI and indicates that shedding may not 
be related to binding to GPVI, however this remains to be investigated. The ability of 
fibrin to induce GPVI shedding provides an alternative physiological agonist to collagen 
for mediating GPVI shedding in vivo. 
 
sGPVI has been a recognised platelet activation marker in thrombo-inflammatory 
conditions, including stroke and microangiopathy (Wurster et al., 2013, Al-Tamimi et 
al., 2011a). This study extended this to show that sGPVI is a marker of platelet 
activation in patients with rheumatoid arthritis, inflammatory bowel disease (IBD) 
patients with active ulcerative colitis (UC) and patients with thermal injury (a model of 
trauma) who develop sepsis.  The level of expression of sGPVI in these cohorts of 
patients allows correlations to be drawn with clinical outcomes, such as iron deficiency 
in the IBD patients and sepsis in the thermal injury patients.  The elevation of sGPVI in 
the patients with thermal injury peaked around day 14 when minimal collagen exposure 
would be expected, suggesting another agonist or mechanism behind the shedding 
observed. sGPVI was shown not to correlate with age or platelet count suggesting 
alternative reasons for the elevations. This with the sGPVI elevations being 
significantly higher in septic patients, suggests a sepsis-driven response to cause platelet 
activation, and not due to initial size of injury. One potential explanation is that there is 
potentially increased disseminated intravascular coagulation (DIC) observed in sepsis 
(Semeraro et al., 2010b), whereby platelets could become further activated by 
polymerised fibrin networks associated with newly formed thrombi, inducing fibrin-
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mediated GPVI shedding. In the future, it will be important to correlate sGPVI levels 
with markers of fibrin formation, such as D-dimer levels to strengthen the evidence that 
sGPVI elevation is a consequence of fibrin activation of platelets. Measurements of 
patients with high levels of fibrin formed, such as in patients with deep vein thrombosis 
(DVT), may also allow further conclusions to whether fibrin mediates the GPVI 
shedding.  
 
Several attempts were made to measure soluble podoplanin and podoplanin-expressing 
microvesicles to establish if they present in inflammatory settings. Podoplanin has been 
previously shown to undergo cleavage after sialadase treatment in vitro (Pan et al., 
2014) and therefore could be released and detected into the circulation. Microvesicles in 
the circulation could also potentially express podoplanin in inflammatory settings. 
However, there was no detection of podoplanin expression on microvesicles in patients 
with inflammatory bowel disease and sepsis when measuring by flow cytometry and the 
podoplanin ELISAs developed were not sensitive enough to detect either microvesicle 
bound or soluble podoplanin at physiological ranges. A more sensitive bioassay would 
need to be developed to rigorously test this although searching of available proteomic 
databases has also failed to find evidence of podoplanin in plasma in inflammatory 
conditions (Burkhart et al., 2014).  
7.1.3. The role of platelets in wound healing  
A cutaneous wound healing model was developed to assess the roles of platelets in 
wound healing, in particular studying if the ITAM receptors, GPVI and CLEC-2, along 
with podoplanin, are involved in wound healing. A series of preliminary experiments 
took wounds from mice deficient in these receptors and ligands were compared to wild-
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type mice to assess differences in wound closure and in structures at certain time points 
post injury. Preliminary results suggest no differences in wound healing in mice with 
deficiencies of CLEC-2 or podoplanin. Preliminary data also showed mice deficient in 
GPVI did not impair wound healing compared to wild-type mice. However, due to the  
limited numbers of mice available at the time, further studies are required to fully 
establish if there is a role for GPVI in wound healing and the molecular basis of this 
role. 
 
 
 7.2 Final Conclusions  
 
The overall findings of this thesis have added to the evidence that GPVI can serve as a 
marker of platelet activation in certain inflammatory conditions and in thermal injury 
patients who develop sepsis. After exploring the mechanisms behind a range of 
Alarmins, histones were the only Alarmins where GPVI had a role. Histone-mediated 
platelet activation in vitro was GPVI dependent; however, multiple mechanisms were 
involved in vivo. Proteolytic cleavage of CLEC-2 (data not shown) and podoplanin gave 
slightly disappoint results and did not show increased levels in the plasma in patients 
with inflammatory conditions. sGPVI, released after GPVI cleavage, was shown to be 
elevated in certain inflammatory disorders, notably in association with sepsis and with 
iron deficiency in inflammatory bowel disease patients, supporting the clinical 
relevance of sGPVI as a platelet activation marker. The finding that fibrin induces GPVI 
shedding further strengthens the evidence that fibrin is a physiological ligand of the 
immunoglobulin receptor and a future potential target for therapeutic intervention in 
inflammatory and thrombosis settings.   
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